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ABSTRACT

Author: Shin, Sunhye. PhD
Institution: Purdue University
Degree Received: August 2018
Title: Regulation of Thermogenic and Inflammatory Response by 18-Carbon Fatty Acids.
Major Professor: Kolapo Ajuwon

Dietary fatty acids, in particular long-chain fatty acids (LCFA), are involved in the regulation of
metabolic, oxidative, and inflammatory responses. This is a mechanism by which fatty acids
participate in the regulation of energy homeostasis and impact development of obesity, type 2
diabetes, and cardiovascular diseases. White and brown adipose tissue play a significant role in
energy storage and expenditure through fatty acid uptake and oxidation. LCFA, especially
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been reported to induce
thermogenesis by activating brown and beige adipocytes to oxidize more fuel molecules.
However, the effects of 18-carbon (18-C) LCFA with same length but with different number and
position of double bonds on metabolism and expression of thermogenic genes in adipose tissue
has not been well studied. It is important to study this group of fatty acids because they are some
of the most abundant fatty acid class in human diets, and there are multiple isomers in terms of
the number and the position of double bonds in their structure. Therefore, the research described
in this dissertation were conducted to investigate effects of 18-C fatty acids on regulation of
expression of metabolic and brown-specific genes.
To determine thermogenic responses of different adipocyte cell types with distinct stages
of differentiation into mature white adipocytes to 18-C fatty acids, fully differentiated
C3H10T1/2, 3T3-L1, murine, or porcine primary adipocytes were treated with 18-C fatty acids,
including stearic acid (STA; C18:0), oleic acid (OLA; C18:1), linoleic acid (LNA; C18:2, n-6),
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α-linolenic acid (ALA; C18:3, n-3), γ-linolenic acid (GLA; C18:3, n-6), and pinolenic acid
(PLA, C18:3, n-6), with or without norepinephrine (NE). In murine primary adipocytes, LNA,
ALA, GLA, and PLA upregulated expression of thermogenic genes; however, other types of
adipocytes did not respond to these PUFA. Although NE increased thermogenic gene expression
in C3H10T1/2 adipocytes, there was no effect of NE in 3T3-L1 adipocytes. In porcine primary
adipocytes, which lack of uncoupling protein 1 (UCP1), NE upregulated oxidative gene
expression, suggesting that increasing fatty acid oxidation may be a compensatory mechanism to
overcome absence of UCP1 in pigs. This study indicates that different adipocytes have different
thermogenic responses to 18-carbon fatty acids and β-adrenergic agonist.
The second experiment was conducted to compare thermogenic effects of 18-C fatty
acids in vivo. Mice (C57BL/6J) were fed high-fat diets (HFD) made of vegetable oils with
different composition of 18-C fatty acids, including shea butter (SHB; STA-rich fat), olive oil
(OO; OLA-rich oil), safflower oil (SFO; LNA-rich oil), and soybean oil (SBO; ALA-rich fat) for
12 weeks. This was followed with or without a terminal NE injection. Compared to SHB group
that had the lowest thermogenic gene expression, OO, SFO, and SBO groups had lower weight
gain and body fat accumulation. Among HFD-fed groups, OO group had the lowest white fat
mass due to its highest heat production level, which led to improved glucose metabolism.
Feeding of SFO, with the highest n-6:n-3 ratio of fatty acids, downregulated oxidative gene
expression and upregulated lipogenic gene expression. Mice that were fed HFD had lower basal
(without NE injection) brown-specific gene expression in both subcutaneous and epididymal
white adipose tissue (WAT), and had diminished NE-induced upregulation of thermogenic genes
in brown adipose tissue (BAT). These data indicate that quantity and quality of dietary fatty
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acids, especially the position of the double bonds of fatty acids, may be important in regulating
their effects on thermogenic gene expression.
LCFA are also involved in regulation of inflammatory responses, which are known to
cause dysregulation of lipid metabolism and thermogenesis, effects of HFD differing in 18-C
fatty acid composition on inflammatory and thermogenic markers were also investigated.
C57BL/6J mice were fed HFD made of SHB (saturated fatty acid-rich), OO (monounsaturated
fatty acid-rich), and SBO (polyunsaturated fatty acid-rich) for 4 weeks with or without a terminal
injection of lipopolysaccharides (LPS). Mice fed OO had the highest BAT mass and
hypothalamic leptin receptor expression, indicating that they may have a higher thermogenesis
than other groups because of the involvement of BAT in non-shivering thermogenesis. In
contrast, SBO-fed mice with the highest weight gain had higher expression of pro-inflammatory
cytokines and downregulation of oxidative genes in WAT compared to other groups. This is
because upregulation of pro-inflammatory cytokines is associated with insulin resistance and
lower thermogenic gene expression in WAT. In support of this, exposure to LPS has been shown
to suppress thermogenic and oxidative gene expression in NE-treated murine primary adipocytes.
However, there was no fatty acid-specific effect in the regulation of response to inflammatory
effect of LPS. This suggests that the degree of saturation of dietary fatty acids with 18 carbons
may not play a key role in regulation of metabolic and inflammatory responses to LPS treatment.
The results presented in this dissertation provide greater understanding of the effect of the
number and position of double bonds in 18-C fatty acids on regulation of energy balance. A
better understanding of the mechanisms of effects of 18-C fatty acids in the regulation of
metabolism will increase our understanding of their roles in the development of obesity and
associated metabolic diseases.

1

LITERATURE REVIEW

1.1
1.1.1

Obesity and Energy Homeostasis
Obesity Prevalence and Dietary Pattern

Obesity is increasing at an epidemic rate worldwide such that its prevalence tripled from 1975 to
2016. According recent statistics available in 2016 on global obesity epidemic, 39% of adults
(who are 18 years or older) were found to be overweight (with body mass index (BMI) greater
than or equal to 25 kg/m2), and 13% were obese (with BMI greater than or equal to 30 kg/m2). In
addition, 41 million children younger than 5 years old and 340 million children and adolescents
between the ages of 5 and 19 were overweight or obese in 2016 [1]. It is expected that 50% of
global population will be overweight or obese by 2030 [2].
Obesity-related health issues include cardiovascular diseases, type 2 diabetes, and certain
types of cancer. Prospective studies have shown that men with BMI between 23.5 and 24.9
kg/m2 and women with BMI between 22.0 and 23.4 kg/m2 have the lowest mortality rate [3], and
individuals with BMI above 25 kg/m2 have 30% increase in general mortality rate for each
increase of 5 kg/m2 in BMI [4].
Obesity results primarily when there is excessive accumulation of white adipose tissue
(WAT) through hyperplasia and hypertrophy [5]. While WAT is specialized for storing surplus
energy as triacylglycerol (TAG), brown adipose tissue (BAT), the other type of adipose tissue in
the body, plays an important role in regulation of body temperature through heat production.
Human adults have a small volume of BAT in the cervical, supra-clavicular, and para-vertebral
regions [6]. Since thermogenesis promotes energy expenditure and suppresses white fat mass
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increase, individuals who have lower amount of BAT would be more susceptible to obesity
development [2]. It has been shown that BAT activity is negatively correlated with BMI and fat
mass in humans [7], and lacking functional BAT, induced by UCP1 ablation, induces obesity in
mice [8].
Among other factors relevant to obesity development, dietary pattern is one of the most
important. Consumption of western type diets, containing high energy density from high contents
of fat and sugar, contributes to the prevalence of obesity [9]. Although dietary fat consumption is
critical for absorption of fat-soluble vitamins and essential fatty acids, it also contributes to
obesity and obesity-related chronic diseases [10]. Dietary fatty acid profile is also a factor that is
involved in determining obesity risk. It has been reported that after the industrial revolution,
intake of fat, trans-fatty acids, and n-6 fatty acids increased astronomically. However, intake of
n-3 fatty acids from marine or vegetable sources increased slightly [11]. This change is
considered to partly account for the increased risk of obesity and obesity-related inflammatory
diseases in recent times [11].

1.1.2

Regulation of Energy Homeostasis and Obesity

Obesity is a disease of energy imbalance when more energy is retained than expended after
consumption of diets. Thus, obesity results from a dysregulation of energy homeostasis. Energy
homeostasis is regulated at both peripheral and central levels through the action of both central
(especially central nervous system) and peripheral organs. These organs work together in a
system to regulate energy intake and expenditure to achieve homeostasis. Peripheral organs, such
as gastrointestinal organs and associated visceral organs, including liver, pancreas, and adipose
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tissue, are keenly involved in the regulation of appetite and energy intake through
communication with the hypothalamus through neuron and endocrine pathways [12].
Cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY) are
major gastrointestinal hormones expressed in small intestines increasing satiety and decreasing
dietary intake [13], and ghrelin is an appetite-stimulating hormone mostly expressed in the
stomach [14]. Insulin, a major glucose regulatory hormone produced in the pancreas, and leptin,
secreted in the adipose tissue, are also involved in appetite suppression [15, 16]. These hormones
work on the hypothalamus, the point in which the integrated regulation of energy intake and
energy expenditure occurs [17].
During energy deficiency, the levels of ghrelin and glucocorticoids are increased, and
leptin and insulin levels fall. In response to this hormonal change, orexigenic pathways are
stimulated, and neuropeptide Y (NPY), agouti-related peptide (AgRP), melanin concentrating
hormone (MCH), and orexin A are expressed in the hypothalamus to stimulate appetite and
increase energy storage. These peptides reduce glycolysis and lipolysis, and promote de novo
lipogenesis to cope with long-term negative energy balance [18, 19].
However, under positive energy balance, pro-opiomelanocortin (POMC), cocaine- and
amphetamine-related transcript (CART), and corticotrophin releasing hormone (CRH) are
expressed in the hypothalamus in response to elevated insulin and leptin levels, and reduced
ghrelin level. These anorexigenic neuropeptides attenuate appetite, stimulate sympathetic
nervous system (SNS) to promote energy expenditure, including thermogenesis, and prevent
excessive body fat accumulation [17, 19].
In obesity, induced by chronic positive energy balance, anorexigenic pathways are
dysregulated. Diet-induced obesity has been shown to downregulate hypothalamic Pomc and
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Cart mRNA expression in the hypothalamus in both mice [20] and rats [21, 22], which leads to
hyperphagia and exacerbation of obesity. This is opposite to the regulation of orexigenic
pathways. In mice, high-fat diet (HFD) feeding downregulates Npy and Agrp mRNA expression
in the hypothalamus, which helps to maintain energy homeostasis by decreasing food intake [20,
23]. It is considered that the dysregulation of POMC/CART pathway is caused by leptin
resistance [23], and decreasing dietary fat content was reported to recover responsiveness of
these neurons to leptin in mice [24]. Thus, it is very clear that multiple organs, acting primarily
through multiple peptides and hormones, and in concert with the central and peripheral nervous
systems, are involved in the regulation of both energy intake and energy expenditure.
Dysregulation of these finely-tuned mechanisms in favor of a positive energy balance is what
leads to obesity.

1.1.3

The Role of Adipose Tissue in the Regulation of Energy Balance

Adipose tissue, the store of excessive energy in the body, produces various secretory proteins
called adipokines, which link nutritional status of the body to hypothalamic regulation of energy
balance [16]. Among the different adipokines, leptin plays the most important role in the control
of energy intake and energy expenditure. Although other cells and organs, including gastric cells,
osteoblasts, and placenta, also express and release leptin, WAT is a major source of leptin [16].
Positive correlations of circulating leptin level with body mass index (BMI) and body fat
percentage indicate that the leptin level reflects nutritional status, and fasting downregulates
leptin level whereas refeeding reverses it [25, 26].
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Leptin exerts strong anorexigenic signal by downregulating energy intake and
upregulating energy expenditure. Leptin administration reduces food intake in both leptindeficient ob/ob mice and wild-type mice [27]. When young ob/ob mice were pair-fed to lean
wild-type mice, ob/ob mice had much lower energy expenditure compared to wild-type mice
[28]. Feeding a cafeteria diet led to higher fat deposition in ob/ob mice than wild-type mice
although they had isocaloric intakes, and this is because leptin deficiency reduces diet-induced
thermogenesis [29]. In obese children with mutated leptin gene, leptin treatment also decreased
dietary intake, which resulted in reduced body weight and fat mass deposition [30].
Leptin receptors, required for leptin effects on regulation of energy balance, are highly
expressed in the hypothalamus [31]. They are involved in transport of leptin across the bloodbrain barrier [32] and help interactions between leptin and hypothalamic neuroendocrine
pathways [33]. Leptin administration downregulates NPY expression at both mRNA [34] and
protein levels [35], reverses fasting-induced AgRP expression and release [36], and reduces
orexin A level [37]. Leptin injection upregulates Pomc and Cart mRNA levels in the
hypothalamus [38, 39], and Ucp1 expression in BAT [40].
When leptin binds to its receptor, signal transducer and activators of transcription 3
(STAT3; a transcription factor required for leptin signaling) is phosphorylated and translocated
into the nucleus, which induces expression of target genes [41]. At the same time, leptin also
upregulates expression of suppressor of cytokine signaling 3 (SOCS3), which suppresses leptin
signaling by inhibiting phosphorylation of STAT3, as a negative regulator of leptin effect to
prevent excessive activation of leptin signaling [42]. In obese states, administration of leptin
exerts less or no effects on energy intake and expenditure. This is because leptin concentration is
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highly increased and SOCS3 expression is upregulated in obesity, which is called leptin
resistance [43].

1.2
1.2.1

Adipose Tissue Metabolism

Molecular Classification and Origin of White, Brown, and Beige Adipocytes

Adipocytes are traditionally divided into two types: white and brown adipocytes. White
adipocytes are unilocular, containing a single giant lipid droplet, which offers a more efficient
way of energy storage. Since the lipid droplet occupies most of the cytoplasm, organelles
including nucleus are pushed to the side in white adipocytes [44]. On the other hand, brown
adipocytes are multilocular and mitochondria-rich, and filled with a number of small lipid
droplets. Activation of BAT facilitates heat generation from the stored lipids. Through
uncoupling protein 1 (UCP1), brown adipocytes dissipate stored energy as heat [45]. Recently, a
new kind of adipocyte, named beige or brite (brown in white) adipocytes, have been discovered.
Beige cells are multilocular UCP1-positive adipocytes which appear in WAT depots. They are
switchable and act like white cells in basal conditions; however, they become brown-like cells in
response to various stimuli including cold adaptation and catecholamine treatment, and increase
energy expenditure by promoting thermogenesis [44].
Even though both brown and beige cells have thermogenic capacities, it is recognized
that they are derived from distinct cell lineages. While brown fat precursor cells express Myf5
(myogenic factor 5 encoding gene; selectively expressed in skeletal myogenic cells), beige cells
do not express Myf5 and come from non-dividing pre-existing cells in WAT [46, 47]. In addition,
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under basal conditions, brown adipocytes have high levels of UCP1 and other thermogenic genes
including peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and cell deathinducing DFFA-like effector a (CIDEA), while beige cells express these genes only when treated
with activators of the β-adrenergic receptors (β-AR) or peroxisome proliferator-activated
receptor (PPAR) γ [48, 49].
Beige and white adipocytes are also considered to have arisen from different precursor
cells. When PPARγ agonists were used to treat differentiated adipocytes derived from stromal
vascular fraction (SVF) of WAT, some cells, but not all, expressed thermogenic genes [49].
Global gene profiling of preadipocytes from SVF of subcutaneous WAT indicated that two
distinct white and beige preadipocytes exist, and only beige cells express thermogenic markers in
response to β-AR agonists [50]. It has been reported that beige adipocytes are abundant in
inguinal subcutaneous WAT [47, 48]. However, visceral fat depots contain Ucp1-expressing
beige adipocytes, as well [51].

1.2.2 β-adrenergic Signaling: Regulation of Thermogenesis and Adipocyte Phenotype
Stimulation of β-adrenergic signaling is required for thermogenesis in both classical brown
adipocytes and beige adipocytes. There are three β-AR subtypes: β1-AR, β2-AR, and β3-AR.
Among these receptors, the most relevant to BAT physiology is β3-AR. The receptors couple
with the α subunit of stimulatory G protein (GαS) and activate adenylyl cyclase (AC). Activated
AC increases the level of intracellular cyclic adenosine monophosphate (cAMP), which activates
protein kinase A (PKA) also known as cAMP-dependent enzyme. PKA phosphorylates and
activates p38 mitogen-activated protein kinase (MAPK) and PGC-1α. PPARα and PPARγ
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interacts with activated PGC-1α, and induces expression of thermogenic genes, including Ucp1
(Figure 1.1) [46].
Lack of all three β-AR in mice leads to reduced Ucp1 expression in brown adipocytes.
Since these brown adipocytes are thermogenically inactive, a β-AR agonist does not increase
oxygen consumption rate of the cells, and cold exposure drops core body temperature of the mice
[52]. In addition, β-AR knockout mice had higher increase in fat mass compared to wild-type

Figure 1.1 β-adrenergic signaling (Modified from Zhang et al [53]). ATF2, activating
transcription factor 2; β-AR, β-adrenergic receptor; cAMP, cyclic adenosine monophosphate;
CREs, cAMP-regulatory elements; CREB, cAMP response element binding protein; FFA, free
fatty acids; p38MAPK, p38 mitogen-activated protein kinase; PGC1α, peroxisome proliferator
activated receptor-γ coactivator-1α; PKA, protein kinase A; PPARα, peroxisome proliferator
activated receptor α; PPARγ, peroxisome proliferator activated receptor γ; PPRE, peroxisome
proliferator response element; PRDM16, PRD1-BF1-RIZ1 homologous domain containing 16;
RXR, retinoid X receptor; UCP1, uncoupling protein 1; Zfp516, zinc-finger protein 516.
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mice without a difference in food intake when either chow or high-calorie diets were fed. This
indicates β-AR plays a critical role in inducing non-shivering thermogenesis through UCP1
upregulation and resistance to diet-induced obesity [52].
Catecholamines and cold exposure are strong stimulators of β-AR [54]. The prolonged
cold exposure and chronic β-adrenergic stimulation have been reported to lead to an adaptive
change in WAT. This also enhances the acquisition of a BAT-like phenotype and the appearance
of multilocular UCP1-positive adipocytes. This change is caused by a gradual reduction in the
size of lipid droplets (LD) due to the persistent activation of lipolysis. The number of small- or
micro-LDs, which appear throughout the cytoplasm after the β-adrenergic stimulation, increases
over time. The appearance of micro-LDs is known to be preceded by the breakdown of the preexisting large LDs. However, recent research data shows that de novo synthesis of LDs also
contributes to this [44].

1.2.3 Regulation of Adipocyte Differentiation and Differences in Obesity
Both white and brown adipocytes arise from multipotent mesenchymal precursor cells that are
able to differentiate into not only adipocytes but also myoblasts, fibroblasts, chondrocytes, and
osteoblasts. Among these cells, Myf5-expressing precursors could become myocytes and brown
adipocytes, but not white adipocytes [55]. The adipocyte life cycle consists of transformation of
undifferentiated preadipocytes, morphologically analogous to fibroblasts, into mature adipocytes
with spherical shape [56].
Preadipocytes are morphologically analogous to fibroblasts and express a high level of
preadipocyte factor-1 (Pref-1) at the growth phase. Since Pref-1 expression is dramatically
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decreased during adipocyte differentiation, it is used as a marker for preadipocytes [57]. When
preadipocytes reach confluence, they enter a growth arrest state prior to the differentiation
process. Growth-arrested cells have one round of DNA replication, which induces clonal
expansion, and increase expression of CCAAT/enhancer binding protein (C/EBP) β [58]. In the
committed white fat precursors, expression of transcription factors, including C/EBPα and
PPARγ, are upregulated [59]. These two transcription factors are known to crosstalk with each
other and induce adipocyte differentiation.
During the differentiation phase, the cells undergo extreme change in cell shape;
consequently, differentiated adipocytes have spherical shape. This morphological change of
adipocytes is involved in an extreme decrease in the expression of actin, tubulin [60], and
fibronectin [61]. At the terminal differentiation stage, C/EBPα and PPARγ target gene
expression levels are greatly increased [61]. The downstream target genes of both C/EBPα and
PPARγ are associated with lipid metabolism, such as lipogenic enzymes such as acetyl-CoA
carboxylase (ACC) and fatty acid synthase (FAS), and fatty acid binding proteins (FABP), the
upregulation of C/EBPα and PPARγ downstream genes promotes lipid accumulation in
adipocytes [62]. In addition, differentiated adipocytes become insulin-sensitive by increasing the
expression of glucose transporters (GLUT) and insulin receptors [63].
In the brown/beige adipogenesis program, PRD1-BF1-RIZ1 homologous domain
containing 16 (PRDM16) plays a significant role. It induces the commitment of the precursors to
brown preadipocytes by binding and modulating the activity of PPARα, PPARγ, and PGC-1α.
This increases mitochondrial biogenesis, and induces expression of brown-specific genes such as
UCP1 and CIDEA [64]. At the same time, PRDM16 suppresses skeletal muscle differentiation
by downregulating myotube-specific gene expression [55]. Prdm16 ablation was shown to
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suppress thermogenic phenotype of brown adipocytes and upregulate white adipocyte- or
myocyte-specific gene expression [65]. Subcutaneous WAT that is prone to brown-phenotype
acquisition highly expresses Prdm16 [64], and reduced Prdm16 expression in WAT decreases
activation of beige adipocytes in response to β-AR or PPARγ agonists [64, 66].
Leptin, a major adipokine, has been reported to regulate adipocyte differentiation.
Ectopic hyperleptinemia induced by infusion of adenovirus-leptin cDNA suppresses expression
of adipocyte markers, such as PPARγ, aP2 (adipocyte protein 2; also known as FABP4), and
LPL (lipoprotein lipase), and increases preadipocyte marker Pref-1 expression in epididymal fat
[67]. In addition, adenovirus-induced hyperleptinemia increased the number of mitochondria
[68], upregulates expression of oxidative genes, including ACO (Acetyl-CoA Oxidase), CPT1
(Carnitine Palmitoyl Transferase-1), UCP1, and UCP2, and downregulates expression of
lipogenic genes, including glycerol-3-phosphate acyltransferase (GPAT), FAS, and ACC, in
WAT [67, 68]. This transformation of white adipocytes into fat-less and mitochondria-rich cells
leads to body fat decrease in rats [67-69].
However, obesity-induced hyperleptinemia does not deplete fat mass due to suppression
of leptin receptor expression and leptin signaling, which is accompanied by reduced activation of
STAT3 and higher expression of SOCS3 [70]. When leptin receptor (Lepr-b) is overexpressed in
mice, body temperature is increased due to higher expression of oxidative genes, including Ucp1
and Pgc1a, and HFD feeding fails to induce body fat accumulation, and adipocyte hypertrophy
and hyperplasia [70].
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1.2.4

Regulation of Adipocyte Lipolysis and Implication for Obesity Susceptibility

In addition to thermogenesis, activation of β-adrenergic signaling leads to lipolysis, fatty acids
mobilization, β-oxidation, and the release of adipokines in WAT [71]. During energy
deprivation, triacylglycerol (TAG), a major source of energy storage, is hydrolyzed sequentially:
TAG is hydrolyzed by adipose triglyceride lipase (ATGL) or hormone-sensitive lipase (HSL) to
a fatty acid and diacylglycerol (DAG). DAG is hydrolyzed by HSL, which generates a fatty acid
and monoacylglycerol (MAG). MAG then releases the final fatty acid and glycerol by
monoglyceride lipase (MGL) [71].
Under basal conditions, perilipin coats the lipid droplet to prevent access of TAG lipases
and lipolysis [72]. In fasted states, catecholamines are released and bound to β-AR on adipocyte,
and β-adrenergic signaling is stimulated. Activation of cAMP-dependent PKA induces
phosphorylation of both perilipin and HSL. Phosphorylated perilipin dissociates from the lipid
droplet and facilitates translocation of phosphorylated and activated HSL to the lipid droplet
[73]. Although ATGL is not a PKA target, ATGL is also phosphorylated during fasting and
mediates TAG hydrolysis [74], and comparative gene identification-58 (CGI-58) binds to ATGL
for increasing the enzyme activity [75].
Insulin, the most potent anti-lipolytic hormone, inhibits lipolysis during refeeding by
activating phosphodiesterase 3B (PDE3B) and protein phosphatase-1 (PP1). When insulin binds
to the insulin receptor (IR), insulin receptor substrate-1 (IRS1) is activated by phosphorylation at
tyrosine residue, and phosphatidyl inositol kinase-3 (PI3K) and PP1 are activated. Activated
PI3K phosphorylates and activates protein kinase B (PKB)/Akt, which activates PDE3B. Since
PDE3B degrades cAMP, PKA activation is attenuated and lipolysis is reduced. Activated PP1
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dephosphorylates and deactivates HSL and perilipin, and suppresses lipolysis [71]. Insulin has
also been shown to cause downregulation of ATGL expression at the mRNA level [76].
During obesity, basal lipolysis is increased due to decreased insulin sensitivity. Obese
animals and humans have attenuated suppression of adipocyte lipolysis mediated by insulin [77,
78]. However, β-AR-stimulated lipolysis is also decreased in obesity. This is because obesity
upregulates anti-lipolytic α-AR expression, downregulates GαS, HSL, and perilipin expression
[71]. Obesity-induced leptin and TNFα overexpression also impairs insulin signaling [79, 80].
Insulin resistance leads to increased release of free fatty acids and glycerol, leading to
dyslipidemia and ectopic storage of lipids in the liver and muscle [81].
Interestingly, there is gender effect in the pattern of body fat distribution and regulation
of lipolysis. Compared to obese women, obese men have higher lipolytic responses both at the
basal level and on β-adrenergic stimulation [82]. This is because visceral fat depots release free
fatty acids more readily than subcutaneous fat depots [83], and obese men are more susceptible
to upper-body or visceral obesity while obese women are prone to have lower-body or
subcutaneous obesity [84]. Obese men have been shown to have 12 times higher sensitivity of
lipolytic β3-AR and 17 times lower sensitivity of anti-lipolytic α2-AR in omental adipocytes
compared to obese women [82]. Since visceral fat is adjacent to the liver, secreted free fatty
acids from visceral fat depots can exert adverse effects on the liver through the portal vein,
which contributes to the development of metabolic diseases, including dyslipidemia, insulin
resistance, atherosclerosis, and hypertension [85]. It has been reported that the higher waist-tohip ratio and abdominal diameter in obese men are related to the higher plasma insulin, glucose,
and TAG levels, the higher systolic and diastolic blood pressure, and the lower high-densi7yty
lipoprotein (HDL) cholesterol level than obese women [82].
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1.3

Inflammatory Responses in Obesity
1.3.1

Chronic Inflammation

1.3.1.1 Overview of Chronic Inflammation
Systemic chronic inflammation is known to play a significant role in the occurrence and the
development of cancers, obesity, diabetes, heart disease, and neurodegenerative diseases [86].
Inflammation-associated chronic diseases are estimated to account for approximately 70% and
63% of all-cause mortality in the United States and worldwide, respectively. Many
environmental factors have been identified as causes or contributors to chronic inflammation,
and these factors include non-nutritional factors, such as infectious, allergic, and irritating
agents; and nutritional factors, such as specific nutrients and the quantity of overall dietary intake
[87].

1.3.1.2 Role of Non-Nutritional Factors in the Regulation of Inflammation
Chronic inflammation and associated diseases may be caused by bacterial, viral, and parasitic
infection; and irritating or allergic responses resulting from chemicals and non-digestible
particles [88]. For instance, helicobacter pylori infection induces chronic mucosal inflammation
in the stomach with an increased infiltration of neutrophils, lymphocytes, and plasma cells into
the lamina propria. Chronic gastritis has been shown to increase the risk of gastric
adenocarcinoma [89]. Hepatitis B and C viruses cause chronic hepatitis, a major risk factor of
hepatocellular carcinoma [90]. Parasitic infection is also known to increase risk of cancers.
Chronic schistosomiasis, which can be caused by schistosoma parasite infection, induces cystitis
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and fibrosis, and increases the incidence of carcinoma of the rectum, bladder, and liver [91]. In
addition to infectious agents, irritating chemicals or non-digestible substances are known to lead
to chronic inflammation. In experimental animals, skin inflammation and skin cancer can be
developed by repeated administration of chemical irritants such as phorbol myristate acetate or
benzoyl peroxide, which produce various inflammatory mediators [90]. It has long been
recognized that many occupational diseases including pulmonary dysfunction and cancer are
caused by chronic exposure to non-digestible agents such as asbestos, coal, and silica dust. These
particles induce chronic lung inflammation because the immune system is not able to eliminate
the substances from the body, and such inflammatory states can be followed by epithelial cancers
including lung carcinoma [91].

1.3.1.3 Role of Nutritional Factors in the Regulation of Inflammation
In addition to non-nutritional environmental factors that are mentioned above, specific nutrients
such as micronutrients appear to regulate inflammation. Although saturated fatty acids are
known to directly induce inflammation through pattern recognition receptors (PRR) and the
downstream signaling pathways, long chain n-3 polyunsaturated fatty acids and the phenolic
compound group of phytochemicals are known to suppress inflammation by upregulating
expression of anti-inflammatory compounds [92]. Other kinds of phytochemicals are also
reported to effectively suppress inflammatory responses, and be efficacious in the treatment and
prevention of diabetes, cancers, cardiovascular diseases, obesity, and neurological diseases [93].
The amount of dietary intake and specific nutrient contents in diet are important factors
regulating inflammation, as well. For instance, overnutrition, which refers to a chronic positive

16

energy balance between energy consumption and energy expenditure, may contribute to
development of metabolic disorders by inducing chronic inflammation. Excessive dietary intake
has been shown to activate immune cells and result in metabolic stress, which can lead to
increase in the risk of chronic diseases including atherosclerosis and insulin resistance [94].
Particularly, chronic overconsumption of macronutrients is known to increase the mass of
adipose tissue as a result of adipocyte hyperplasia and hypertrophy. Hypertrophic adipocytes are
known to secrete a myriad of inflammatory cytokines, chemokines, or adipokines, which
promote infiltration of pro-inflammatory macrophages into the WAT [92]. Adipose tissue
inflammation can be transferred to other tissues involved in meta-inflammation, including liver,
skeletal muscle, and hypothalamus through adipokines in the bloodstream [2].

1.3.2

Characterization of Adipose Tissue Inflammation in Obesity

Obesity-induced systemic and low-level chronic inflammation is a significant contributor to the
progression and development of the diverse diseases, such as insulin resistance, cardiovascular
diseases, and cancers [95]. Various types of leukocytes, including macrophages, dendritic cells,
and T cells, reside in adipose tissue. Obesity stimulates quantitative and qualitative changes of
these inflammatory components. This change plays a key role in chronically elevated levels of
inflammatory cytokines and adipokines in obesity [95].
Adipose tissue macrophages (ATM), a dominant immune cell type in adipose tissue, form
10 to 15% of SVF of adipose tissue in lean state, and up to 50% of SVF in obese state [96].
There are two types of adipose tissue macrophages (ATM). Type 1 macrophages (M1) are
classically activated macrophages which secrete pro-inflammatory markers, such as tumor
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necrosis factor (TNF) α and interleukin (IL) 6, and generate reactive oxygen species (ROS) by
activating inducible nitric oxide synthase (iNOS). Type 2 macrophages (M2) are alternatively
activated macrophages which secrete anti-inflammatory markers, such as IL-10 and arginase that
block iNOS activity [97].
In lean subjects, M2 macrophages are more widely found in healthy adipose tissue and
control tissue homeostasis [97]. M2 macrophages express not only anti-inflammatory cytokines
but also catecholamine that are able to activate beige adipocytes by stimulating β-adrenergic
signaling pathway in WAT [98]. However, overnutrition induces ATM polarization from antiinflammatory M2 to pro-inflammatory M1 state, and increases the number of M1 macrophages.

Figure 1.2 ATM polarization and its function in adipose tissue with progressive obesity
(Modified from Lumeng et al [97]). CCR2, C-C motif chemokine receptor 2; CLS, crown-like
structure; FFA, free fatty acid; HFD, high-fat diet; IL-6, interleukin-6; IL-10, interleukin-10;
iNOS, inducible nitric oxide synthase; JNK, Jun N-terminal kinase; MCP-1, monocyte
chemoattractant protein 1; NF-κB, nuclear factor-κB; TNF-α, tumor necrosis factor-α.
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This alteration changes cytokine secretion and causes inflammation, which makes adipocytes
express and secrete monocyte chemotactic protein 1 (MCP-1), and MCP-1 recruits more M1
macrophages. Infiltrated M1 macrophages are located around dead adipocytes and form crownlike structures (CLS), which increases pro-inflammatory cytokine secretion (Figure 1.2) [96, 97,
99].

1.3.3 Mechanism of Inflammatory Signaling in Adipose Tissue in Obesity and Association
with Insulin Resistance
Increased infiltration of pro-inflammatory M1 macrophage activates nuclear factor-kappa B (NFĸB) signaling [97]. NF-ĸB, typically composed of p65 and p50 subunits, is a protein complex
which controls the transcription of genes associated with a variety of biologic processes,
including cellular stress responses, inflammation, innate and adaptive immunity, proliferation,
and cell survival [100].
Under basal condition, NF-ĸB is sequestered in the cytoplasm by binding to an inhibitory
protein IĸB, and transcriptionally inactive. In response to a variety of stimuli including oxidative
stress and genotoxic stress, TNF receptor-associated factor 6 (TRAF6)-included receptor
complex is recruited, and the activated receptor complex activates myeloid differentiation
primary response 88 (MyD88). Subsequently, NF-ĸB essential modulator (NEMO) activates IĸB
kinase (IKK) α and IKKβ, which phosphorylate IĸB [100]. Phosphorylated IĸB is ubiquitinated
and degraded by the proteasome [101], which allows NF-ĸB to translocate into the nucleus and
upregulate transcription of its downstream target genes involved in inflammation and immune
responses, such as cyclooxygenase (COX) 2 and IL-6 (Figure 1.3) [101]. NF-ĸB target genes
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also include numerous cytokine receptors, which modulate or amplify inflammatory responses;
and several pattern recognition receptors (PRR), such as toll-like receptors (TLR), retinoic acidinducible gene-I (RIG)-like receptors (RLR), and nucleotide-binding oligomerization domain
(NOD)-like receptors (NLR), which recognize pathogen-associated molecular patterns (PAMP)
[100]. Therefore, a constitutive activation of NF-ĸB is strongly connected to a number of
inflammatory diseases [101].

Figure 1.3 NF-ĸB signaling pathway (Modified from Lee et al [101]). IKK, IĸB kinase;
NEMO, NF-ĸB essential modulator; TLR, toll-like receptor; TNFR, tumor necrosis factor
receptor; Ub, ubiquitin.
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Insulin resistance is a good example of NF-ĸB-mediated inflammatory diseases. In
obesity, activation of NF-ĸB signaling can induce insulin resistance by inducing adipocyte
dedifferentiation or inducing phosphorylation of IRS1 at serine/threonine residues.
During differentiation, adipocytes express differentiation markers, including PPARγ and
C/EBPα. When they are fully differentiated, they express fatty acid synthase (FAS), fatty acid
binding proteins (FABP), and glucose transporters (GLUT), and become insulin sensitive [62].
Pro-inflammatory cytokines, target genes of NF-ĸB, are known to suppress adipogenesis in
human [102] and murine adipocytes [103]. Culturing human adipocytes in macrophageconditioned media and activated-macrophage conditioned media activates NF-ĸB signaling in
adipocytes by increasing phosphorylation of NF-ĸB p65 subunit and degradation of IĸB, which
results in downregulation of PPARγ, C/EBPα, FABP4, and FAS expression [104]. Since these

Figure 1.4 Insulin signaling transduction (a) under normal conditions (b) under obesityinduced inflammation (Modified from Birnbaum et al [105]). FFA, free fatty acid; IKK, IĸB
kinase; IRS-1, insulin receptor substrate-1; PI 3-kinase, phosphoinositide 3-kinase; TNF-α,
tumor necrosis factor-α.
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adipocytes are not insulin-sensitive, they cannot uptake glucose for TAG synthesis, leading to
ectopic lipid storage.
Under normal conditions (Figure 1.4a), IRS1 is phosphorylated at tyrosine residue in
response to binding of insulin to insulin receptor, resulting in increased glucose uptake and
decreased glucose output [105]. However, in obesity-induced inflammation (Figure 1.4b), NFĸB signaling is activated, and concentration of TNF-α or free fatty acids is increased. This
activates IĸB kinase (IKK), which phosphorylates serine or threonine residues of IRS1, inhibits
subsequent signaling reactions, and reduces glucose uptake [105].

1.4
1.4.1

Metabolic Effects of Long Chain Fatty Acids (LCFA)

Effects of LCFA on Adipocyte Differentiation and Lipid Metabolism

Dietary fatty acids and their metabolites have been reported modulate gene transcription,
translation, and post-translational modifications. Polyunsaturated fatty acids (PUFA) are able to
suppress transcription of lipogenic genes by functioning as activators or ligands for PPAR
isoforms and as antagonists of liver X receptors (LXR), and by downregulating the expression of
the sterol regulatory element-binding proteins (SREBP) [106].
PPAR proteins are ligand-activated transcription factors, and LCFAs act as natural
ligands for PPAR [107]. PPARγ activation controls the process of adipocyte differentiation
[108], but the effect of PPARγ is determined by the type of ligands activating the receptor [106].
Although PPARγ ligands promote differentiation of myoblasts and fibroblasts into adipocytes in
vitro [109, 110], synthetic PPARγ ligand treatments result in hyperplasia but not hypertrophy.
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While high-fat fed animals had both hypertrophy and hyperplasia [111], PUFA generally are able
to suppress both hyperplasia and hypertrophy induced by high-fat feeding [112]. PUFA activate
PPARγ better than saturated fatty acids and monounsaturated fatty acids (MUFA), and
compounds containing 16-20 carbons have the highest binding affinity [107].
PPARα regulates fatty acid oxidation, and PPARδ, expressed in the initial stages of
adipocyte differentiation [113], is considered to modulate clonal expansion causing increased
cell proliferation [114]. PUFA are known to activate PPARα and PPARδ better than MUFA or
saturated fatty acids (SFA) [107], and long-chain fatty acids are more efficient than very longchain fatty acids [115].
PUFA are also known to interfere with SREBP-1 and alter lipogenic gene expression
[116]. PUFA lower SREBP-1c mRNA levels, inhibit maturation of SREBP, and accelerate the
degradation of mature SREBP-1 [117, 118]. During adipocyte differentiation, highly induced and
proteolytically activated SREBP-1 mRNA directly transactivates the C/EBPβ promoter [119]
and induces expression of PPARγ [120]. LXRα, induced during adipocyte differentiation,
activates expression of PPARγ, SREBP-1c, and several lipogenic genes [121]. PUFA are potent
LXR antagonists compared to saturated and monounsaturated fatty acids [122].

1.4.2

Effects of LCFA on Thermogenesis and Adipose Tissue Phenotype

1.4.2.1 Peroxisome Proliferator-activated Receptors (PPAR) activation
PPAR isoforms interact with PGC-1α and bind to peroxisome proliferator response elements
(PPRE), which regulate expression of their target genes, including thermogenic genes [46].
Higher expression of PPARδ in BAT increases β-oxidation and expression of UCP1 and UCP3
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[107]. In immortalized brown adipocytes, chemical inhibition or genetic suppression of PPARα
and PPARδ is known to reverse upregulation of Ucp1 and Pgc1a induced by β-AR agonism
[123]. Deficiency of PPARδ in both WAT and BAT led to a rapid weight gain through impaired
thermogenesis in a mouse model due to lack of functional UCP1 [124].
LCFA are known natural ligands for PPAR proteins, and PUFA induce higher PPAR
activity than SFA and MUFA [107, 125]. Omega-3 PUFA have been reported to increase
thermogenic gene expression by PPAR activation [126]. Fish oil, rich in n-3 fatty acids such as
eicosapentaenoic acid (EPA; C20:5) and docosahexaenoic acid (DHA; C22:6), upregulates Ucp1
mRNA level [127] and stimulates thermogenic activity in BAT in rats [128]. Fish oil-rich HFD
suppresses HFD-induced weight gain and fat mass increase, and improves glucose tolerance and
dyslipidemia in mice by enhancing expression of thermogenic genes, including Ucp1, Pgc1a,
and Adrb3 (β3-AR encoding gene) [129]. EPA treatment also upregulates mitochondrial and
thermogenic gene expression in human and mouse inguinal subcutaneous adipocytes [130, 131].

1.4.2.2 Free Fatty Acid Receptor 4 (FFAR4) activation and microRNA expression
In addition to PPAR activation, n-3 PUFA are known to promote thermogenesis through other
mechanisms, such as activation of free fatty acid receptor 4 (FFAR4) or modulation of
microRNA (miR) expression [132]. FFAR4, also called as G-coupled protein receptor (GPR)
120, is a functional receptor for n-3 PUFA and expressed by n-3 PUFA treatment. In brown
adipocytes, EPA led to upregulation of Ucp1 and Cidea mRNA expression. However, when
FFAR4 was genetically suppressed, EPA-induced brown-specific gene upregulation was
reversed [132]. Knocking out FFAR4 in mice led to lower oxygen consumption rate in response

24

to β-adrenergic stimulation [133]. There is evidence that certain microRNA may be involved as
mediators of FFAR4 activation in response to PUFA. MicroRNAs are single-stranded noncoding RNA composed of 19 to 22 nucleotides. Notably, miR-30b and miR-378 induce
thermogenesis as downstream targets of cAMP signaling [134, 135]. Fish oil enrichment resulted
in higher core body temperature in HFD-fed mice compared to mice fed palm oil- or olive oilenriched HFD, which was associated with increased expression of miR-30b and miR-378 in
BAT [132]. These data indicate that n-3 PUFAs are able to mediate thermogenesis through
activation of FFAR4 and upregulation of miR-30b and miR-378.

1.4.2.3 Importance of n-6/n-3 Ratio of Fatty Acids and Oxylipin Formation
It has been reported that the ratio of n-6/n-3 in dietary fatty acids is critical in the regulation of
white adipogenesis and browning of WAT. In humans, the large increase in the prevalence of
overweight and obesity parallels the increase in the dietary n-6/n-3 ratio in the past 30 years [11],
and n-6 ARA levels in plasma or adipose tissue are positively correlated with body weight or
BMI [136, 137]. In both animal models and human subjects, diets with high ratio of n-6/n-3
increase body fat accumulation [138-140], and impair leptin signaling and energy homeostasis
[141, 142].
Arachidonic acid (ARA; C20:4, n-6) is an adipogenic component found in fetal bovine
serum (FBS) that is known to induce adipocyte differentiation, and ARA-derived prostacyclin
(prostaglandin I2 or PGI2) stimulates formation of white adipocytes [143]. Carbaprostacyclin, a
stable analog of prostacyclin induces lipid accumulation through the prostacyclin receptor (IP)
that is expressed on the surface of preadipocytes [144]. Body fat accumulation is suppressed in
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response to deletion of IP, indicating that prostacyclin signaling plays a key role in adipogenesis
[145]. In addition, cyclooxygenase (COX) metabolites, including PGE2 and PGF2α, inhibit
thermogenic gene expression by modulating PPARγ activity [146], and COX inhibition induced
by indomethacin increases the number of beige adipocytes in subcutaneous WAT [147]. Chronic
β-adrenergic stimulation decreases PG and PGI levels, and ARA supplementation impairs
brown-like phenotype acquisition of WAT induced by CL316,243 (a β3-AR agonist) [146]. In
contrast, n-3 EPA and DHA have been shown to block effects of ARA-derived eicosanoids [148150], which results in upregulation of thermogenesis and fatty acid oxidation, and reduction of
body fat mass [151, 152]. Given that linoleic acid (C18:2, n-6) can be elongated to ARA, the
composition of LNA can significantly affect adipocyte differentiation and browning via this
conversion to ARA and regulation of the COX pathway.

1.4.2.4 Transient Receptor Potential Vanilloid 1 (TRPV1) Activation by n-3 fatty acids
Transient receptor potential vanilloid 1 (TRPV1) is a non-selective cation channel expressed on
peripheral sensory neurons. Since TRPV1 modulates activity of sympathetic nervous system
(SNS) [153] through β-adrenergic signaling, deletion of TRPV1 leads to abolish SNS-mediated
energy expenditure [154]. As well as capsaicin [155] and capsinoids [156], n-3 fatty acids are
known as TRPV1 ligands [157]. Fish oil, rich in n-3 EPA and DHA, has been reported to
increase body temperature and oxygen consumption by inducing browning of WAT [154]. In
addition, fish oil induces elevation of cAMP concentration [132, 154] and β-blocker propranolol
prevents the effect of fish oil [154]. These data confirm that n-3 fatty acids stimulate β-

26

adrenergic receptors through TRPV1 activation. Thus, dietary content of n-3 fatty acid is an
important factor in regulating adipocyte browning via activation of the TRPV1 receptor.

1.4.3

Effects of LCFA on Inflammation

1.4.3.1 Pattern Recognition Receptors (PRR) activation
Pattern recognition receptors (PRR), also known as innate immune system receptors, recognize
pathogen-associated molecular patterns (PAMP), which induces synthesis of reactive oxygen or
nitrogen species, expression of pro-inflammatory cytokines, and activation of adaptive immune
responses [158]. Toll-like receptors (TLR), a good example of PRR, control inflammation and
immune responses by recognizing a variety of PAMP derived from viruses, bacteria, or fungi
[159]. Among multiple types of TLR, TLR4 is the first found TLR in humans, and agonized by
lipopolysaccharides (LPS), a structural component found in Gram-negative bacteria and
composed of polysaccharide and lipid A [160].
LPS binds to LPS-binding protein (LBP), which promotes binding of LPS to cluster of
differentiation 14 (CD14). CD14 leads LPS to cell surface and helps LPS bind to TLR4 [159].
This binding recruits MyD88 and IL-1 receptor-associated kinase (IRAK), promoting association
of TRAF6 that activates mitogen-activated protein kinase (MAPK). Through MAPK, TRAF6
activates IKK, inducing phosphorylation and degradation of IκB. Free NF-κB translocates into
the nucleus and upregulates pro-inflammatory cytokines [158].
Obesity or diabetes are shown to upregulate TLR2 and TLR4 in cellular membrane of
blood monocytes or subcutaneous white adipocytes [161]. TLR2 and TLR4 expression is
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positively correlated with BMI [162]. Since insulin suppresses TLR4 expression, insulin
resistance can exacerbate inflammation by increasing TLR4 expression [2].
SFA, such as palmitic acid (C16:0), stimulate inflammatory responses through TLR4,
whereas MUFA and PUFA are not able to activate TLR4 signal transduction [163]. This is
because lipid A, a part of LPS, has 6 SFA molecules with 12 to 16 carbons. When these fatty
acids were replaced with MUFA or PUFA, effects of LPS in pro-inflammatory responses were
highly suppressed [2]. SFA also activate TLR2 and NF-κB signaling, whereas DHA (C22:6, n-3)
inhibits TLR2 expression and NF-κB signaling [164] and improves insulin sensitivity in both
skeletal muscle and WAT of mice fed HFD [165]. In addition, EPA and DHA were shown to
suppress recruitment of TLR4 for lipid rafts [166]. Increased consumption of SFA in obesity is
linked to increased TLR4 activation and increased inflammation. Conversely, consumption of
EPA and DHA is associated with reduced activation of NF-κB and inflammation [167, 168].

1.4.3.2 Involvement of Fatty Acids in Eicosanoid Formation
Eicosanoids are signaling molecules that mediate multiple inflammatory pathways and include
prostaglandins (PG), leukotrienes (LT), thromboxanes (TX), and prostacyclins (PGI). Since they
are derived from n-6 fatty acid arachidonic acids (ARA; C20:4), formation of eicosanoids links
fatty acids and inflammation [169].
Upon binding of an agonist with G protein-coupled receptors (GPCR), phospholipase C
(PLC) is activated and hydrolyzes membrane-bound phosphatidylinositol 4,5-bisphosphate
(PIP2) into 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG activates protein
kinase C (PKC), which activates MAPK and extracellular signal-related kinase (ERK). MAPK
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phosphorylates and activates cytosolic phospholipase A2 (cPLA2). IP3, on the other hand, opens
calcium channels located on the endoplasmic membrane and causes the release of calcium into
the cytosol. The increased intracellular Ca2+ concentration induces p-cPLA2 translocation from
cytosol to the membrane which has ARA (C20:4, n-6)-contained phospholipids. p-cPLA2
cleaves ARA esterified with the sn-2 position of membrane phospholipids [170].
Cyclooxygenase (COX), lipoxygenase (LO), which is activated by ERK, and cytochrome
p450 (CYP) pathway converts the ARA to one or more eicosanoid products by oxygenation.
COX converts ARA into PG and TX, and LO converts ARA into hydroperoxyeicosatetraenoic
acid (HPETE) and generates LT. PGE2, expressed from macrophages, monocytes, and epithelial
cells, is responsible for pain and fever, and activates cytokine generation; and LTB4 expressed
from neutrophils is the most potent chemotactic agent [169].
Eicosanoids derived from n-6 and n-3 fatty acids have different effects on intensity of
inflammation. Compared to even-series eicosanoids derived from n-6 fatty acids, including PGE2
and LTB4; odd-series eicosanoids derived from n-3 fatty acids, including, including PGE3 and
LTB5, tend to be less active in promoting platelet aggregation, inflammation, and vascular
muscle contraction [171]. Since n-3 fatty acids, including EPA, compete with n-6 ARA in its
incorporation into the membrane phospholipids and in metabolism by COX, LO, and CYP,
dietary consumption of n-3 fatty acids could prevent excessive production of n-6 fatty acidderived eicosanoids by reducing the availability of ARA in the phospholipid membrane and the
metabolism of ARA [172]. In many previous studies, n-3 fatty acids, including α-linolenic acid
(ALA), EPA, and DHA, inhibit expression of pro-inflammatory genes by mitigating NF-κB
signaling [2, 167, 168] and reduce mortality rates caused by chronic diseases such as
cardiovascular diseases [2].
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1.4.3.3 Fatty Acids and the Endocannabinoid System
Endocannabinoids are bioactive lipid mediators that control both innate and adaptive immune
responses [173]. In addition to endogenous cannabinoid CB1 and CB2 receptors,
endocannabinoids activate other molecular targets, including transient receptor potential (TRP)
channels and PPAR isoforms [174, 175]. Endocannabinoid system, which consists of
endocannabinoids, their enzymes, and receptors, is dysregulated in chronic diseases, such as
cancer [176], metabolic [177], and cardiovascular disorders [178], and modulation of the system
attenuates inflammatory responses by reducing cytokine release, leukocyte infiltration, and
reactive oxygen or nitrogen species production [179].
The most studied endocannabinoids, anamide (or arachidonoylethanolamide; AEA) and
2-arachidonoylglycerol (2-AG), are derived from n-6 ARA [11], and dietary intake of n-6 and n3 fatty acids determine their concentrations. Linoleic acid (LNA; C18:2, n-6)-rich diet has been
shown to elevate AEA and 2-AG levels, and induce larger size of adipocytes and more
infiltration of macrophages in mice [180]. However, in white adipocytes derived from
epididymal WAT, n-3 fatty acid treatment reduced AEA and 2-AG levels [181], and mice fed n3 sufficient diet had lower 2-AG levels compared to compared to those fed n-3 deficient diet
[182]. Concentrations of other anti-inflammatory endocannabinoids N-eicosapentaenoyl
ethanolamine and N-docosahexaenoyl ethanolamine increased with n-3 PUFA consumption in
both obese mice and humans, and this was negatively correlated with insulin resistance [181].
Dietary n-3 fatty acids have also been reported to stimulate polarization of ATM toward an antiinflammatory M2 state, decrease macrophage infiltration, and improve insulin sensitivity in mice
[183, 184]. Thus, the endocannabinoid system may be critical in the regulation of adipocyte
metabolism, differentiation, and browning by 18-C fatty acids.
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1.4.3.4 Fatty Acids and PPAR activation
PPARα and PPARγ, which can be activated by fatty acids, are also known to suppress the
activity of NF-ĸB and the expression of NF-ĸB target genes, which eventually alleviate
inflammation in diverse inflammatory diseases such as obesity and type 2 diabetes [185]. PPARα
and PPARγ agonists inhibit NF-ĸB signaling pathway by directly interacting with NF-ĸB
complex or through competition with NF-ĸB for binding to transcriptional co-activators [186].
PPARα has been reported to suppress inflammatory pathways by reducing activation of NF-ĸB
signaling in macrophages and aortic smooth muscle cells [101], and PPARγ is also known to
downregulate inflammatory pathways in a diversity of cells [187]. PPARγ upregulates several
genes associated with anti-inflammatory actions [101], and downregulates chemokine and
chemokine receptor expression in adipocytes and macrophages, respectively [187]. PPARγ
depletion activates inflammatory responses in TNF-α-stimulated mature 3T3-L1 adipocytes
[187], and the constitutive activation of inflammatory signaling promotes the occurrence and
development of several inflammatory diseases [101]. EPA and DHA were shown to control
expression of genes involved in inflammatory responses in addition genes involved in lipid
metabolism by interacting with PPARα and PPARγ [188].

1.5

Conclusion

Identifying natural inducers of thermogenic gene expression in both BAT and WAT can provide
efficient and safe strategies for treatment and prevention of obesity and obesity-related chronic
diseases, such as type 2 diabetes, cardiovascular disease, and cancers [44, 50]. Previous studies
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have suggested that long-chain PUFA effectively regulate multiple metabolic responses and can
serve as critical regulators of brown and beige adipocyte activation. As natural ligands for
PPARs, LCFA promotes interaction between PPAR and PGC-1α and thermogenic gene
expression [46], and PUFA-induced FFAR or TRPV1 activation, microRNA expression, and
oxylipin formation are involved in thermogenic processes, as well [132]. Fatty acids with the
different number and position of double bonds are also able to regulate inflammatory responses
through PRR activation and production of eicosanoids or endocannabinoids [2], which
suppresses thermogenesis [189]. Although 18-carbon fatty acids are the most abundant fatty acid
class in diet and have multiple isomers in terms of the number and the position of double bonds,
only few studies investigated the effects of the fatty acids with 18 carbons on the regulation of
thermogenic and metabolic responses. Therefore, the objectives of this thesis were to determine:
1) Effects of 18-carbon fatty acids on brown-specific gene expression in 4 different types of
adipocytes (Chapter 2).
2) Effects of diets differing in composition of 18-carbon fatty acids on adipose tissue
thermogenesis in mice fed high-fat diets (Chapter 3).
3) Effects of 18-carbon fatty acids on both thermogenic and inflammatory markers in response to
lipopolysaccharide treatment in mice and murine primary adipocytes (Chapter 4).
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DIVERGENT RESPONSE OF MURINE AND PORCINE
ADIPOCYTES TO STIMULATION OF BROWNING GENES BY 18CARBON POLYUNSATURATED FATTY ACIDS AND BETAADRENERGIC AGONISTS

2.1

Abstract

Long-chain fatty acids (LCFA) are known to activate brown and beige adipocytes. However,
very little is known about the effects of the number and the position of double bonds in LCFA
with same length on brown fat-specific gene expression. To determine the specificity of LCFA in
the regulation of these genes in different adipocyte models, fully differentiated 10T1/2, 3T3-L1,
murine or porcine primary adipocytes (obtained from the subcutaneous fat pad of C57BL/6 mice
or Landrace x Yorkshire x Duroc crossbred piglets, respectively) were treated with 50 µM of the
following 18-carbon fatty acids: stearic acid (STA; 18:0), oleic acid (OLA; 18:1, ∆9), linoleic
acid (LNA; 18:2, ∆9,12), α-linolenic acid (ALA; 18:3, ∆9,12,15), γ-linolenic acid (GLA; 18:3,
∆6,9,12), or pinolenic acid (PLA; 18:3, ∆5,9,12) for 24 hours with or without 4-hour
norepinephrine (NE) treatment. Expression levels of thermoregulatory markers were measured
by quantitative real-time PCR. LNA, ALA, GLA, and PLA upregulated Ucp1 expression and
tended to upregulate Pgc1a expression in murine primary adipocytes, but not in 10T1/2, 3T3-L1,
and porcine primary adipocytes. In murine primary adipocytes, NE induced a higher expression
of Ucp1 and Pgc1a than non-NE-treated cells, and PLA augmented the NE effect. In 10T1/2
cells, NE upregulated Ucp1 and Pgc1a expression, but there was no fatty acid effect. However,
3T3-L1 cells were insensitive to both fatty acid and beta-adrenergic agonist stimulation. These
results indicate that different adipocyte cell types have different levels of sensitivity to both
LCFA and beta agonists in regard to induction of brown fat-specific gene expression.
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2.2

Introduction

Adipocytes are traditionally classified as either white adipocytes or brown adipocytes. White
adipocytes contain a large single lipid droplet, whereas brown adipocytes are multilocular with
numerous small lipid droplets. The ability to store large amount of lipids makes the white
adipocytes efficient at energy storage in the form of triacylglycerol, unlike brown adipocytes that
are efficient at generating heat [1, 2] through uncoupling protein (UCP1) mediated non-shivering
adaptive thermogenesis [2]. Beige adipocytes are recently identified inducible multilocular
UCP1-positive cells, which reside in white adipose tissue (WAT) depots [3]. Since they are
switchable, they are white cells in basal conditions, but in response to various stimuli such as
cold exposure and beta-adrenergic stimulation, they become brown-like cells. This brown-like
phenotype acquisition is termed “browning” or “beiging” of WAT, which is considered as a
promising strategy for obesity prevention and treatment [1, 3].
β-adrenergic receptor (β-AR) stimulation is required to induce thermogenesis in
adipocytes [4]. The signaling cascade starts when catecholamines bind to β-AR, leading to the
activation of adenylyl cyclase (AC), and increase in intracellular cyclic adenosine
monophosphate (cAMP) concentration and protein kinase A (PKA) activity. Activated PKA
activates p38 mitogen-activated protein kinase (MAPK) and PGC-1α. Activated PGC-1α then
interacts with peroxisome proliferator activated receptor (PPAR), retinoid X receptor (RXR), and
thyroid receptor, leading to induction of Ucp1 and other thermogenic genes [5].

47
Long-chain fatty acids (LCFA) are effective for regulating multiple metabolic processes
and the activity of key transcription factors. Polyunsaturated fatty acids (PUFA) are reported to
activate brown and beige adipocytes [6]. PUFA-rich diet-fed rats had a higher UCP1 content in
brown adipose tissue (BAT) compared to rats fed saturated fatty acid-rich diet [7]. Linoleic acid
and eicosapentaenoic acid (EPA) induced Ucp1 mRNA expression in BAT in mice [8]. Also,
EPA promoted brown and beige adipogenesis of mouse primary preadipocytes from BAT and
WAT depots [9], and enhanced beige phenotype acquisition and mitochondrial function in
human primary adipocytes [10]. However, effects of the number and the position of double
bonds, in fatty acids with same length, on brown fat-specific gene expression in mature
adipocytes have not been determined yet.
More importantly, the effect of the different LCFA in different adipocyte cell types has
not been investigated. The different adipocyte cell types commonly used in research are at
different stages of differentiation into white adipocytes, and so may respond differently to fatty
acid and adrenergic stimulation. The 3T3-L1 cells are the most commonly used cells because
they are fully committed to the white adipocytes phenotype and are able to store lipids in the
cytoplasm [11] after hormonally-induced stimulation. However, C3H10T1/2 (10T1/2) cells are
multipotent stem cells which can be differentiated into myocytes, chondrocytes, brown and white
adipocytes, and are at an earlier stage of commitment to becoming adipocytes than 3T3-L1 [12].
Murine adipose primary stromovascular cells are mostly preadipocytes that can be hormonally
induced to become adipocytes, but are also pliable in that they can be differentiated into brown,
beige, and white adipocytes [13]. Pig adipose-derived stromavascular cells represent a good
model for studying adipocyte metabolism in the absence of UCP1 because pigs do not have a
functional UCP1 protein. These cells acquire a white adipocyte phenotype after differentiation
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[14]. Therefore, this study was conducted to clarify the effect of the different LCFA in
phenotypic acquisition by the different cell types.

2.3

Materials and Methods
2.3.1

Cell Culture

Murine primary stromovascular cells were obtained from the subcutaneous inguinal fat pads of
C57BL/6 mice with collagenase digestion as described previously [15], and grown in Dulbecco’s
modified Eagle’s medium/F12 (DMEM/F12; Sigma-Aldrich, St Louis, Missouri) supplemented
with 10% fetal bovine serum (FBS; Corning, Corning, New York) and 1% antibiotic antimycotic
solution at 37°C and 5% CO2. Two days after confluence, cell differentiation was initiated with
DMEM/F12 with 10% FBS, 1.7μM insulin, 1μM dexamethasone, 500μM
isobutylmethylxanthine (IBMX), 1μM rosiglitazone, 17μM pantothenic acid, and 33μM biotin
for 6 days. Medium was changed every 3 days.
C3H10T1/2 (10T1/2; ATCC, Manassas, Virginia) cells were grown in DMEM containing
4500 mg/L glucose and L-glutamine (Sigma-Aldrich, St Louis, Missouri) supplemented with
10% bovine calf serum (BCS; HyClone, Logan, Utah), 1% antibiotic antimycotic solution
(Corning, Corning, New York), and 50ng/mL bone morphogenetic protein 4 (BMP4; PeproTech,
Rocky Hill, New Jersey) at 37°C and 5% CO2. Two days after confluence, cell differentiation
was initiated with DMEM with 10% FBS, 1.7μM insulin, 1μM dexamethasone, 500μM
isobutylmethylxanthine (IBMX), 1μM rosiglitazone, 17μM pantothenic acid, and 33μM biotin
for 6 days. Medium was changed every 3 days.
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3T3-L1 cells (ATCC, Manassas, Virginia) were grown in DMEM containing 4500 mg/L
glucose and L-glutamine supplemented with 10% BCS and 1% antibiotic antimycotic solution at
37°C and 5% CO2. Two days after confluence, cell differentiation was initiated with DMEM
with 10% FBS, 1.7μM insulin, 1μM dexamethasone, and 500μM IBMX. After 2 days, medium
was changed to DMEM with 10% FBS and 1.7μM insulin, and after another 2 days, changed to
DMEM with 10% FBS.
Porcine preadipocytes were isolated from subcutaneous adipose tissue from Landrace x
Yorkshire x Duroc crossbred piglets (Sus Scrofa) with collagenase digestion as described
previously [15], and cultured in DMEM/F12 with 10% FBS and 1% antibiotic antimycotic
solution at 37°C and 5% CO2. At 2 days of post-confluence, cells were induced to differentiate in
DMEM/F12 with 10% FBS, 1.7μM insulin, 1μM dexamethasone, 1μM rosiglitazone, 17μM
pantothenic acid, 33μM biotin, 1nM triiodothyronine (T3) for 9 days.
In all cell types, on the day of experiment, media was changed to DMEM with 10% FBS
without any of the differentiation-inducing supplements. All experiments were repeated 3-6
times (technical replicates).

2.3.2 Fatty Acid Preparation
Eighteen-carbon fatty acids, stearic acids (STA; 18:0), oleic acid (OLA; 18:1, ∆9), linoleic acid
(LNA; 18:2, ∆9,12), α-linolenic acid (ALA; 18:3, ∆9,12,15), γ-linolenic acid (GLA; 18:3,
∆6,9,12), and pinolenic acid (PLA; 18:3, ∆5,9,12), were of the purest grade (> 98% purity, free
from heavy metals, Cayman, Ann Arbor, Michigan), and dissolved in 0.9% NaCl solution. To
enhance solubility of STA in 0.9% NaCl, the solution was heated to 80°C, then cooled to 55°C.
Each fatty acid solution was mixed with 20% bovine serum albumin (BSA) in 0.9% NaCl to
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make the final concentration of the fatty acids to 5mM, and sterilized through a 0.2µm syringe
filter.
To determine the effects of the fatty acids on mature white adipocytes, murine cells
(10T1/2, 3T3-L1, and primary stromovascular cells) were treated for 24 hours with 50µM of the
fatty acids bound to BSA on day 6 of differentiation. Porcine cells on day 9 of differentiation
were also treated for 24 hours. For all cells, BSA was used as control.

2.3.3

Norepinephrine (NE) and β-Adrenergic Agonist Treatment

To determine combined effects of fatty acid treatment and β-adrenergic agonist stimulation,
10μM of NE (a non-selective β-adrenergic receptor agonist; Cayman, Ann Arbor, Michigan) was
used to treat cells for another 4 hours after initial 24-hour fatty treatment. To examine effects of
specific β-adrenergic receptor activation, 10μM of dobutamine (β1-agonist; Cayman, Ann Arbor,
Michigan), bambuterol (β2-agonist; Cayman, Ann Arbor, Michigan), or CGP12177Hydrochloride (β3-agonist; Tocris, Ballwin, Missouri) was used to treat differentiated cells for 4
hours.

2.3.4

Quantitative Real-time PCR

RNA was extracted using Trizol (Ambion, Austin, Texas), and 1 µg of RNA was reverse
transcribed to cDNA using M-MLV reverse transcriptase (Promega, Madison, Wisconsin).
Quantitative real-time PCR was performed on a Bio-rad iQ5 system (Bio-rad, Hercules,
California) using RT2 SYBR Green Fluor qPCR Mastermix (Qiagen, Germantown, Maryland).
Conditions for the PCR reactions were 95°C for 5 minutes, and then 50 cycles of 95°C for 10
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seconds, 55°C for 20 seconds, and 72°C for 20 seconds. We quantified expression of genes that
have been shown to be expressed in brown adipose tissue, including Ucp1, Pgc1a [16], Cidea
[1], and Prdm16 [17], and the rate limiting enzyme for fatty acid transport into mitochondria,
Cpt1a, by RT-PCR with normalization relative to 18S rRNA. Fold changes of gene expression
were calculated by the ΔΔCt method. Specific primer sequences used are shown in Table 2.1,
and amplification efficiency of the primers was 95% to 105%.

2.3.5

Statistical Analysis

One-way analysis of variance (ANOVA) was performed to determine overall significant
differences among different fatty acid treatment or specific β-adrenergic receptor activation.
Two-way ANOVA was performed to determine overall fatty acid and norepinephrine effects.
Tukey’s post-hoc test was used for individual comparisons. Data were presented as means ±
SEM and analyzed using SAS 9.4 (SAS Institute Inc., Cary, North Carolina).

2.4
2.4.1

Results

Effects of Fatty Acids on Brown-Fat Specific Gene Expression

The effect of LCFA exposure on expression level of selected metabolic genes (Ucp1, Pgc1a,
Cidea, Prdm16, and Cpt1a) in the different cell types was determined after the cells were treated
with 50µM of the fatty acids for 24 hours (Figure 2.1-2.4).
In murine primary adipocytes (Figure 2.1), brown and beige fat-specific uncoupling
protein Ucp1 was upregulated at the mRNA level by PUFA treatment. LNA, ALA, GLA, and
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PLA significantly upregulated Ucp1 expression in murine primary adipocytes (2-fold higher than
control, P<0.0001). The mRNA level of Pgc1a, a transcriptional coactivator of thermogenic
genes including Ucp1, tended to be higher in LNA-, ALA-, GLA-, or PLA-treated cells
(P=0.0705). The expression of the lipid droplet-associated cytoplasmic protein, Cidea, was lower
in STA, OLA, and GLA groups (59%, 45%, 32% lower than control, respectively; P<0.0001).
However, LCFA treatment did not affect expression of Prdm16, a key factor inducing brown
adipocyte phenotype, and Cpt1a, which mediates fatty acid oxidation required for thermogenesis,
at the mRNA level.
GLA-treated 10T1/2 adipocytes (Figure 2.2) tended to have higher Ucp1 expression
(P=0.0910). However, the mRNA expression of Pgc1a, Cidea, Prdm16, and Cpt1a were not
upregulated by fatty acid treatment in 10T1/2 cells.
In 3T3-L1 adipocytes (Figure 2.3), OLA and GLA tended to upregulate Ucp1 expression
(P=0.0840). None of the fatty acids did upregulate Pgc1a expression compared to the control
group. However, LNA- or PLA-treated cells had higher expression level of Pgc1a compared to
STA-treated cells (P=0.0410). No effect of fatty acids on Cidea and Cpt1a mRNA levels was
seen, and Prdm16 was not detected in 3T3-L1 cells.
In porcine adipocytes (Figure 2.4), there was no effect of fatty acid treatments on the
transcription of Ucp1 gene (although porcine adipocytes do not have a functional UCP1 protein,
Ucp1 gene is transcribed, and the transcript was measured). Pgc1a expression was below
detection limit and Prdm16 mRNA was not altered by fatty acid treatment. However, LNA and
PLA tended to upregulate mRNA level of Cpt1a (P=.0622).
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2.4.2

Combined Effects of Fatty Acid Treatment and β-Adrenergic Stimulation

To determine combined effects of fatty acids and β-adrenergic stimulation, cells were treated
with the non-selective β-agonist NE for an additional 4 hours after 24 hours of LCFA (50μM)
treatment (Figure 2.5-2.8).
In murine primary adipocytes (Figure 2.5), both FA and NE treatments were effective to
upregulate Ucp1 (FA, P=0.0030; NE, P=0.0031) and Pgc1a expression (FA, P=0.0170; NE,
P=0.0651). PLA was also effective in augmenting the upregulation of Ucp1 induced by NE
treatment. However, NE treatment downregulated Cidea mRNA level, and there was no fatty
acid effect. Expression of Prdm16 and Cpt1a expression was not altered by the two treatments.
Although NE-treated 10T1/2 cells (Figure 2.6) had higher Ucp1 and Pgc1a mRNA level
(P=0.0387, P=0.0124, respectively), and lower Cidea mRNA level (P=0.0056), FA treatment did
not have an additional effect. There was no effect of FA and NE treatment on Prdm16 and Cpt1a
expression in 10T1/2 cells.
In 3T3-L1 cells (Figure 2.7), there was no treatment effect on Ucp1, Pgc1a, Cidea, or
Cpt1a expression. NE treatment did not induce transcription of Prdm16.
In porcine primary adipocytes (Figure 2.8), neither NE nor LCFA changed Ucp1 and
Cidea expression level. Pgc1a transcripts were not detected after the treatments and Prdm16
expression was not different. However, Cpt1a expression was upregulated by both FA and NE
(P=0.0049, P=0.0276, respectively).
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2.4.3 Effects of Higher Concentration of Fatty Acids on NE-Induced Thermogenic Gene
Expression
To determine if NE effect masked the fatty acid effect, we pretreated increased concentration
(150µM) of fatty acids for 24 hours and treated NE for 4 hours. In mouse-derived adipocytes, the
higher concentration of fatty acids led to similar results as with 50µM of fatty acids (Figure 2.92.11). However, in NE-treated porcine primary adipocytes, 150μM of fatty acids tended to
upregulate Pgc1a expression (FA, P=0.0638; NE, P=0.0253) (Figure 2.12). This is in contrast to
results from pretreatment with 50μM of LCFA which did not affect Pgc1a expression (Figure
2.8). In addition, although NE and individual fatty acids did not significantly induce Prdm16, a
combination of NE and STA induced a higher level of Prdm16 relative to BSA treated control
(P=0.0095).

2.4.4 Effects of Specific β-Adrenergic Receptor Agonists on Brown Fat Marker Expression
Since NE, a non-selective β-agonist, was shown to induce brown fat markers, cells were treated
with selective β-adrenergic receptor (β-AR) agonists to determine effects of specific β-AR on
thermogenic gene expression (Figure 2.13-2.16).
In murine primary adipocytes (Figure 2.13), β1-AR and β3-AR agonists tended to
upregulate Ucp1 expression (P=0.0667). Pgc1a expression was upregulated by the β3-AR
agonist treatment (P=0.0219), and β2-AR and β3-AR agonist treatment upregulated Cpt1a
expression (P=0.0156). The β-AR agonist treatment did not influence Cidea and Prdm16 mRNA
expression levels.
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Although β1-AR and β3-AR agonist-treated 10T1/2 cells (Figure 2.14) had higher Ucp1
expression (P=0.0033), there was no effect of the agonists on Pgc1a, Cidea, Prdm16, and Cpt1a
expression in the cells.
3T3-L1 cells (Figure 2.15) were highly insensitive to agonist treatment. Among the
genes, only Cpt1a expression tended to be upregulated by β3-AR agonist (P=0.0686).
In porcine primary adipocytes (Figure 2.16), β1-AR agonist highly induced Ucp1 and
Pgc1a transcription (P<0.0001, P<0.0001, respectively). Cpt1a expression was also upregulated
by β3-AR agonist (P=0.0054). No effect of the agonists on Cidea and Prdm16 expression was
observed.

2.5

Discussion

Acquisition of brown-like phenotype by WAT has been proposed as a potential metabolic
strategy for diminishing the incidence of obesity and associated metabolic disorders. Therefore,
several recent studies have been conducted to investigate effects of various dietary bioactive
compounds for their potential to activate inducible brown-like phenotype in white adipocytes.
PUFA is reported as one of the effective stimuli to promote thermogenic capacity of adipocytes
[7-10]. However, there are no studies in which effects of different fatty acids with same chain
length on beige adipocyte activation in multiple adipocyte model has been studied.
In this study, the induction of Ucp1 and Pgc1a in murine primary white adipocytes by
NE, β3-AR agonists, and 18-carbon PUFA (LNA, ALA, GLA, and PLA) confirms that the fatty
acids can serve as metabolic modifiers by increasing thermogenic capacity of white adipocytes.
Eighteen-carbon PUFA-induced thermogenesis has been reported in in vivo studies [8, 18-20].
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Rats fed safflower oil, rich in LNA, had higher oxygen consumption and fat oxidation rate after
meals compared to beef tallow-fed rats [18]. ALA-rich perilla oil [8] and GLA-rich borage oil
[19] increased Ucp1 mRNA expression in BAT in rats. Korean pine nut oil, rich in PLA,
upregulated Ucp1 expression in BAT at both mRNA and protein level in mice [20]. In these
studies, upregulation of thermogenesis resulted in less body fat accumulation.
The possible mechanism of PUFA-induced thermogenesis could be through the activation
of peroxisome proliferator-activated receptors (PPAR). This is because LCFA act as natural
ligands for all three PPAR subtypes [21], and PPAR agonists have been shown to upregulate
thermogenic genes [22-25]. Rosiglitazone, a PPARγ agonist, promoted Ucp1 mRNA expression
in mouse primary brown preadipocytes [22], in mouse primary white adipocytes [23], and in
human multipotent adipose-derived stem cells [24]. Other PPARγ agonists, including 15-deoxyΔ12,14-Prostaglandin J2 and BRL49653, also activated Ucp1 gene transcription in differentiated
brown adipocytes isolated from mouse BAT; and PPARα agonists, including fenofibrate,
bezafibrate, and Wy14,643, led to the same outcome [25]. In contrast, when PPARα and PPARδ
were chemically inhibited or genetically suppressed, Ucp1 and Pgc1a upregulation induced by βadrenergic stimulation was decreased in immortalized brown adipocytes [26]. These data support
a possibility that 18-carbon PUFA may induce brown-like phenotype in murine primary white
adipocytes through PPAR activation.
In fully differentiated murine primary adipocytes, PLA augmented NE-induced Ucp1 and
Pgc1a upregulation. PLA is a unique fatty acid found in pine nut oil, and Korean pine nut oil was
reported to decrease body weight gain [27], and attenuate body fat accumulation [28] in vivo. It
also promoted thermogenic response of BAT by activating p38 MAPK [20] and induced hepatic
fatty acid oxidation in high-fat diet-induced obese mice [29]. In C2C12 myocytes, PLA
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increased PPARα and PPARδ activity, and upregulated Ucp3 and Pgc1a expression [20]. This
may imply that PLA may act as a significant inducer of the thermogenic response in murine
primary white adipocytes.
Although fatty acid treatment alone was not effective, NE or selective β3-AR agonist
treatment significantly upregulated thermogenic gene expression in mature 10T1/2 adipocytes.
However, these cells had much lower relative expression of Ucp1 (indicated by higher Ct in the
simultaneously performed PCR) than murine primary adipocytes, indicating that brown fatspecific gene expression is less inducible in fully differentiated 10T1/2 adipocytes compared to
murine primary adipocytes. The lower Ucp1 expression in 10T1/2 white adipocytes may be
caused by BMP4 that was used to treat 10T1/2 stem cells during proliferation phase to induce
adipogenic lineage commitment [12]. BMP4 was reported to induce lipid accumulation in
10T1/2 stem cells by upregulating adipocyte markers, such as PPARγ, C/EBPα, and aP2 [30],
but in brown preadipocytes, it suppressed Ucp1 expression [31]. Also, mice in which Bmp4 was
overexpressed had reduced BAT mass and activity, and white-like adipocytes were observed in
the interscapular BAT [32]. These results suggest that BMP4 drives white adipose differentiation
and but may inhibit brown and beige adipogenesis, which may explain the comparatively lower
thermogenic gene expression level in mature 10T1/2 white adipocytes.
However, in contrast to the expression of Ucp1 and Pgc1a, another brown fat-specific
gene, Cidea, was downregulated by fatty acids and NE treatment in murine primary adipocytes,
and by NE treatment in 10T1/2 adipocytes. Although Cidea is highly expressed in BAT, more
than 50-fold compared to other tissues [33], induction of Cidea expression does not always
accompany thermogenic gene induction. In mouse liver, upregulation of Cidea did not alter
Ucp1 mRNA expression [34]. In addition, Cidea ablation resulted in lean and obesity-resistant
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phenotype in mice by inducing higher body temperature and oxygen consumption rate, which
suggests that CIDEA inhibits thermogenesis [35]. In the same study, it was observed that CIDEA
was co-precipitated with UCP1 in 293T cells, and co-expression of CIDEA with UCP1 inhibited
uncoupling activity of UCP1 in yeast cells [35]. These indicate that CIDEA suppresses UCP1
activity by binding to UCP1, and CIDEA-induced UCP1 inhibition is considered to improve
UCP1-mediated thermogenesis by increasing the threshold for UCP1 activity [33].
In the current study, while β3-AR agonist tended to upregulate Cpt1a expression in
mature 3T3-L1 white adipocytes, none of the other treatments induced thermogenic gene
expression in these cells. This result is consistent with earlier studies that reported no induction
of thermogenic gene expression in fully differentiated 3T3-L1 cells [36-39]. All-trans retinoic
acid failed to upregulate Ucp1 expression in 3T3-L1 adipocytes, although it upregulated fatty
acid oxidation-related genes and downregulated lipogenic genes [36]. Furthermore, resveratrol
did not induce Ucp1 expression in mature 3T3-L1 cells, although it significantly upregulated its
expression in primary adipocytes derived from mouse embryonic fibroblasts [37] and in
differentiating 3T3-L1 preadipocytes [38]. BMP7, which induces brown adipogenesis by
upregulating P38 MAPK activation and Ucp1 expression [39], was not effective in 3T3-L1 white
adipocytes whereas it upregulated UCP1 expression in 10T1/2 cells [31], in murine, and in
human primary preadipocytes isolated from subcutaneous fat depot [40]. These results suggest
that mature 3T3-L1 adipocytes may be resistant to trans-differentiation into brown-like
adipocytes.
Pigs lack a functional UCP1 due to the deletion of exons 3 to 5 in the Ucp1 sequence
[14]. In this study, the transcript of exon 6 was measured to quantify Ucp1 mRNA expression in
porcine primary white adipocytes. Neither the LCFA nor the specific adrenergic agonists, except
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β1-AR agonist, induced Ucp1 transcription. However, β1-AR agonist highly upregulated both
Ucp1 and Pgc1a expression, which might be due to the high β1-AR expression in pig
subcutaneous adipose tissue [41]. The relative expression (in percentages) of β1-AR, β2-AR, and
β3-AR in adipose tissue is 73, 20, and 7 [41]. Although LCFA treatment alone did not induce
Pgc1a transcription in porcine adipocytes, NE treatment upregulated Pgc1a expression when the
cells were pretreated with the high concentration (150µM) of fatty acids. Since Pgc1a increases
oxidative metabolism by inducing mitochondrial biogenesis, it remains a possibility that Pgc1a
was upregulated to enhance fatty acid oxidation capacity to match the increased fatty acid
supply. In support of this possibility, Cpt1a expression was upregulated by NE, a physiological,
but non-selective adrenergic agonist, presumably to further increase fatty acid oxidation. In the
piglets, noradrenaline has been shown to produce thermogenic responses [42] by increasing
metabolic rate in white adipose tissue [43]. This implies that enhanced fatty acid oxidation in
white fat may be a compensatory mechanism of thermogenic induction to overcome the absence
of UCP1 in pigs.
PRDM16 plays a significant role in the brown adipogenesis program by modulating
PPAR and PGC-1α activity and inducing UCP1 expression [44]. Prdm16 overexpression
increased beige adipogenesis in mice [17], and Prdm16 knockdown decreased thermogenic
characteristics of brown adipocytes [45]. However, in this study, neither fatty acids, NE, nor βAR agonists upregulated its expression in 10T1/2 and murine primary adipocytes. In 3T3-L1
Prdm16 transcript was undetectable, perhaps suggesting that 3T3-L1 has a lower ability to
acquire brown-like phenotype compared to 10T1/2 and murine primary white adipocytes. In
porcine primary adipocytes, although neither the individual fatty acids, NE nor the selective βAR agonists upregulated Prdm16 expression, its significant induction by a combination of NE
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and high-level STA (150µM) may indicate the importance of simultaneous β-AR activation and
high level of STA in the induction of Prdm16 through mechanisms that are still unclear.
A major limitation of this study is that only gene expression information could be
presented due to the low abundance of quantifiable proteins for the browning markers studied.
Nevertheless, the current results indicate that brown fat-specific gene expression is highly
inducible in murine primary white adipocytes compared to other mouse-derived adipocytes, and
18-carbon PUFA might enhance browning by acting as metabolic modifiers of the browning
process (Figure 2.17). Therefore, although speculative, increased dietary PUFA consumption or
PUFA supplementation of human diets could lead to induction of thermogenic gene expression
in WAT, and this may translate to increased thermogenesis and reduction of obesity risk.
However, additional studies in animals and humans are needed to determine the overall effects of
LCFA on adipose tissue phenotype.
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Table 2.1 The primer sequences used for quantitative Real-time PCR1
Species

Gene

Forward Primer

Reverse Primer

Product Length

Mouse/Pig

18S

ATC CCT GAG AAG TTC CAG CA

CCT CTT GGT GAG GTC GAT GT

153

Mouse

Ucp1

GGG CCC TTG TAA ACA ACA AA

GTC GGT CCT TCC TTG GTG TA

196

Mouse

Pgc1a

GTC CTT CCT CCA TGC CTG AC

GTG TGG TTT GCT GCA TGG TT

151

Mouse

Cidea

GCC GTG TTA AGG AAT CTG CTG

GTA TGT GCC CGC ATA GAC CA

81

Mouse

Prdm16

GGC TCA AGG AGG AGG AGA GA

AGG TCC GGG TCA GGT TCA TA

122

Mouse

Cpt1a

GGA CTC CGC TCG CTC ATT

GAG ATC GAT GCC ATC AGG GG

118

Pig

Ucp1

GGA TCC TGG AAC GTC AT

AGA TTC CCA CTG GTC TGT T

128

Pig

Pgc1a

TAA AGA TGC CGC CTC TGA CT

TGA CCG AAG TGC TTG TTC AG

168

Pig

Cidea

TGG GCT CCT GCA ATA AAC CC

CGA CTG AGT TTT GCT TCT CTG TG

104

Pig

Prdm16

CCC GCC TGG TGT AGG AAT TT

TGG GGT GTT TGT AAC GGA GG

83

Pig

Cpt1a

GTC AGC GTA GCA AGT GGA CA

GTG ACG TTA CAT CCC CTG CT

195

1

18S, 18S ribosomal RNA; Ucp1, Uncoupling protein 1; Pgc1a, Peroxisome proliferator-activated receptor gamma coactivator 1alpha; Cidea, Cell death-inducing DFFA-like effector A; Prdm16, PR domain containing 16; Cpt1a, Carnitine palmitoyl-transferase
1A.
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Figure 2.1 Effects of 18-carbon fatty acids on brown fat-specific gene expression in murine
primary adipocytes.
Differentiated inguinal fat pad-derived adipocytes were treated for 24 hours with 50 µM of each
fatty acid or BSA. Gene expression was determined by RT-PCR. Data are presented as means ±
SEM (n=6 for each group). Different superscript letters (A, B, and C) indicate significant
treatment difference at P < 0.05 by Tukey’s multiple comparison test.
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Figure 2.2 Effects of 18-carbon fatty acids on brown fat-specific gene expression in 10T1/2
adipocytes.
Differentiated C3H10T1/2 adipocytes were treated for 24 hours with 50 µM of each fatty acid or
BSA. Gene expression was determined by RT-PCR. Data are presented as means ± SEM (n=6
for each group).
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Figure 2.3 Effects of 18-carbon fatty acids on brown fat-specific gene expression in 3T3-L1
adipocytes.
Differentiated 3T3-L1 adipocytes were treated for 24 hours with 50 µM of each fatty acid or
BSA. Gene expression was determined by RT-PCR. Data are presented as means ± SEM (n=6
for each group). Different superscript letters (A and B) indicate significant treatment difference
at P < 0.05 by Tukey’s multiple comparison test. N.D.= not detected.
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Figure 2.4 Effects of 18-carbon fatty acids on brown fat-specific gene expression in porcine
primary adipocytes.
Differentiated subcutaneous fat pad-derived adipocytes were treated for 24 hours with 50 µM of
each fatty acid or BSA. Gene expression was determined by RT-PCR. Data are presented as
means ± SEM (n=3 for each group). N.D.= not detected.
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Figure 2.5 Combined effects of 50 μM fatty acids and β-adrenergic stimulation in murine
primary adipocytes.
Differentiated inguinal fat pad-derived adipocytes were treated for 24 hours with 50 µM of each
fatty acid or BSA followed by additional 4-hour treatment of 10 µM norepinephrine (NE). Gene
expression was determined by RT-PCR. Data are presented as means ± SEM (n=3 for each
group). Different superscript letters (A, B, and C) indicate significant treatment difference at P <
0.05 by Tukey’s multiple comparison test.
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Figure 2.6 Combined effects of 50 μM fatty acids and β-adrenergic stimulation in 10T1/2
adipocytes.
Differentiated C3H10T1/2 adipocytes were treated for 24 hours with 50 µM of each fatty acid or
BSA followed by additional 4-hour treatment of 10 µM norepinephrine (NE). Gene expression
was determined by RT-PCR. Data are presented as means ± SEM (n=3 for each group). Different
superscript letters (A, B, and C) indicate significant treatment difference at P < 0.05 by Tukey’s
multiple comparison test.
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Figure 2.7 Combined effects of between 50 μM fatty acids and β-adrenergic stimulation in
3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated for 24 hours with 50 µM of each fatty acid or
BSA followed by additional 4-hour treatment of 10 µM norepinephrine (NE). Gene expression
was determined by RT-PCR. Data are presented as means ± SEM (n=3 for each group). N.D.=
not detected.
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Figure 2.8 Combined effects of between 50 μM fatty acids and β-adrenergic stimulation in
porcine primary adipocytes.
Differentiated subcutaneous fat pad-derived adipocytes were treated for 24 hours with 50 µM of
each fatty acid or BSA followed by additional 4-hour treatment of 10 µM norepinephrine (NE).
Gene expression was determined by RT-PCR. Data are presented as means ± SEM (n=3 for each
group). Different superscript letters (A, B, and C) indicate significant treatment difference at P <
0.05 by Tukey’s multiple comparison test. N.D.= not detected.
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Figure 2.9 Effects of 150 μM fatty acids on NE-induced thermogenic gene expression in
murine primary adipocytes.
Differentiated inguinal fat pad-derived adipocytes were treated for 24 hours with 150 µM of each
fatty acid or BSA followed by additional 4-hour treatment of 10 µM norepinephrine (NE). Gene
expression was determined by RT-PCR. Data are presented as means ± SEM (n=3 for each
group). Different superscript letters (A, B, and C) indicate significant treatment difference at P <
0.05 by Tukey’s multiple comparison test.
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Figure 2.10 Effects of 150 μM fatty acids on NE-induced thermogenic gene expression in
10T1/2 adipocytes.
Differentiated C3H10T1/2 adipocytes were treated for 24 hours with 150 µM of each fatty acid
or BSA followed by additional 4-hour treatment of 10 µM norepinephrine (NE). Gene
expression was determined by RT-PCR. Data are presented as means ± SEM (n=3 for each
group). Different superscript letters (A and B) indicate significant treatment difference at P <
0.05 by Tukey’s multiple comparison test.
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Figure 2.11 Combined effects of between 150 μM fatty acids and β-adrenergic stimulation
in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated for 24 hours with 150 µM of each fatty acid or
BSA followed by additional 4-hour treatment of 10 µM norepinephrine (NE). Gene expression
was determined by RT-PCR. Data are presented as means ± SEM (n=3 for each group). N.D.=
not detected.
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Figure 2.12 Effects of 150 μM fatty acids on NE-induced thermogenic gene expression in
porcine primary adipocytes.
Differentiated subcutaneous fat pad-derived adipocytes were treated for 24 hours with 150 µM of
each fatty acid or BSA followed by additional 4-hour treatment of 10µM norepinephrine (NE).
Gene expression was determined by RT-PCR. Data are presented as means ± SEM (n=3 for each
group). Different superscript letters (A, B, and C) indicate significant treatment difference at P <
0.05 by Tukey’s multiple comparison test.
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Figure 2.13 Effects of selective β-adrenergic agonists on brown fat-specific gene expression
in murine primary adipocytes.
Differentiated inguinal fat pad-derived adipocytes were treated for 4 hours with 10 µM of
dobutamine (β1-agonist), bambuterol (β2-agonist), or CGP12177-Hydrochloride (β3-agonist).
Gene expression was determined by RT-PCR. Data are presented as means ± SEM (n=4 for each
group). Different superscript letters (A and B) indicate significant treatment difference at P <
0.05 by Tukey’s multiple comparison test.
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Figure 2.14 Effects of selective β-adrenergic agonists on brown fat-specific gene expression
in 10T1/2 adipocytes.
Differentiated C3H10T1/2 adipocytes were treated for 4 hours with 10 µM of dobutamine (β1agonist), bambuterol (β2-agonist), or CGP12177-Hydrochloride (β3-agonist). Gene expression
was determined by RT-PCR. Data are presented as means ± SEM (n=4 for each group). Different
superscript letters (A, B, and C) indicate significant treatment difference at P < 0.05 by Tukey’s
multiple comparison test.
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Figure 2.15 Effects of selective β-adrenergic agonists on brown fat-specific gene expression
in 3T3-L1 adipocytes.
Differentiated 3T3-L1 adipocytes were treated for 4 hours with 10 µM of dobutamine (β1agonist), bambuterol (β2-agonist), or CGP12177-Hydrochloride (β3-agonist). Gene expression
was determined by RT-PCR. Data are presented as means ± SEM (n=4 for each group). N.D.=
not detected.
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Figure 2.16 Effects of selective β-adrenergic agonists on brown fat-specific gene expression
in porcine primary adipocytes.
Differentiated subcutaneous fat pad-derived adipocytes were treated for 4 hours with 10 µM of
dobutamine (β1-agonist), bambuterol (β2-agonist), or CGP12177-Hydrochloride (β3-agonist).
Gene expression was determined by RT-PCR. Data are presented as means ± SEM (n=4 for each
group). Different superscript letters (A and B) indicate significant treatment difference at P <
0.05 by Tukey’s multiple comparison test.

82

Figure 2.17 Ucp1, Prdm16, and Ppara mRNA expression in different mouse-derived
adipocytes.
Differentiated murine primary (inguinal fat pad-derived), C3H10T1/2, and 3T3-L1 adipocytes
were treated for 24 hours with BSA. Gene expression was determined by RT-PCR. Data are
presented as means ± SEM (n=3-6 for each group). Different superscript letters (A and B)
indicate significant treatment difference at P < 0.05 by Tukey’s multiple comparison test. N.D.=
not detected.
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EFFECTS OF DIETS DIFFERING IN COMPOSITION
OF 18-C FATTY ACIDS ON ADIPOSE TISSUE THERMOGENIC
GENE EXPRESSION IN MICE FED HIGH-FAT DIETS

3.1

Abstract

Dietary fatty acids play important roles in the regulation of fat accumulation or metabolic
phenotype of adipocytes, either as brown or beige fat. However, a systematic comparison of
effects of diets with different composition of 18-C fatty acids on browning/beiging phenotype
has not been done. In this study, we compared the effects of different dietary fats, rich in specific
18-carbon fatty acids, on thermogenesis and lipid metabolism. Male C57BL/6 mice were fed a
control diet containing 5.6% kcal fat from lard and 4.4% kcal fat from soybean oil (CON) or
high-fat diets (HFD) containing 25% kcal from lard and 20% kcal fat from shea butter (stearic
acid-rich fat; SHB), olive oil (oleic acid-rich oil; OO), safflower oil (linoleic acid-rich oil; SFO),
or soybean oil (mixed oleic, linoleic, and α-linolenic acids; SBO) ad libitum for 12 weeks, with
or without a terminal 4-h norepinephrine (NE) treatment. When compared to SHB, feeding OO,
SFO, and SBO resulted in lower body weight gain. The OO fed group had the highest
thermogenesis level, which resulted in lower body fat accumulation and improved glucose and
lipid metabolism. Feeding SFO downregulated expression of lipid oxidation-related genes and
upregulated expression of lipogenic genes, perhaps due to its high n-6:n-3 ratio. In general,
HFD-feeding downregulated Ucp1 expression in both subcutaneous and epididymal white
adipose tissue, and suppressed NE-induced Pgc1a expression in brown adipose tissue. These
results suggest that the position of double bonds in dietary fatty acids, as well as the quantity of
dietary fat, may have a significant effect on the regulation of oxidative and thermogenic
conditions in vivo.
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3.2

Introduction

Obesity, which is a condition of excessive adipose tissue accumulation [1], increases the risk of
metabolic disorders, such as type 2 diabetes, dyslipidemia, and cardiovascular diseases [2].
Consumption of high fat diet contributes to obesity development because fatty acids increase
caloric density of diets, and dietary fatty acids and their metabolites modulate the transcription of
lipogenic and lipolytic genes [3]. However, fatty acids differentially regulate metabolism and
exert divergent effects on obesity occurrence. For example, as compared to monounsaturated
(MUFA) or saturated fatty acids (SFA), polyunsaturated fatty acids (PUFA) are potent
suppressors of transcription of lipogenic genes through peroxisome proliferator-activated
receptors (PPAR) mediated mechanisms [4], as antagonists of liver X receptors (LXR) [5], or by
downregulating the expression of the sterol regulatory element-binding proteins (SREBP) [6].
PUFAs are also able to increase energy expenditure by stimulating thermogenesis in
classical brown adipocytes and beige adipocytes [7-10]. Brown adipocytes are known to
dissipate energy through thermogenesis, whereas white adipocytes mostly store energy [11].
However, beige adipocytes that reside in white adipose tissue (WAT) depots act like brown
adipocytes in response to cold exposure and β-adrenergic stimulation [12]. Several studies have
been done on the metabolic effects of fish oil-derived fatty acids, eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), on adipose tissue phenotype. Treatment with EPA promoted
thermogenic capacity in mouse primary white and brown adipocytes [7, 8], and dietary fish oil
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upregulated thermogenic markers in murine brown adipose tissue (BAT) [9, 10] and WAT [10].
However, very few studies have been conducted to compare the effects 18-carbon fatty acids, the
most abundant dietary fatty acids, on the regulation of brown/beige phenotype and
thermogenesis.
Therefore, this study was conducted to examine effects of diets rich in different 18carbon fatty acids on adipose tissue thermogenic gene expression profile. To investigate effects
of different isomers of 18-carbon fatty acids, diets rich in shea butter (high stearic acid; STA,
18:0), olive oil (high oleic acid; OLA, 18:1), safflower oil (high linoleic acid; LNA, 18:2), or
soybean oil (mixed OLA, LNA, and α-linolenic acid; ALA, 18:3) were fed to mice. We also
tested effect of acute β-adrenergic stimulation with norepinephrine to determine if interaction
existed between dietary fat and β-adrenergic receptor activation on thermogenic gene expression
in adipose tissue and overall metabolic phenotype.

3.3

Materials and Methods

3.3.1

Animals and Diets

All of the animal procedures were approved and carried out in accordance with the regulations of
the Purdue Animal Care and Use Committee. Four-week-old male C57BL/6J mice were
purchased from the Jackson Laboratory and were maintained on a chow diet for four days before
being assigned to one of five diet groups; control diet containing 5.6% kcal fat from lard and
4.4% kcal fat from soybean oil (CON) or high-fat diets (HFD) containing 25% kcal from lard
and 20% kcal fat from shea butter (SHB; STA rich), olive oil (OO; OLA rich), safflower oil
(SFO; LNA rich), or soybean oil (SBO; mixture of OLA, LNA, and ALA). All diets, including
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the CON diet, were based on purified ingredients to keep the diet matrices across diets the same
for easy comparison. In addition, the ratio of vegetable oil to lard was kept at approximately 1.25
in all diets for uniformity. Diets were made to contain oils from different sources, rather than a
single source, so that these diets would be more akin to human diets, which typically have oils
from different sources, as much as possible.
Mice (n = 8 per group) were fed the experimental diets ad libitum for 12 weeks. Table
3.1 shows the composition of the experimental diets. Mice were housed in environmentally
controlled housing (temperature = 72 ± 2 °F; humidity = 35 ± 5%), and a 12 hour-light-dark
cycle. Body weight was measured once a week, and food intake was measured two times a week.
At the end of the experimental period, mice were injected with norepinephrine (NE; 2 mg/kg
body weight) or phosphate-buffered saline (PBS; 2 mL/kg body weight) after an 8 h fast, and
euthanized with CO2 asphyxiation 4 h after the injection. Serum was separated from blood after
centrifugation at 2000 × g for 10 min at 4 °C. Subcutaneous and epididymal white adipose tissue
(WAT), brown adipose tissue (BAT), liver, hamstring muscle, and hypothalamus were removed,
weighed, and snap-frozen in liquid nitrogen, and stored at −80 °C until subsequent analyses.

3.3.2

Fatty Acid Composition of Diets

Total lipids were extracted from powdered diets using modified Folch method [13]. Fatty acids
in extracted lipid samples were trans-esterified to form fatty acid methyl esters (FAME) with
sodium methoxide in methanol. FAMEs were extracted with hexane, and the extracts were
analyzed by gas chromatography (Varian 3900 gas chromatography system with CP-8400
autosampler; Agilent, Santa Clara, CA, USA). Fatty acid composition of diets is shown in Table
3.2.
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3.3.3

Indirect Calorimetry

After 8 weeks of feeding the experimental diets, O2 consumption (VO2) and CO2 production
(VCO2) of mice (n = 4 per group) were measured for three days using the Oxymax Open Circuit
Indirect Calorimeter (Columbus Instrument, Columbus, OH, USA). The respiratory exchange
ratio (RER) was calculated as VCO2 divided by VO2. Heat production was calculated as VO2 *
(3.815 + 1.232 * RER). Weight-normalized heat production was calculated as heat production
divided by metabolic body weight (Wt0.75).

3.3.4

Intraperitoneal Glucose Tolerance Test

After 10 weeks of the experiment, glucose was administered by intraperitoneal injection to the
mice (n = 4 per group) at 1.5 g/kg body weight after 8 h fasting. Blood was collected from the
tail vein before the injection (0), and 15, 30, 45, 60, 120 min thereafter. Blood glucose
concentration was determined using the FreeStyle Lite® blood glucose meter kit (Abbott,
Chicago, IL, USA), and the area under the curve (AUC) was calculated.

3.3.5

Lipid, Glucose, and Insulin Concentrations

Serum, hepatic, and muscular TAG was measured using the Sigma Triglyceride Reagent (SigmaAldrich, St Louis, MO, USA). Serum non-esterified fatty acid (NEFA) and glucose
concentrations were measured using Wako HR Series NEFA-HR (2) and Wako Autokit Glucose
(Wako Diagnostics, Mountain View, CA, USA). Serum insulin concentration was measured
using the Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Chicago, IL, USA). Total
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lipids from the liver and hamstring muscle were extracted using isopropanol. After
centrifugation, TAG content of the supernatant determined with the Sigma Triglyceride Reagent
(Sigma-Aldrich, St Louis, MO, USA).

3.3.6

Western Blot

Protein was extracted from BAT, epididymal WAT, liver, and hamstring muscle tissues using
RIPA lysis buffer added with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA),
phosphatase inhibitor (Sigma-Aldrich, St. Louis, MO, USA), Phenylmethylsulfonyl Fluoride
(PMSF), and Na3VO4. Protein concentration was determined by bicinchoninic acid (BCA) assay
(Sigma-Aldrich, St. Louis, MO, USA). Protein lysates were separated by SDS-polyacrylamide
gel electrophoresis and transferred to nitrocellulose membrane. After blocking, membrane was
incubated with mouse anti-UCP1 (R&D Systems, Minneapolis, MN, USA), mouse anti-PGC-1α
(Invitrogen, Carlsbad, CA, USA), rabbit anti-p-PKA, rabbit anti-PKA (Santa Cruz, Dallas, TX,
USA), rabbit anti-p-Akt, rabbit anti-Akt, rabbit anti-p-AMPK, rabbit anti-AMPK, rabbit anti-βactin (Cell Signaling, Danvers, MA, USA), and mouse anti-GAPDH (Millipore, Burlington, MA,
USA). Then membrane was incubated with HRP-conjugated anti-mouse or anti-rabbit IgG (Cell
Signaling, Danvers, MA, USA), and imaged with Immobilon Western Chemiluminescent HRP
substrate (Millipore, Burlington, MA, USA). Band density was normalized relative to β-actin or
GAPDH.
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3.3.7

Quantitative Real-time PCR

Total RNA was extracted from BAT, subcutaneous WAT (sWAT), epididymal WAT (eWAT),
liver, hamstring muscle, and hypothalamus using Trizol (Ambion, Austin, TX, USA), and
reverse transcribed to cDNA using M-MLV reverse transcriptase (Promega, Madison, WI,
USA). Quantitative real-time PCR was performed on a Bio-Rad iQ5® system (Bio-Rad,
Hercules, CA, USA) using RT2 SYBR Green Fluor qPCR Mastermix (Qiagen, Valencia, CA,
USA). The mRNA levels of Ucp1, Prdm16, Pgc1a, Tfam, Cpt1a, Cpt1b, Cpt2, Ppara, Ppard,
Pparg, Npy, Agrp, Pomc, Lepr, Adrb1, Adrb2, Adrb, Gatm, and Serca2b were quantified and
normalized relative to 18S rRNA. Fold changes of gene expression were calculated by the ΔΔCt
method. Specific primer sequences used are shown in Table 3.3.

3.3.8

Statistical Analysis

One-way or two-way analysis of variance (ANOVA) with Tukey’s post-hoc test was performed
to determine significant differences among groups. Data are presented with the means ± SEM
and analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

3.4
3.4.1

Results

Body Weight, Calorie Intake, Growth Efficiency, and Tissue Weight

Body weights were significantly different among groups after 12 weeks of feeding (P < 0.0001).
When compared to CON, SHB, and SBO groups had higher body weight (37% and 23% higher,
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respectively). The SHB group had a higher calorie intake (P = 0.0119). The SHB and SBO
groups had higher growth efficiency (P = 0.0011) than CON. Subcutaneous and epididyimal
WAT (sWAT and eWAT, respectively) weights (g WAT weight/100 g body weight) were also
different. The SHB and SBO groups had 4.41 and 4.12 times higher sWAT weight (P = 0.0081);
and 2.75 and 2.30 times higher eWAT weight (P = 0.0010) than CON (Table 3.4).

3.4.2

Indirect Calorimetry

HFD-fed groups had lower respiratory exchange ratio (RER) than CON (P < 0.0001). As
compared to CON, oxygen consumption and weight-normalized heat production were higher in
the OO and SBO groups, and lower in the SHB and SFO groups (P < 0.0001; Figure 3.1).

3.4.3

Intraperitoneal Glucose Tolerance Test

After glucose administration, blood glucose concentrations were higher in the HFD-fed groups
when compared to CON (P < 0.0001). However, there was no difference in AUC among groups
(P = 0.9257; Figure 3.2).

3.4.4

Lipid, Glucose, and Insulin Concentrations

Serum and hepatic TAG concentrations were higher in the NE-injected than vehicle-treated mice
(P = 0.0374, P = 0.0002, respectively). Compared to CON, the SFO group had a higher muscle
TAG level (P = 0.0012). Serum NEFA concentrations were higher in NE-treated mice (P =
0.0044), and lower in SHB and OO groups than CON (P = 0.0146). Serum glucose and insulin
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concentrations were significantly higher in the SHB and SFO groups compared to CON (P =
0.0003, P = 0.0036, respectively), and NE-injected mice had lower serum glucose concentration
than vehicle-treated mice (P = 0.0002). Glucose:insulin ratio was not different among groups
(Table 3.5).

3.4.5

Protein Expression

Abundance of UCP1 protein was not different among groups in BAT and eWAT. Protein level of
PGC1α was not different in BAT as well. The ratios of p-Akt/Akt, p-AMPK/AMPK, and pPKA/PKA were not different among groups in BAT (Figure 3.3), eWAT (Figure 3.4), liver
(Figure 3.5), and hamstring muscle (Figure 3.6).

3.4.6

Effects of Diets on Thermogenic Gene Expression in BAT

Although there was no difference in Ucp1 expression, Prdm16 expression was higher in the SFO
group as compared to CON (2.17-fold; P = 0.0063), and in CON, NE induced 4.55-fold higher
Prdm16 expression (P = 0.0002). When compared to CON, the OO and SFO groups had lower
Pgc1a expression levels (0.32- and 0.33-fold, respectively; P = 0.0107), and NE upregulated its
expression (P < 0.0001). The NE-induced Pgc1a upregulation was greater in the CON group
than the HFD-fed groups. The level of Cpt1a mRNA expression was higher in the SHB group
(1.95-fold; P = 0.0404), and NE treatment upregulated its expression (P = 0.0475; Figure 3.4).
The SFO group had a higher Adrb1 mRNA expression than the SBO group (P = 0.0158), and the
SHB group had higher Adrb3 mRNA expression than the OO group (P = 0.0571). Injection with
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NE downregulated Adrb2 and Adrb3 mRNA expression (P = 0.0028, P = 0.0187, respectively;
Table 3.6).

3.4.7

Effects of Diets on Thermogenic Gene Expression in sWAT

Expression of Ucp1 in the HFD-fed groups was lower than the CON group (0.02- to 0.08-fold; P
= 0.0003), and Ucp1 expression level in sWAT was negatively correlated with sWAT
percentage (r = −0.3117, P = 0.0502). There was no diet effect on Pgc1a mRNA expression, but
NE lowered its level in the HFD-fed groups (P = 0.0256). Furthermore, the HFD-fed groups had
higher Cpt1a mRNA level (P = 0.0002; Figure 3.5). When compared to CON, the SHB group
had a higher Tfam mRNA level (P = 0.0037). The levels of β-adrenergic receptor mRNA were
not different among the groups; however, NE downregulated Adrb3 mRNA expression (P =
0.0012). The OO group had lower Serca2b mRNA expression than SHB group (P = 0.0281;
Table 3.7).

3.4.8

Effects of Diets on Thermogenic Gene Expression in eWAT

The SHB group had a lower Ucp1 expression than CON (0.24-fold; P = 0.0032), and NE
treatment upregulated Ucp1 expression (P < 0.0001). Expression level of Ucp1 in eWAT was
negatively correlated with body weight increase (r = −0.3156, P = 0.0472). Expression of
Prdm16 was higher in the SHB group (5.91-fold; P = 0.0019). Additionally, the SHB and SBO
groups had lower Pgc1a mRNA expression (0.21- and 0.39-fold, respectively; P < 0.0001), and
Pgc1a expression level was negatively correlated with body weight increase (r = −0.7163, P <
0.0001) and eWAT percentage (r = −0.5306, P = 0.0004). When compared to CON, the OO and
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SFO groups had a higher Cpt1a mRNA level (2.35- and 2.10-fold, respectively; P = 0.0163;
Figure 3.6), Tfam expression level (2.09- and 1.73-fold, respectively; P = 0.0012), and Adrb1
mRNA level (1.92- and 3.83-fold; P = 0.0010). The SHB, OO, and SBO groups had lower
Adrb2 mRNA expression (0.11-, 0.35-, and 0.45-fold; P < 0.0001), and the SHB group had
lower Adrb3 mRNA expression (0.23-fold; P = 0.0115) than CON (Table 3.8).

3.4.9 Dietary Effects on Expression of Genes Involved in Lipid Metabolism in the Liver
Treatment with NE upregulated Cpt1a and Cpt1b expression (P = 0.0014, P < 0.0001,
respectively). The SHB group had a higher Cpt1a expression (1.56-fold; P < 0.0001), and the
SFO group had lower Cpt2 expression (0.37-fold; P < 0.0001) than CON. As compared to CON,
the SHB and OO groups had a higher Ppara expression (2.70- and 2.03-fold, respectively; P <
0.0001). Likewise, the SHB and SBO groups had a higher Ppard expression than CON (1.86and 1.49-fold, respectively; P < 0.0001). The SHB, SFO, and SBO groups also had higher Pparg
expression than CON (10.86-, 5.55-, and 9.15-fold, respectively; P < 0.0001). In addition, when
compared to CON, the SFO group had a lower expression of Adrb2 (0.49-fold; P < 0.0001),
whereas the SHB, OO, and SBO groups had a higher Adrb3 expression (2.74-, 3.01-, and 2.78fold, respectively; P < 0.0001) relative to CON. However, treatment with NE downregulated
Adrb3 expression (P = 0.0060, Table 3.9).
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3.4.10 Dietary Effects on Expression of Genes Involved in Lipid Metabolism in Hamstring
Muscle
When compared to CON, the SHB group had a higher Cpt1a expression (2.38-fold; P = 0.0056),
and the HFD-fed groups had higher Cpt1b expression (1.62- to 3.04-fold; P < 0.0001).
Expression of Ppara was higher in SHB, SFO, and SBO groups (3.07-, 2.28-, and 2.02-fold,
respectively; P = 0.0008), and the SHB group had a higher Pparg expression (8.34-fold; P =
0.0010) than CON. Expression of Ppard was higher in SHB and OO groups (2.43- and 1.79-fold,
respectively; P = 0.0003), and NE upregulated its expression (P = 0.0003). Expression of Adrb1
was higher in SHB and SFO groups than CON (3.60- and 3.02-fold; P = 0.0062, Table 3.10).

3.4.11 Dietary Effects on Expression of Neuropeptides and β-Adrenergic Receptors in
Hypothalamus
β-adrenergic receptor mRNA level was significantly different among the groups although Npy,
Agrp, Pomc, and Lepr mRNA expression were not. As compared to the SBO group, the SFO
group had lower Adrb1 and Adrb3 mRNA expression (P = 0.0369, P = 0.0074, respectively);
and, the CON, OO, and SFO groups had lower Adrb2 mRNA expression (P = 0.0001, Table
3.11).

3.5

Discussion

We have investigated the effects of dietary fatty acid isomers with 18 carbons on thermogenesis
and metabolic markers in HFD-fed mice. Proportionately, 18-carbon fatty acids represent the
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largest fatty acid class in human diets, but their relative metabolic effects on thermogenic gene
expression in adipose tissue has not been well studied. Overall effects of dietary fatty acids in
energy balance is evident in the weight gain after consumption of the diets. Mice fed SHB (STArich fat) had the highest weight gain, growth efficiency, and white adipose mass. The SHB group
also had the lowest oxygen consumption and heat production among the five dietary groups. It is
possible that the downregulation of thermoregulatory genes, including Ucp1, Pgc1a, and Adrb3
in eWAT of the SHB group is partly responsible for the higher weight gain in this group. SHB
group had much higher serum glucose and insulin concentrations than CON, which may suggest
an existence of insulin resistance in this group.
However, when compared to SHB-fed mice, mice fed OO (OLA-rich oil), SFO (LNArich oil), or SBO (mixture of OLA, LNA, and ALA) had lower body weight gain. Among HFDfed groups, OO-fed mice had the least body fat accumulation. This may be tied to the highest
oxygen consumption and heat production in this group. In support of this possibility, the OO
group also had higher expression of epididymal thermoregulatory markers, Pgc1a, Adrb2, and
Adrb3 than SHB group, and higher Tfam, Cpt1a, and Adrb1 than CON. This result will be in
agreement with the previously reported thermogenic effects of OO [14, 15]. Rats fed OO had
higher expression levels of Ucp1, Ucp2, and Ucp3 in BAT, and Ucp3 in skeletal muscle, and this
was associated with increased total body oxygen consumption [14]. Feeding OO also increased
energy expenditure in healthy normal weight men [15], and the Mediterranean diet, which is rich
in OO, was shown to significantly reduce body weight and body mass index in multiple
randomized controlled trials [16]. Oleic acid, an n-9 fatty acid, potentially contributes to the
thermogenic phenotype of the OO-fed mice. In C2C12 myocytes, OLA stimulates β-adrenergic
signaling by increasing cyclic adenosine monophosphate (cAMP) concentration and protein
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kinase A (PKA) activity, and eventually induces PGC-1α activation and fatty acid oxidation [17].
In the current study, OO feeding tended to attenuate the increase in serum glucose and insulin
concentrations caused by HFD feeding. This could reflect the metabolic effects of OLA in the
OO diet in increasing fatty acid oxidation. This potential effect could result in increased
clearance of excessive fatty acids and reduce obesity-induced chronic inflammation.
It is quite interesting that oxygen consumption and heat production in SFO-fed mice were
as low as SHB-fed mice even though SFO contains higher percentage of PUFA as compared to
SHB. Serum glucose and insulin concentrations in the SFO group were also similar to the SHB
group. This may indicate that dietary PUFA level alone may not be sufficient to determine
metabolic outcome, and suggests a possibility that the balance of individual fatty acids in the
diets may be critical. In this respect, the SFO diet has a high content of LNA. In the body, LNA
may be elongated to arachidonic acid (ARA), which is a fatty acid that has been reported to
inhibit brown-like phenotype acquisition of differentiated human multipotent adipose-derived
stem cells [18], in contrast to n-3 fatty acids that upregulated thermogenic markers in WAT [10,
19]. The high n-6:n-3 ratio in SFO could also be a possible link to the low thermogenesis in the
SFO group. A link between a high n-6:n-3 ratio and insulin resistance has previously been
reported [20].
However, mice fed the SBO diet, rich in LNA, had higher oxygen consumption and heat
production than SFO-fed mice. This may be because SBO contains ALA, and the n-6:n-3 ratio of
SBO is much lower than that of SFO. The SBO group had higher body weight, growth
efficiency, and body fat accumulation. Previous studies showed that SBO increased feed
efficiency and weight gain in mice [21], and dietary LNA increased body fat mass [22] and
adipocyte size [22, 23] in mice. It was also reported that LNA increased activity of endogenous
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lipid mediators synthesized from ARA in membrane phospholipids, and these induce obesity by
upregulating de novo fatty acid synthesis in the liver [21]. Although ALA can be converted to
EPA and DHA that are known prevent obesity and inflammation, the efficiency of this
conversion is very low [24, 25]. Therefore, the extra LNA in the diet of SBO fed mice could
potentially contribute to the body fat accumulation in these mice.
We also determined possible combined effects of dietary fatty acids and β-adrenergic
stimulation on thermogenesis. Fatty acids are known natural ligands for PPARs, such as PPARγ
[4], which bind to peroxisome proliferator response element (PPRE) within the promoter region
of genes such as PGC-1α. Fatty acids may also promote interaction of PPARγ with PGC-1α,
leading to the induction of thermogenic genes, including Ucp1 [12]. Stimulation of β-adrenergic
signaling is a known mechanism of thermogenic activation in BAT and induction of oxidative
genes in multiple tissues that may alter the oxidation and metabolism of the fatty acids provided
in the diets [26]. To do this, we injected NE (a non-selective β-adrenergic receptor agonist) to
mice 4 h before sacrifice. The observed elevation of serum TAG and NEFA and hepatic TAG
concentration in NE-injected mice, and the lower serum glucose concentration compared to
vehicle-injected mice, would be consistent with activation of beta-adrenergic stimulus. βadrenergic stimulation induces lipolysis in adipose tissue and glucose uptake in skeletal muscle
and adipose tissue [27]. These data indicate the activation of β-adrenergic signaling and a
possible redirection of adipose TAG into the liver.
In BAT, NE upregulated expression of mitochondrial genes, such as Pgc1a and Cpt1a,
and its effect was greater in the CON group than HFD-fed groups. Although NE treatment
induced >8-fold higher Pgc1a expression in CON group, it only induced 1.5- to 3-fold higher
expression in the HFD-fed groups. In addition, NE was effective in inducing Cpt1a expression in
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the CON group (2.72-fold), but its effect in the HFD-fed groups was slight and insignificant
(average of 1.11-fold in all HFD-fed groups). Although there was no overall effect of NE on
Prdm16 expression, NE-injected CON mice had 4-fold higher expression compared to PBSinjected CON mice. Feeding HFD was previously reported to reverse adenylyl cyclase activation
induced by epinephrine or CL316,243 treatment in BAT of C57BL/6 mice [28]. These data
imply that high-fat feeding suppresses thermogenic response of BAT to β-adrenergic stimulation.
These data may also indicate that HFD with different fatty acid composition similarly inhibited
the NE effect; thus, fatty acid level, not composition, may be important in this respect.
The reported downregulation of Adrb3 in BAT and in sWAT by NE has also been
reported before. Administration of NE increased thyroid hormone secretion in mice [29], and
thyroid hormone downregulated β3-AR expression at the mRNA level in BAT [30].
Downregulation of adrenergic receptor expression by NE is a known mechanism of adrenergic
receptor desensitization [31], and this is a mechanism to prevent an overstimulation of the
pathway. The lower expression of Pgc1a in sWAT of NE-treated mice could be related to the
NE-induced downregulation of Adrb3 in sWAT. Additionally, Adrb3 gene transcript has been
shown to be degraded by treatment of insulin [32] and glucocorticoids [33] in 3T3-F442A
adipocytes, suggesting that Adrb3 mRNA level is tightly regulated to control fat mobilization
and oxidation [34]. The reduction in the Adrb2 expression in BAT also appears related to the
general theme of adrenergic receptor downregulation and desensitization by prolonged NE
exposure.
Administration of NE led to upregulated Ucp1 expression in eWAT but not sWAT.
Subcutaneous fat depots are known to have more beige precursor cells than visceral fat depots
[35]. Consistent with this observation, we also observed much higher expression of Ucp1 in
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sWAT as compared to eWAT (Figure 3.7). Chronic activation of β-adrenergic signaling is
known to induce trans-differentiation of pre-existing beige adipocytes; therefore, subcutaneous
fat depots acquire brown-like phenotype more than visceral fat depots [36]. However,
CL316,243, a β3-AR agonist, was reported to increase the number of BrdU+ UCP1+ cells in
epididymal fat but not in the inguinal fat [37]. This indicates that β-adrenergic stimulation
initiates proliferation of beige precursor cells in visceral fat depots, prior to inducing transdifferentiation, and this is potentially for robust induction of brown-like phenotype in the
browning-resistant fat depots [36]. This mechanism may be connected to the observed
upregulation of Ucp1 by NE in eWAT in this study.
Feeding of HFD suppressed acquisition of brown-like phenotype in both sWAT and
eWAT by downregulating Ucp1 expression. We also observed a negative correlation between
body adiposity (percentage of sWAT and eWAT, and body weight increase) and Ucp1
expression level in sWAT and eWAT. This indicates that the Ucp1 expression level might be
important in determining the overall degree of body adiposity, perhaps by setting the threshold of
wasteful energy utilization. In support of this possibility, lower Ucp1 expression was previously
observed in subcutaneous fat of HFD-fed obese rats [38] and in differentiated beige adipocytes
derived from human subcutaneous WAT of obese individuals [39]. In mice, high-fat feeding
induced differentiation of beige precursor cells in epididymal fat toward to white adipocytes
[39]. Obesity has also been shown to inhibit metabolic responses of BAT to ephedrine [40],
insulin, or cold exposure [41]; however, it is still unknown whether HFD-induced Ucp1
downregulation is related to causation, or whether it is a consequence of obesity [39]. We also
observed that HFD feeding downregulated expression of Adrb2 and Adrb3 in eWAT. Similar
results have been reported in obese individuals [42]. In both visceral and subcutaneous fat,
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expression of Adrb2 and Adrb3 was lower in the obese when compared to normal weight
individuals [42]. Due to the major role of β2- and β3-AR in activating lipolysis to provide fatty
acids for thermogenesis [43], lower expression of Adrb2 and Adrb3 may be linked to the higher
body fat accumulation in HFD-fed groups.
To determine if UCP1-independent thermogenic mechanisms were also involved in the
observed metabolic phenotype from diets and NE injection, we measured the expression of Gatm
[44] and Serca2b [45], which were recently reported to enhance UCP1-independent
thermogenesis in beige fat. However, expression of Gatm mRNA was not different among
groups in both sWAT and eWAT, Serca2b expression in sWAT was only lower in the OO group
than SHB group. The lack of a major treatment effects on these genes suggest that these UCP1independent thermogenic mechanisms might not have played a significant role in the metabolic
phenotype that was observed in this experiment.
Although our major focus was the effect of diets and NE on adipose tissue metabolic
markers, we also investigated effects on the liver and skeletal muscle. Hepatic TAG levels were
higher in SHB, SFO, and SBO groups than CON group, although this was not statistically
significant. When compared to CON group, the SHB group had 11-fold higher hepatic Pparg
mRNA expression; however, fatty acid oxidation-related genes, such as Cpt1a, Ppara, and
Ppard, were also upregulated in this group. It has been previously reported that patients suffering
from non-alcoholic fatty liver disease (NAFLD) [46] and obese individuals with insulin
resistance [47] had greater hepatic mitochondrial oxidation, indicating the SHB diet may be
making more fatty acids available for both hepatic storage and oxidation. However, as compared
to the SHB group, the OO group had lower Pparg expression in the liver, as previously reported
that OO-rich Mediterranean diet reduced intrahepatic lipid level even without weight reduction
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in NAFLD patients [48]. Downregulation of Cpt1a and Cpt2 expression in OO group may be
caused by the lower level of liver fat available for oxidation. On the other hand, the SFO-fed
mice had lower Adrb1, Adrb2, Adrb3, Cpt1a, Cpt2, Ppara, and Ppard expression than OO-fed
mice despite their higher Pparg expression. NAFLD patients are known to have higher n-6: n-3
ratio in hepatic phospholipids [49]; therefore, the high n-6:n-3 ratio of SFO could have led to an
induction of lipogenesis and the suppression of lipid oxidation or secretion in the liver.
Results obtained in the muscle mirrors those of the liver. SHB-fed mice had 8-fold higher
Pparg expression in the hamstring muscle as compared to CON group. They also had higher
mRNA levels of Cpt1a, Cpt1b, Ppara, and Ppard, perhaps indicating a higher level of both fatty
acid storage and oxidation in the skeletal muscle and liver of the SHB-fed mice. However,
consumption of n-6 fatty acid rich diets leads to downregulation of muscle oxidative genes in the
present study. When compared to SHB-fed mice, SFO-fed mice had lower Cpt2 and Ppard
expression, leading to higher muscle TAG level; and, SBO-fed mice also had lower Cpt1a,
Ppard, and Adrb1 expression. Omega-6 fatty acids were previously observed to induce higher
muscle TAG accumulation in rats [50]. Treatment with NE seemed to promote fatty acid
oxidation by upregulating Ppara and Ppard expression and downregulating Pparg expression.
Downregulation of Adrb3 mRNA level by NE implies that muscular fat oxidation is also tightly
controlled by negative feedback regulation through adrenergic receptor downregulation [34].
Finally, we determined the effects of diets on hypothalamic expression of neuropeptides,
leptin receptor, and β-adrenergic receptors because overall metabolism and thermogenesis is
under hypothalamic control. Although neuropeptide Y (NPY; an orexigenic neuropeptide) is
known to suppress thermogenesis of BAT and browning of WAT [51], hypothalamic expression
of neuropeptides, including NPY, was not different among groups. However, SFO group had the

102
lowest hypothalamic Adrb2 expression, and this could be caused by the high n-6: n-3 ratio in
SFO. In support of this possibility, β-adrenergic receptor expression is upregulated by n-3 rich
fish oil in murine brains [52], but downregulated by n-3 deficient diet in rat hypothalamus [53].
Central β-agonist treatment is also reported to induce thermogenesis by increasing BAT mass
and browning of WAT [54]. Therefore, the low hypothalamic Adrb2 expression in the SFO
group could contribute the lower oxygen consumption and heat generation in this group.
In sum, dietary OO consumption reduced weight gain and body fat accumulation, and
this is associated with upregulation of thermogenesis, and improved lipid metabolism in the liver
and skeletal muscle. The high n-6:n-3 ratio of SFO increased lipogenesis and reduced lipid
oxidation and thermogenesis. However, overall HFD feeding led to the suppression of
acquisition of brown-like phenotype in both sWAT and eWAT, and the responsiveness of BAT
to NE treatment. This might be due to the HFD-induced downregulation of Adrb2 and Adrb3 in
sWAT and eWAT, and the lower expression of Ucp1 in these fat tissues. These data indicate that
both quantity and quality of dietary fat, especially the position of double bonds in fatty acids,
may play key roles in the regulation of thermogenic response in diets.
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Table 3.1 Composition of the experimental diets1.
Control
High-fat
(10% Kcal Fat)
(45% Kcal Fat)
g
Kcal
g
Kcal
Casein
200
800
200
800
L-cystine
3
12
3
12
Sucrose
172.8
691
172.8
691
Cornstarch
452.2
1808.8
72.8
291
Dyetrose
75
300
100
400
2
SHB, OO, SFO, or SBO
20
180
90
810
Lard
25
225
112.5
1012.5
t-Butylhydroquinone
0.004
0
0.018
0
Cellulose
50
0
50
0
3
Mineral Mix
35
0
35
0
4
Vitamin Mix
10
40
10
40
Choline Bitartrate
2
0
2
0
Total
1045
4057
848.1
4057
kcal/ g diet
3.69
4.64
1
Resource: Dyets, Inc., Bethlehem, PA, USA.
2
SHB, shea butter; OO, olive oil; SFO, safflower oil; SBO, soybean oil
3
Thirty-five grams of mineral mix (Research Diets, Inc., New Brunswick, NJ, USA, S10026)
provides 1.0g sodium, 1.6g chloride, 0.5g magnesium, 0.33g sulfur, 59mg manganese, 45mg iron,
29mg zinc, 6mg copper, 2mg chromium, 1.6mg molybdenum, 0.16mg selenium, 0.9mg fluoride,
0.2 mg, iodine and 3.99g sucrose.
4
Ten grams of vitamin mix (Research Diets, Inc., V10001) provides 4000 IU vitamin A, 1000 IU
vitamin D3, 50 IU vitamin E, 30 mg niacin, 16 mg pantothenic acid, 7 mg vitamin B6, 6 mg
vitamin B1, 6 mg vitamin B2, 2 mg folic acid, 0.5 mg menadione, 0.2 mg biotin, 10 μg vitamin
B12 and 9.78 g sucrose.

Table 3.2 Fatty acid composition of the experimental diets (% of fatty acids)1.

Myristic acid (C14:0)
Palmitic acid (C16:0)
Palmitoleic acid (C16:1, ∆9)
Stearic acid (C18:0)
Oleic acid (C18:1, ∆9)
Linoleic acid (C18:2, ∆9,12)
α-Linolenic acid (C18:3, ∆9,12,15)
Arachidonic acid (C20:4, ∆5,8,11,14)
Eicosapentaenoic acid (C20:5, ∆5,8,11,14,17)
Docosahexaenoic acid (C22:6, ∆4,7,10,13,16,19)

10% Fat
CON
1.046
17.148
0.976
8.604
27.793
32.187
3.374
0.142
0.100
0.072

45% Fat
SHB
0.728
13.287
0.998
23.781
38.828
15.201
0.858
0.159
0.011
0.044

OO
0.681
18.595
1.863
7.503
44.971
18.772
1.023
0.148
0.022
0.037

SFO
0.709
13.887
0.963
7.144
27.233
43.238
0.817
0.149
0.066
0.060

SBO
0.685
15.740
0.944
7.808
28.916
35.580
3.731
0.154
0.032
0.062

Total saturated fatty acids
Total monounsaturated fatty acids
Total polyunsaturated fatty acids

27.552
30.803
37.663

38.422
41.411
18.221

27.498
49.470
21.519

22.465
29.937
45.818

24.986
31.784
41.364

Total n-6 fatty acids
32.976
16.031
19.549
44.059
36.412
Total n-3 fatty acids
3.822
1.622
1.397
1.213
4.097
n-6:n-3 ratio
8.628
9.883
13.994
36.322
8.887
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25% lard; SFO, 20% safflower oil + 25%
lard; SBO, 20% soybean oil + 25% lard.
1
Fatty acid composition was determined by a gas chromatography.
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Table 3.3 The primer sequences used for quantitative Real-time PCR1.
Gene
Function
Forward Primer
Reverse Primer
18S
Endogenous control
ATC CCT GAG AAG TTC CAG CA
CCT CTT GGT GAG GTC GAT GT
Ucp1
Thermogenesis
GGG CCC TTG TAA ACA ACA AA
GTC GGT CCT TCC TTG GTG TA
Prdm16
Thermogenesis
GGC TCA AGG AGG AGG AGA GA
AGG TCC GGG TCA GGT TCA TA
Pgc1a
Thermogenesis
GTC CTT CCT CCA TGC CTG AC
GTG TGG TTT GCT GCA TGG TT
Tfam
Thermogenesis
GAG CGT GCT AAA AGC ACT GG
GAC AAG ACT GAT AGA CGA GGG G
Cpt1a
Fatty acid oxidation
GGA CTC CGC TCG CTC ATT
GAG ATC GAT GCC ATC AGG GG
Cpt1b
Fatty acid oxidation
AAG TTC AGA GAC GAA CGC CC
CAG GCC TCT TCT TCC ACC AG
Cpt2
Fatty acid oxidation
GCT TTC CAA CCC GAT CTC CT
TGT GAG CGG AAG ATC CCA AC
Ppara
Fatty acid oxidation
CCC TGA ACA TCG AGT GTC GA
AAT AGT TCG CCG AAA GAA GCC
Ppard
Fatty acid oxidation
TCC ATC GTC AAC AAA GAC GGG
ACT TGG GCT CAA TGA TGT CAC
Pparg
Lipid accumulation
TTG ACC CAG AGC ATG GTG C
GAA GTT GGT GGG CCA GAA TG
Npy
Orexigenic neuropeptide
TGG CCA GAT ACT ACT CCG CT
TCT TCA AGC CTT GTT CTG GGG
Agrp
Orexigenic neuropeptide
CCC TGT CCT AGA CCT TCC AGA
GTG CCT CCC ATT GTG TTG TCT
Pomc
Anorexigenic neuropeptide CAA CCT GCT GGC TTG CAT C
CGT ACT TCC GGG GGT TTT CA
Lepr
Leptin signaling
CAG AAT GAC GCA GGG CTG TA
AGA GTG TCC GTT CTC TTT TGG A
Adrb1
β-adrenergic signaling
CTA CAA CGA CCC CAA GTG CT
ACG TAG AAG GAG ACG ACG GA
Adrb2
β-adrenergic signaling
TAC ACA GGG GAG CCA AAC AC
TCA CAA AGC CTT CCA TGC CT
Adrb3
β-adrenergic signaling
AGT TTG AGA GCA GGA ATC CAG G
CCA AGA TGG TGC TTA GAG AGC C
Gatm
Creatine biosynthesis
TTT GCA CAG AGA AGC CAG GTT A
TGT GCA TTG GAT TGG GGT CT
2+
Serca2b
Ca -ATPase
TTT GCC GCT CAT TTT CCA GAT CA
ACA CAC TCT TTA CCG GGT TGT T
1
18S, 18S ribosomal RNA; Ucp1, Uncoupling protein 1; Prdm16, PR domain containing 16; Pgc1a, Peroxisome proliferator-activated
receptor gamma coactivator 1-alpha; Tfam, Mitochondrial transcription factor A; Cpt1a, Carnitine palmitoyl-transferase 1A; Cpt1b,
Carnitine palmitoyl-transferase 1B; Cpt2, Carnitine palmitoyl-transferase 2; Ppara, Peroxisome proliferator-activated receptor α;
Ppard, Peroxisome proliferator-activated receptor δ; Pparg, Peroxisome proliferator-activated receptor γ; Npy, Neuropeptide Y; Agrp,
Agouti-related peptide; Pomc, Proopiomelanocortin; Lepr, Leptin receptor; Adrb1, Beta-1 adrenergic receptor; Adrb2, Beta-2
adrenergic receptor; Adrb3, Beta-3 adrenergic receptor; Gatm, Glycine amidinotransferase, mitochondrial; Serca2b,
sarco/endoplasmic reticulum Ca2+-ATPase 2b.
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Table 3.4 Body weight, calorie intake, growth efficiency, and tissue weight.
10% Fat
CON
17.88±0.61
26.00±0.69C
8.13±0.59C
9.27±0.28B
10.39±0.57B
0.59±0.09B

45% Fat
SHB
17.73±0.51
35.79±0.81A
18.06±0.71A
12.97±0.02A
16.58±0.65A
2.60±0.46A

OO
17.83±0.50
29.33±0.66BC
11.50±0.73BC
10.68±0.09AB
12.82±0.82AB
1.25±0.17AB

SFO
17.89±0.45
30.41±0.90BC
12.33±0.93B
10.43±0.19B
14.01±0.89AB
1.88±0.45AB

SBO
17.88±0.62
31.95±1.93AB
14.08±1.47B
11.14±0.04AB
15.03±1.57A
2.43±0.64A

P-value

Body weight at 0 week (g)
0.9931
Body weight at 12 week (g)
<0.0001
Body weight gain (g)
<0.0001
Calorie intake (kcal/day)
0.0119
1
Growth efficiency (mg/kcal)
0.0011
Subcutaneous WAT
0.0081
(g/100g body weight)
Epidydimal WAT
1.38±0.18C
3.80±0.42A
2.12±0.21BC
2.79±0.51ABC
3.18±0.48AB
0.0010
(g/100g body weight)
Brown adipose tissue
0.34±0.02AB
0.38±0.04A
0.20±0.02C
0.24±0.03BC
0.36±0.05AB
0.0009
(g/100g body weight)
Liver (g/100g body weight)
3.72±0.18
3.36±0.12
3.33±0.06
3.22±0.11
3.21±0.19
0.0956
Thigh (g/100g body weight)
0.86±0.04
0.80±0.05
1.05±0.06
0.95±0.08
1.06±0.14
0.1160
Data are presented as means ± SEM, n = 8 for each group.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25% lard; SFO, 20% safflower oil + 25%
lard; SBO, 20% soybean oil + 25% lard.
For each variable, diets were compared among each other and means assigned different superscripts A, AB, BC, or C) if they are
significantly different from each other at P < 0.05 by Tukey’s multiple comparison test. For any variable, if a diet has a common
superscript with another diet, it means they are not significantly different from each other. Only diets without a common superscript are
significantly different from each other.
1
Growth efficiency (mg/kcal) = Weight gain (mg)/Total calorie intake (kcal).

111

112

Figure 3.1 Indirect calorimetry (a) Respiratory exchange ratio (RER) (b) O2 consumption
(c) Weight-normalized heat generation.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard.
After eight weeks of feeding the experimental diets, O2 consumption and CO2 production of mice
were measured for three days using the Oxymax open circuit indirect calorimeter.
Data were separated into day or night time for each diet.
Bars represent means ± SEM (n = 4 for each diet group).
Diets were compared among each other (after combining day and night data within each diet), and
assigned different superscripts A, B, C, or D) if they were significantly different from each other
at P < 0.05 by Tukey’s multiple comparison test.
D*T, Interaction effect between diet and time.
Asterisks (*) indicate significant differences due to time effect (day or night time) within each diet
group when diet*time interaction effect was significant by ANOVA.
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Figure 3.2 Intraperitoneal glucose tolerance test (a) Blood glucose level (b) Area under
curve.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard.
After 10 weeks of feeding the experimental diets, glucose was intraperitoneally injected to mice
at 1.5 g/kg body weight after 8-h fasting. Blood was collected from the tail vein before the
injection, and 15, 30, 45, 60, and 120 min after injection.
Data are presented as means ± SEM (n = 4 for each group).
Different superscript letters A and B indicate significant differences between all the high fat diets
(SHB, OO, SFO, and SBO), which all have a common superscript A, and CON with superscript B
(P < 0.05) by Tukey’s multiple comparison test.

Table 3.5 Lipid, Glucose, and Insulin Concentrations.
10% Fat
45% Fat
TRT mean3
P-value4
TRT
CON
SHB
OO
SFO
SBO
Serum TAG
PBS
0.87±0.05
0.69±0.08
0.98±0.20
1.00±0.12
0.85±0.09
0.87±0.05
D; 0.9803
(mg/mL)
N; 0.0374
NE
1.01±0.17
1.21±0.08
0.97±0.20
0.98±0.10
1.07±0.12
1.05±0.06*
2
D*N;
0.1894
Diet mean
0.94±0.09
0.95±0.11
0.97±0.13
0.99±0.07
0.96±0.08
Liver TAG
PBS
0.19±0.04
0.22±0.01
0.17±0.04
0.21±0.05
0.21±0.07
0.20±0.02
D; 0.5666
(mg/mg
NE
0.28±0.04
0.36±0.03
0.30±0.01
0.35±0.05
0.39±0.10
0.34±0.02*
N; 0.0002
2
protein)
D*N; 0.9033
Diet mean
0.23±0.03
0.29±0.03
0.24±0.03
0.28±0.04
0.30±0.07
Muscle TAG
PBS
0.21±0.03
0.16±0.02
0.20±0.02
0.24±0.03
0.22±0.02
0.20±0.01
D; 0.0012
(mg/mg
NE
0.16±0.01
0.16±0.02
0.24±0.02
0.34±0.06
0.19±0.03
0.22±0.02
N; 0.8868
2
B
B
AB
A
AB
protein)
D*N; 0.1315
Diet mean
0.18±0.02
0.16±0.01
0.22±0.02
0.30±0.04
0.20±0.02
Serum NEFA
PBS
0.077±0.003
0.058±0.006
0.057±0.007
0.062±0.004
0.066±0.006
0.064±0.003
D; 0.0146
(mM)
NE
0.087±0.009
0.067±0.005
0.070±0.005
0.074±0.007
0.079±0.003
0.075±0.003*
N; 0.0044
2
A
B
B
AB
AB
D*N; 0.9844
Diet mean
0.082±0.005
0.062±0.004
0.063±0.005
0.068±0.004
0.073±0.004
Serum
PBS
118.3±27.2
280.2±41.3
252.5±50.8
340.7±41.6
162.7±9.7
230.9±23.6
D; 0.0003
Glucose
NE
101.0±11.0
179.5±49.7
114.5±40.0
194.7±22.2
104.0±13.8
138.7±15.4*
N; 0.0002
2
C
AB
ABC
A
BC
(mg/dL)
D*N; 0.3867
Diet mean
109.7±14.0
229.9±35.4
183.5±39.7
267.7±35.2
133.4±13.6
Serum
PBS
0.20±0.02
2.12±0.86
0.99±0.23
1.19±0.51
1.12±0.38
1.12±0.25
D; 0.0036
Insulin
NE
0.38±0.03
1.24±0.29
0.35±0.17
0.91±0.28
0.93±0.37
0.76±0.13
N; 0.2604
2
B
A
AB
A
AB
(ng/mL)
D*N; 0.2493
Diet mean
0.30±0.04
1.62±0.40
0.62±0.16
1.03±0.25
1.01±0.25
Glucose:
PBS
6.07±1.19
2.65±1.55
3.22±1.19
3.94±1.52
2.10±1.07
3.60±0.62
D; 0.1321
Insulin ratio
NE
2.68±0.35
1.46±0.17
3.34±1.67
2.69±0.74
2.10±0.86
2.45±0.31
N; 0.3044
2
D*N; 0.7640
Diet mean
4.13±0.84
1.97±0.64
3.29±0.69
3.22±0.74
2.10±0.61
Data are presented as means ± SEM, n = 7–8 for each diet group.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25% lard; SFO, 20% safflower oil + 25%
lard; SBO, 20% soybean oil + 25% lard.
TAG, triacylglycerol. NEFA, non-esterified fatty acid.
1
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For each variable, diets were compared among each other (after combining PBS and NE data within each diet), and assigned different
superscripts A, B, AB, ABC, C, or D) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison
test. For each variable, if a diet has a common superscript with another diet, it means they are not significantly different from each other.
Only diets without a common superscript are significantly different from each other.
Asterisks (*) indicate significant differences caused by NE; P < 0.05.
1 TRT, treatment (PBS or NE injection). Mice were injected with norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered
saline (PBS; 2 mL/kg body weight) as a vehicle after 8-h fasting at the end of the experimental period, and euthanized after another 4-h
fasting.
2 Overall mean of each diet group.
3 Overall mean of PBS-treated mice or NE-treated mice.
4 D, Diet effect; N, NE effect; D*N, Interaction effect.
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Figure 3.3 Protein expression in BAT (a) UCP1/β-actin (b) PGC1α/β-actin (c) p-Akt/Akt (d)
p-AMPK/AMPK (e) p-PKA/PKA.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil +
25% lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard. Mice were

117
injected with norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered saline (PBS; 2
mL/kg body weight) as a vehicle after 8-h fasting at the end of the experimental period, and
euthanized after another 4-h fasting. Protein expression was determined by Western blot. Data
are presented as means ± SEM (n = 8 for each diet group; n = 4 each for PBS and NE treatment).
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Figure 3.4 Protein expression in epididymal WAT (a) UCP1/β-actin (b) p-Akt/Akt
(c) p-AMPK/AMPK (d) p-PKA/PKA.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil +
25% lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard.
Mice were injected with norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered saline
(PBS; 2 mL/kg body weight) as a vehicle after 8-h fasting at the end of the experimental period,
and euthanized after another 4-h fasting.
Protein expression was determined by Western blot.
Data are presented as means ± SEM (n = 8 for each diet group; n = 4 for each PBS and NE
treatment).
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Figure 3.5 Protein expression in the liver (a) p-Akt/Akt (b) p-AMPK/AMPK.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil +
25% lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard.
Mice were injected with norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered saline
(PBS; 2 mL/kg body weight) as a vehicle after 8-h fasting at the end of the experimental period,
and euthanized after another 4-h fasting.
Protein expression was determined by Western blot.
Data are presented as means ± SEM (n = 8 for each diet group; n = 4 for each PBS and NE
treatment).
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Figure 3.6 Protein expression in hamstring muscle (a) p-AMPK/AMPK (b) p-PKA/PKA.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil +
25% lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard.
Mice were injected with norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered saline
(PBS; 2 mL/kg body weight) as a vehicle after 8-h fasting at the end of the experimental period,
and euthanized after another 4-h fasting.
Protein expression was determined by Western blot.
Data are presented as means ± SEM (n = 8 for each diet group; n = 4 for each PBS and NE
treatment).
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Figure 3.7 Expression of genes involved in thermogenesis in BAT (a) Ucp1 (b) Prdm16 (c)
Pgc1a (d) Cpt1a.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil +
25% lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard.
Mice were injected with norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered saline
(PBS; 2 mL/kg body weight) as a vehicle after 8-h fasting at the end of the experimental period,
and euthanized after another 4-h fasting.
Gene expression was determined by RT-PCR.
Data are presented as means ± SEM (n = 8 for each diet group; n = 4 for each PBS and NE
treatment).
Diets were compared among each other (after combining PBS and NE data within each diet), and
assigned different superscripts A, B, or AB) if they were significantly different from each other
at P < 0.05 by Tukey’s multiple comparison test. If a diet has a common superscript with another
diet, it means they are not significantly different from each other. Only diets without a common
superscript are significantly different from each other.
D*N, Interaction effect between diet and NE.
Asterisks (*) indicate significant differences caused by NE within each diet group when interaction
effect was significant.

Table 3.6 Expression of genes involved in thermogenesis in BAT.
10% Fat
45% Fat
P-value4
TRT
CON
SHB
OO
SFO
SBO
TRT mean3
Tfam
PBS
1.00±0.13
1.18±0.16
1.16±0.35
1.70±0.67
0.90±0.09
1.19±0.15
D; .3645
N; .2831
NE
1.42±0.34
1.00±0.11
1.55±0.40
0.95±0.33
0.94±0.12
1.37±0.14
2
D*N;
.8852
Diet mean
1.21±0.19
1.09±0.10
1.35±0.26
1.83±0.35
0.92±0.07
Adrb1
PBS
1.00±0.25
2.16±0.63
1.61±0.51
2.28±0.74
1.13±0.32
1.64±0.24
D; .0158
N; .6536
NE
1.12±0.11
1.70±0.37
1.22±0.38
2.12±0.36
0.80±0.09
1.40±0.16
2
AB
AB
AB
A
B
D*N; .8581
Diet mean
1.06±0.13
1.93±0.35
1.42±0.30
2.20±0.38
0.97±0.16
Adrb2
PBS
1.00±0.29
0.97±0.46
0.50±0.12
0.69±0.16
0.50±0.09
0.73±0.12
D; .0926
N; .0028
NE
0.49±0.16
0.53±0.03
0.38±0.08
0.19±0.05
0.40±0.07
0.40±0.04*
2
D*N; .2197
Diet mean
0.75±0.18
0.75±0.23
0.44±0.07
0.44±0.12
0.45±0.06
Adrb3
PBS
1.00±0.05
2.60±0.45
1.16±0.38
1.12±0.46
2.18±0.45
1.61±0.22
D; .0571
N; .0187
NE
0.91±0.29
1.38±0.37
0.67±0.20
1.33±0.26
0.66±0.17*
0.99±0.13*
2
AB
A
B
AB
AB
D*N; .1022
Diet mean
0.96±0.14
1.99±0.36
0.92±0.22
1.22±0.25
1.42±0.36
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and NE.
For each gene, diets were compared among each other (after combining PBS and NE data within each diet), and assigned different
superscripts A, B, or AB) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test. For
each gene, if a diet has a common superscript with another diet, it means they are not significantly different from each other. Only
diets without a common superscript are significantly different from each other.
TRT, treatment (PBS or NE injection). CON, control; SHB, shea butter; OO, olive oil; SFO, safflower; SBO, soybean oil.
1
Mice were injected with norepinephrine (NE; 2mg/kg body weight) or phosphate-buffered saline (PBS; 2mL/kg body weight) as a
vehicle after 8-hour fasting at the end of the experimental period, and euthanized after another 4-hour fast. Asterisks (*) indicate
significant differences caused by NE; P < 0.05.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or NE-treated mice.
4
D, Diet effect; N, NE effect; D*N, Interaction effect.
1
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Figure 3.8 Expression of genes involved in thermogenesis in subcutaneous WAT (a) Ucp1
(b) Prdm16 (c) Pgc1a (d) Cpt1a.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil +
25% lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard.
Mice were injected with norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered saline
(PBS; 2 mL/kg body weight) as a vehicle after 8-h fasting at the end of the experimental period,
and euthanized after another 4-h fasting.
Gene expression was determined by RT-PCR.
Data are presented as means ± SEM (n = 8 for each diet group; n = 4 for each PBS and NE
treatment).
Diets were compared among each other (after combining PBS and NE data within each diet), and
assigned different superscripts A or B) if they were significantly different from each other at P <
0.05 by Tukey’s multiple comparison test. If a diet has a common superscript with another diet,
it means they are not significantly different from each other. Only diets without a common
superscript are significantly different from each other.
D*N, Interaction effect between diet and NE.
Asterisks (*) indicate significant differences caused by NE within each diet group when interaction
effect was significant.
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Table 3.7 Expression of genes involved in thermogenesis in subcutaneous WAT.
10% Fat
45% Fat
P-value4
TRT1
CON
SHB
OO
SFO
SBO
TRT mean3
Tfam
PBS
1.00±0.16
1.54±0.29
1.13±0.17
0.71±0.22
1.30±0.33
1.14±0.12
D; .0037
N; .1590
NE
0.78±0.12
1.80±0.17
1.59±0.15
0.92±0.13
1.85±0.59
1.39±0.16
2
BC
A
ABC
C
AB
D*N; .5674
Diet mean
0.89±0.10
1.67±0.16
1.36±0.14
0.81±0.12
1.57±0.33
Adrb1
PBS
1.00±0.39
3.20±1.14
4.06±1.84
1.96±0.73
3.38±0.75
2.72±0.50
D; .3094
N; .6586
NE
2.01±0.66
7.12±4.70
0.94±0.22
2.27±0.79
2.35±0.64
2.94±0.99
2
D*N; .4348
Diet mean
1.51±0.40
5.16±2.36
2.50±1.04
2.12±0.50
2.87±0.50
Adrb2
PBS
1.00±0.23
0.39±0.11
0.41±0.06
0.48±0.10
0.48±0.08
0.55±0.07
D; .0991
N; .4997
NE
0.98±0.30
0.40±0.03
0.48±0.16
0.37±0.15
0.61±0.14
0.57±0.09
2
D*N;
.6491
Diet mean
0.99±0.18
0.40±0.05
0.44±0.08
0.42±0.09
0.54±0.08
Adrb3
PBS
1.00±0.28
0.88±0.19
0.63±0.21
0.64±0.20
0.68±0.21
0.76±0.09
D; .6837
N; .0012
NE
0.21±0.05
0.36±0.05
0.30±0.13
0.34±0.15
0.22±0.05
0.29±0.04*
D*N; .9539
Diet mean2
0.61±0.20
0.62±0.13
0.46±0.13
0.49±0.13
0.45±0.13
Gatm
PBS
1.00±0.45
1.45±0.32
0.83±0.14
1.67±0.88
1.16±0.12
1.17±0.15
D; .1889
N; .1402
NE
1.33±0.67
1.41±0.63
0.97±0.62
0.16±0.10
0.70±0.13
0.91±0.23
2
D*N; .1909
Diet mean
1.16±0.38
1.43±0.33
0.90±0.29
0.66±0.40
0.93±0.12
Serca2b
PBS
1.00±0.13
0.90±0.26
0.49±0.11
1.10±0.45
0.99±0.19
0.88±0.09
D; .0281
N; .2571
NE
0.92±0.21
1.09±0.21
0.42±0.13
0.42±0.10
0.77±0.14
0.73±0.09
2
AB
A
B
AB
AB
D*N; .3167
Diet mean
0.96±0.11
1.00±0.16
0.46±0.08
0.65±0.19
0.88±0.12
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and NE.
For each gene, diets were compared among each other (after combining PBS and NE data within each diet), and assigned different
superscripts A, B, C, AB, BC, or ABC) if they were significantly different from each other at P < 0.05 by Tukey’s multiple
comparison test. For each gene, if a diet has a common superscript with another diet, it means they are not significantly different from
each other. Only diets without a common superscript are significantly different from each other.
TRT, treatment (PBS or NE injection). CON, control; SHB, shea butter; OO, olive oil; SFO, safflower; SBO, soybean oil.
1
Mice were injected with norepinephrine (NE; 2mg/kg body weight) or phosphate-buffered saline (PBS; 2mL/kg body weight) as a
vehicle after 8-hour fasting at the end of the experimental period, and euthanized after another 4-hour fast. Asterisks (*) indicate
significant differences caused by NE; P < 0.05.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or NE-treated mice.
4
D, Diet effect; N, NE effect; D*N, Interaction effect.
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Figure 3.9 Expression of genes involved in thermogenesis in epididymal WAT (a) Ucp1 (b)
Prdm16 (c) Pgc1a (d) Cpt1a.
CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil +
25% lard; SFO, 20% safflower oil + 25% lard; SBO, 20% soybean oil + 25% lard.
Mice were injected with norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered saline
(PBS; 2 mL/kg body weight) as a vehicle after 8-h fasting at the end of the experimental period,
and euthanized after another 4-h fasting.
Gene expression was determined by RT-PCR.
Data are presented as means ± SEM (n = 8 for each diet group; n = 4 for each PBS and NE
treatment).
Diets were compared among each other (after combining PBS and NE data within each diet), and
assigned different superscripts A, B, AB, B, C, or BC) if they were significantly different from
each other at P < 0.05 by Tukey’s multiple comparison test. If a diet has a common superscript
with another diet, it means they are not significantly different from each other. Only diets
without a common superscript are significantly different from each other.
D*N, Interaction effect between diet and NE.
Asterisks (*) indicate significant differences caused by NE within each diet group when interaction
effect was significant.
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Table 3.8 Expression of genes involved in thermogenesis in epididymal WAT.
10% Fat
45% Fat
P-value4
TRT1
CON
SHB
OO
SFO
SBO
TRT mean3
Tfam
PBS
1.00±0.27
1.43±0.05
2.46±0.39
2.03±0.39
1.78±0.13
1.74±0.16
D; .0012
N; .2622
NE
1.36±0.22
1.90±0.28
2.46±0.33
2.05±0.32
1.71±0.31
1.89±0.14
2
B
AB
A
A
AB
D*N; .6077
Diet mean
1.18±0.17
1.67±0.16
2.46±0.24
2.04±0.23
1.74±0.15
Adrb1
PBS
1.00±0.10
0.91±0.08
2.63±0.43
2.87±1.18
1.82±0.60
1.85±0.31
D; .0010
N; .3781
NE
0.68±0.11
1.41±0.85
1.67±0.24
3.56±0.99
1.41±0.47
1.75±0.34
2
C
BC
AB
A
ABC
D*N; .7068
Diet mean
0.84±0.09
1.16±0.41
2.15±0.29
3.22±0.72
1.62±0.36
Adrb2
PBS
1.00±0.25
0.09±0.01
0.26±0.05
0.55±0.20
0.40±0.14
0.46±0.10
D; <.0001
N; .4351
NE
0.88±0.16
0.11±0.03
0.40±0.06
0.45±0.13
0.45±0.07
0.46±0.07
2
A
C
B
AB
B
D*N;
.7806
Diet mean
0.94±0.14
0.10±0.02
0.33±0.04
0.50±0.11
0.42±0.08
Adrb3
PBS
1.00±0.52
0.16±0.03
0.43±0.07
0.54±0.18
0.39±0.20
0.51±0.12
D; .0115
N; .2402
NE
0.26±0.05
0.13±0.05
0.61±0.14
0.33±0.06
0.27±0.11
0.32±0.05
D*N; .5301
Diet mean2
0.63±0.28A
0.15±0.03B
0.52±0.08A 0.44±0.10AB 0.33±0.11AB
Gatm
PBS
1.00±0.23
2.67±0.97
1.58±0.18
1.61±0.62
2.26±0.63
1.82±0.27
D; .3930
N; .6620
NE
0.97±0.11
1.16±0.20
1.73±0.45
3.59±2.02
1.10±0.13
1.71±0.43
2
D*N; .2182
Diet mean
0.98±0.12
1.91±0.54
1.66±0.23
2.60±1.21
1.68±0.37
Serca2b
PBS
1.00±0.17
1.23±0.29
0.98±0.12
1.22±0.78
1.34±0.16
1.15±0.12
D; .7201
N; .4115
NE
1.48±0.17
1.24±0.22
1.00±0.19
1.50±0.39
1.29±0.25
1.30±0.11
2
D*N; .8570
Diet mean
1.24±0.14
1.24±0.17
0.99±0.10
1.36±0.37
1.31±0.14
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and NE.
For each gene, diets were compared among each other (after combining PBS and NE data within each diet), and assigned different
superscripts A, B, C, AB, BC, or ABC) if they were significantly different from each other at P < 0.05 by Tukey’s multiple
comparison test. For each gene, if a diet has a common superscript with another diet, it means they are not significantly different from
each other. Only diets without a common superscript are significantly different from each other.
TRT, treatment (PBS or NE injection). CON, control; SHB, shea butter; OO, olive oil; SFO, safflower; SBO, soybean oil.
1
Mice were injected with norepinephrine (NE; 2mg/kg body weight) or phosphate-buffered saline (PBS; 2mL/kg body weight) as a
vehicle after 8-hour fasting at the end of the experimental period, and euthanized after another 4-hour fast. Asterisks (*) indicate
significant differences caused by NE; P < 0.05.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or NE-treated mice.
4
D, Diet effect; N, NE effect; D*N, Interaction effect.

Table 3.9 Expression of genes involved in lipid metabolism in the liver.
10% Fat
45% Fat
TRT
CON
SHB
OO
SFO
SBO
Cpt1a
PBS
1.00±0.15
1.76±0.27
0.86±0.04
0.75±0.11
1.16±0.15
NE
1.49±0.18
2.12±0.09
1.75±0.37
0.89±0.17
1.40±0.14
2
BC
A
B
C
Diet mean
1.24±0.14
1.94±0.15
1.31±0.24
0.82±0.10
1.28±0.11B
Cpt1b
PBS
1.00±0.60
0.69±0.28
0.51±0.07
0.34±0.08
0.46±0.12
NE
2.64±0.94*
1.86±0.14*
1.24±0.31
0.71±0.07
1.30±0.25*
Diet mean2
1.82±0.60
1.27±0.26
0.87±0.20
0.53±0.09
0.88±0.20
Cpt2
PBS
1.00±0.16
1.76±0.31
1.01±0.30
0.63±0.23
1.70±0.27
NE
1.57±0.27
1.70±0.22
0.98±0.17
0.37±0.05
2.24±0.43
Diet mean2 1.29±0.18AB
1.73±0.18A
0.99±0.16B
0.48±0.11C
1.97±0.25A
Ppara
PBS
1.00±0.16
2.75±0.55
1.78±0.20
0.81±0.12
1.60±0.14
NE
0.94±0.15
2.49±0.06
2.15±0.36
0.94±0.14
1.06±0.16
2
C
A
AB
C
Diet mean
0.97±0.10
2.62±0.26
1.97±0.20
0.88±0.09
1.33±0.14BC
Ppard
PBS
1.00±0.07
2.33±0.31
1.46±0.21
0.80±0.13
1.63±0.06
NE
1.51±0.23
2.33±0.39
2.11±0.40
0.63±0.08
2.08±0.20
2
B
A
AB
C
Diet mean
1.25±0.15
2.33±0.23
1.78±0.24
0.71±0.08
1.86±0.13A
Pparg
PBS
1.00±0.63
14.97±6.04
2.57±1.07
5.91±2.17
11.11±5.61
NE
1.30±0.35
10.07±1.42
1.60±0.30
6.86±1.23
9.93±3.23
Diet mean2
1.15±0.34C
12.52±3.02A 2.09±0.55BC 6.38±1.17AB 10.52±3.01AB
Adrb1
PBS
1.00±0.19
1.68±0.29
1.03±0.13
0.77±0.09
1.67±0.47
NE
0.70±0.08
1.38±0.43
1.32±0.44
0.61±0.05
1.12±0.10
2
AB
A
AB
B
Diet mean
0.85±0.11
1.53±0.24
1.18±0.22
0.69±0.05
1.39±0.25A
Adrb2
PBS
1.00±0.20
1.73±0.47
1.15±0.26
0.73±0.17
1.72±0.31
NE
1.62±0.18
1.92±0.44
1.64±0.16
0.56±0.07
2.69±1.02
2
A
A
A
B
Diet mean
1.31±0.17
1.83±0.30
1.39±0.17
0.65±0.09
2.20±0.52A
Adrb3
PBS
1.00±0.24
3.13±0.57
2.98±0.84
1.12±0.20
2.80±0.53
NE
0.68±0.17
1.47±0.11
2.08±0.57
0.75±0.14
1.88±0.47
Diet mean2
0.84±0.15B
2.30±0.41A
2.53±0.50A
0.94±0.13B
2.34±0.37A
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and NE.
1

TRT mean3
1.11±0.10
1.53±0.13*
0.60±0.13
1.55±0.24*
1.25±0.14
1.37±0.18
1.59±0.19
1.52±0.17
1.44±0.14
1.73±0.17
7.11±1.95
5.95±1.11
1.23±0.14
1.03±0.13
1.27±0.15
1.69±0.26
2.21±0.30
1.37±0.19*

P-value4
D; <.0001
N; .0014
D*N; .3902
D; .1463
N; <.0001
D*N; .8161
D; <.0001
N; .5232
D*N; .3722
D; <.0001
N; .6882
D*N; .3077
D; <.0001
N; .1157
D*N; .1621
D; <.0001
N; .4138
D*N; .7329
D; .0037
N; .1056
D*N; .7239
D; < .0001
N; .0983
D*N; .4050
D; <.0001
N; .0060
D*N; .9523
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For each gene, diets were compared among each other (after combining PBS and NE data within each diet), and assigned different
superscripts A, B, C, AB, or BC) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
For each gene, if a diet has a common superscript with another diet, it means they are not significantly different from each other. Only
diets without a common superscript are significantly different from each other.
TRT, treatment (PBS or NE injection). CON, control; SHB, shea butter; OO, olive oil; SFO, safflower; SBO, soybean oil.
1
Mice were injected with norepinephrine (NE; 2mg/kg body weight) or phosphate-buffered saline (PBS; 2mL/kg body weight) as a
vehicle after 8-hour fasting at the end of the experimental period, and euthanized after another 4-hour fast. Asterisks (*) indicate
significant differences caused by NE; P < 0.05.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or NE-treated mice.
4
D, Diet effect; N, NE effect; D*N, Interaction effect.
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Table 3.10 Expression of genes involved in lipid metabolism in hamstring muscle.
10% Fat
45% Fat
TRT
CON
SHB
OO
SFO
SBO
Cpt1a
PBS
1.00±0.32
3.27±0.95
2.56±0.41
2.23±0.34
1.08±0.38
NE
1.91±0.72
3.68±0.64
2.11±0.42
2.48±0.26
2.00±0.23*
Diet mean2
1.46±0.40B
3.47±0.54A 2.33±0.28AB 2.35±0.20AB
1.54±0.27B
Cpt1b
PBS
1.00±0.16
2.70±0.22
2.46±0.19
4.57±1.16
1.80±0.12
NE
1.32±0.10
2.40±0.23
3.38±0.74
2.50±0.33*
1.96±0.16
Diet mean2
1.16±0.11C 2.55±0.16AB 2.92±0.40AB
3.53±0.68A
1.88±0.10B
Cpt2
PBS
1.00±0.10
1.38±0.27
0.98±0.21
0.70±0.15
1.46±0.30
NE
1.10±0.13
1.13±0.17
0.93±0.12
0.65±0.12
1.29±0.06
Diet mean2 1.05±0.08AB 1.26±0.16A 0.95±0.11AB
0.67±0.09B
1.37±0.14A
Ppara
PBS
1.00±0.20
4.07±0.67
3.77±1.11
4.47±1.58
2.33±0.25
NE
2.46±0.36*
6.55±1.96
2.40±0.24
3.39±0.85
4.64±1.14
2
B
A
AB
A
Diet mean
1.73±0.33
5.31±1.07
3.08±0.59
3.95±0.85
3.49±0.70A
Ppard
PBS
1.00±0.23
3.77±0.80
3.27±0.65
2.01±0.46
1.90±0.14
NE
2.98±0.57*
5.90±0.85
3.85±0.73
2.82±0.27
3.08±0.57
2
C
A
AB
BC
Diet mean
1.99±0.47
4.84±0.67
3.56±0.47
2.42±0.29
2.49±0.35BC
Pparg
PBS
1.00±0.50
9.54±3.05
3.95±2.61
4.15±1.62
2.66±1.38
NE
0.66±0.44
4.31±0.92
2.19±0.65
1.69±0.73
0.82±0.32
Diet mean2
0.83±0.32B
6.92±1.78A 3.07±1.29AB 2.92±0.94AB
1.74±0.74B
Adrb1
PBS
1.00±0.47
4.71±0.83
2.70±0.97
4.78±1.83
2.09±0.70
NE
1.48±0.58
4.23±1.33
2.52±0.52
2.71±0.74
1.15±0.21
2
C
A
ABC
AB
Diet mean
1.24±0.36
4.47±0.73
2.61±0.51
3.74±1.00
1.62±0.38BC
Adrb2
PBS
1.00±0.09
1.82±0.46
1.00±0.11
2.48±1.11
2.80±0.91
NE
2.64±0.57*
2.28±0.66
1.15±0.05
2.12±1.02
1.98±0.39
2
Diet mean
1.82±0.41
2.05±0.38
1.07±0.06
2.30±0.70
2.39±0.48
Adrb3
PBS
1.00±0.48
4.49±1.49
1.84±1.45
1.92±0.63
5.49±4.79
NE
1.40±1.11
1.68±0.60
1.32±0.33
0.30±0.12*
1.39±0.71
Diet mean2
1.20±0.56
3.09±0.91
1.58±0.69
1.11±0.43
3.44±2.37
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and NE.
1

TRT mean3
2.03±0.29
2.44±0.25
2.50±0.35
2.31±0.22
1.13±0.11
1.02±0.07
3.13±0.47
3.89±0.57
2.39±0.31
3.72±0.36*
4.26±1.04
1.93±0.40
3.06±0.54
2.42±0.39
1.82±0.32
2.03±0.27
2.95±1.02
1.22±0.29

P-value4
D; .0056
N; .0767
D*N; .3134
D; < .0001
N; .9869
D*N; .0368
D; .0017
N; .6353
D*N; .9554
D; .0008
N; .0648
D*N; .0646
D; .0003
N; .0003
D*N; .2038
D; .0010
N; .0758
D*N; .9245
D; .0015
N; .5095
D*N; .8918
D; .1238
N; .3365
D*N; .2223
D; .1711
N; .0811
D*N; .3841
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For each gene, diets were compared among each other (after combining PBS and NE data within each diet), and assigned different
superscripts A, B, C, AB, or BC) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
For each gene, if a diet has a common superscript with another diet, it means they are not significantly different from each other. Only
diets without a common superscript are significantly different from each other.
TRT, treatment (PBS or NE injection). CON, control; SHB, shea butter; OO, olive oil; SFO, safflower; SBO, soybean oil.
1
Mice were injected with norepinephrine (NE; 2mg/kg body weight) or phosphate-buffered saline (PBS; 2mL/kg body weight) as a
vehicle after 8-hour fasting at the end of the experimental period, and euthanized after another 4-hour fast. Asterisks (*) indicate
significant differences caused by NE; P < 0.05.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or NE-treated mice.
4
D, Diet effect; N, NE effect; D*N, Interaction effect.
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Table 3.11 Expression of neuropeptides and β-adrenergic receptors in hypothalamus.
10% Fat
45% Fat
P-value4
TRT
CON
SHB
OO
SFO
SBO
TRT mean3
Npy
PBS
1.00±0.17
0.57±0.09
0.88±0.18
0.63±0.18
0.61±0.10
0.74±0.07
D; .2584
N; .2376
NE
0.87±0.10
0.70±0.25
0.75±0.10
1.03±0.18
0.89±0.13
0.85±0.07
2
D*N;
.3851
Diet mean
0.94±0.09
0.63±0.13
0.82±0.10
0.83±0.14
0.75±0.09
Agrp
PBS
1.00±0.13
0.63±0.19
1.24±0.27
0.87±0.13
0.90±0.04
0.93±0.08
D; .1844
N; .2821
NE
0.95±0.11
1.03±0.24
0.93±0.17
0.84±0.10
1.58±0.35
1.07±0.10
2
D*N; .2086
Diet mean
0.97±0.08
0.83±0.16
1.08±0.16
0.85±0.07
1.24±0.21
Pomc
PBS
1.00±0.12
1.40±0.64
1.01±0.38
1.33±0.72
1.64±0.52
1.28±0.21
D; .3427
N; .7490
NE
1.00±0.15
1.56±0.44
0.66±0.11
0.57±0.07
2.22±0.56
1.20±0.19
2
D*N; .6512
Diet mean
1.00±0.09
1.48±0.36
0.84±0.19
0.95±0.36
1.93±0.37
Lepr
PBS
1.00±0.54
1.67±1.42
0.50±0.15
0.31±0.20
0.87±0.75
0.87±0.32
D; .9608
N; .1132
NE
0.20±0.10
0.27±0.16
0.22±0.06
0.31±0.12
0.37±0.14
0.28±0.05
2
D*N; .4320
Diet mean
0.60±0.30
0.97±0.71
0.36±0.09
0.31±0.11
0.62±0.36
Adrb1
PBS
1.00±0.22
1.12±0.27
1.07±0.29
0.60±0.13
1.12±0.15
0.98±0.10
D; .0369
N; .0829
NE
0.82±0.26
0.75±0.24
0.62±0.08
0.48±0.05
1.23±0.19
0.78±0.09
2
AB
AB
AB
B
A
D*N; .6751
Diet mean
0.91±0.16
0.94±0.18
0.85±0.16
0.54±0.07
1.18±0.11
Adrb2
PBS
1.00±0.13
1.14±0.24
1.34±0.24
0.83±0.16
1.62±0.20
1.19±0.10
D; .0001
N; .7753
NE
1.09±0.10
1.46±0.21
0.91±0.12
0.75±0.03
1.88±0.19
1.22±0.11
2
BC
AB
BC
C
A
D*N; .2080
Diet mean
1.04±0.08
1.30±0.16
1.13±0.15
0.79±0.08
1.75±0.14
Adrb3
PBS
1.00±0.13
0.94±0.31
1.11±0.56
0.66±0.14
1.33±0.25
1.03±0.14
D; .0074
N; .3380
NE
1.19±0.07
1.15±0.23
0.82±0.10
0.53±0.02
1.89±0.34
1.12±0.13
2
AB
AB
AB
B
A
D*N; .8187
Diet mean
1.09±0.08
1.05±0.18
0.96±0.27
0.56±0.09
1.61±0.22
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and NE.
For each gene, diets were compared among each other (after combining PBS and NE data within each diet), and assigned different
superscripts A, B, AB, BC, or C) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
1
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For each gene, if a diet has a common superscript with another diet, it means they are not significantly different from each other. Only
diets without a common superscript are significantly different from each other.
TRT, treatment (PBS or NE injection). CON, control; SHB, shea butter; OO, olive oil; SFO, safflower; SBO, soybean oil.
1
Mice were injected with norepinephrine (NE; 2mg/kg body weight) or phosphate-buffered saline (PBS; 2mL/kg body weight) as a
vehicle after 8-hour fasting at the end of the experimental period, and euthanized after another 4-hour fast. Asterisks (*) indicate
significant differences caused by NE; P < 0.05.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or NE-treated mice.
4
D, Diet effect; N, NE effect; D*N, Interaction effect.
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Figure 3.10 Ucp1 mRNA expression in different adipose tissue depots.
Mice were fed control diet containing 10% kcal fat for 12 weeks, and injected with
norepinephrine (NE; 2 mg/kg body weight) or phosphate-buffered saline (PBS; 2 mL/kg body
weight) as a vehicle after 8-h fasting at the end of the experimental period, and euthanized after
another 4-h fasting.
Ucp1 mRNA expression was determined by RT-PCR.
BAT, brown adipose tissue; sWAT, subcutaneous white adipose tissue; eWAT, epididymal white
adipose tissue.
Data are presented as means ± SEM (n = 8 for each tissue; n = 4 for each PBS and NE
treatment).
Tissues were compared among each other (after combining PBS and NE data within each diet),
and assigned different superscripts (A or B) if they were significantly different from each other
at P < 0.05 by Tukey’s multiple comparison test. If a tissue has a common superscript with
another diet, it means they are not significantly different from each other. Only tissues without a
common superscript are significantly different from each other.
T*N, Interaction effect between tissue and NE.

134

LIPOPOLYSACCHARIDE REGULATES
THERMOGENIC AND INFLAMMATORY GENES IN MICE FED
HIGH-FAT DIETS WITH DISTINCT 18-CARBON FATTY ACID
COMPOSITION

4.1

Abstract

Fatty acids are involved in the regulation of inflammatory responses in obesity. However, despite
being the largest dietary fatty acid class, the effect of 18-carbon fatty acids with different degrees
of saturation on inflammatory, metabolic, and thermogenic markers have not been well studied.
Therefore, the objective of this study was to test if diets with different 18-carbon fatty acid
profiles differentially regulate inflammatory and metabolic genes. Male C57BL/6 mice were fed
one of 4 different diets: a control diet containing 5.6% kcal fat from lard and 4.4% kcal fat from
soybean oil (CON) or three high-fat diets (HFD) containing 25% kcal fat from lard and 20% kcal
fat from either shea butter oil (saturated fatty acid-rich fat; SHB), olive oil (monounsaturated
fatty acid-rich fat; OO), or soybean oil (polyunsaturated fatty acid-rich fat; SBO) ad libitum for 4
weeks with or without a terminal 4-hour lipopolysaccharide (LPS) treatment. Compared to CON,
HFD-fed mice had higher weight gain and fat accumulation. The OO group had the highest BAT
mass while the SBO group had higher Il6 and lower Cpt1a expression in WAT than other HFD
groups. Treatment with LPS upregulated expression of proinflammatory cytokines, and this was
associated with induction of insulin resistance and downregulation of thermogenic gene
expression. However, the diets did not have differential effects on inflammatory response to
LPS. These data indicate that saturation degree of 18-C fatty acids is not an important factor on
response to LPS with regard to metabolic and inflammatory indicators.
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4.2

Introduction

Chronic positive energy balance increases fat mass by inducing adipocyte hyperplasia and
hypertrophy. Obesity is also associated with hypertrophic adipocytes that secrete inflammatory
cytokines and chemokines, which promote infiltration of proinflammatory macrophages into
white adipose tissue (WAT) [1]. Proinflammatory effects of certain adipokines cause
dysregulation of lipid and energy metabolism [2-6] and development of metabolic disorders,
such as insulin resistance and atherosclerosis [7]. There is renewed interest in understanding the
fundamental mechanisms that link inflammation and metabolic dysregulation. For example,
activation of pattern recognition receptor (PRR) inhibits proliferation of immortalized brown
preadipocytes [2]. It also attenuates isoproterenol-induced Ucp1 mRNA expression in brown
adipocytes [3], and causes downregulation of Pgc1a mRNA expression in C3H10T1/2
adipocytes [2]. In addition, co-culturing C3H10T1/2 adipocytes with RAW 264.7 macrophages
leads to suppression of Ucp1 mRNA expression [6]. However, relatively little information still
exists on the role of dietary fatty acids in the metabolic dysregulation caused by inflammation.
Our work [8] and those of others [9, 10] have shown that dietary fatty acids play key
roles in regulating inflammation and thermogenesis. Saturated fatty acids (SFA) and n-6
polyunsaturated fatty acids (PUFA) activate inflammatory signals [8, 9], whereas long chain n-3
PUFA suppress inflammation by inhibiting production of pro-inflammatory eicosanoids [9]. It
has also been shown that n-3 PUFA promote thermogenesis by upregulating thermogenic gene
expression in both brown adipose tissue (BAT) and WAT [10]. However, studies of specific
effects of 18-carbon fatty acids, the largest dietary fatty acid class, have not been previously
investigated in the context of regulation of both inflammatory and thermogenic gene expression.
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Therefore, the objective of this study was to determine interaction of 18-carbon fatty acids with
the metabolic and inflammatory effects of LPS administration in mice.

4.3

Materials and Methods

4.3.1

Animals and Diets

All animal procedures were approved and carried out in accordance with the Purdue Animal
Care and Use Committee. Five-week old male C57BL/6J mice (originally obtained from Jackson
Lab, Bar Harbor, ME, USA) were assigned to one of 4 diet groups; control diet containing 5.6%
kcal fat from lard and 4.4% kcal fat from soybean oil (CON) or high-fat diets (HFD) containing
25% kcal from lard and 20% kcal fat from shea butter (SHB; SFA-rich fat), olive oil (OO; monounsaturated fatty acid; MUFA-rich oil), or soybean oil (SBO; PUFA-rich oil). Mice (n = 8 per
group) were fed the experimental diets ad libitum for 4 weeks. All diets were made of vegetable
oils and lard to make them more similar to human diets that typically have multiple sources of
fat. Table 4.1 shows the composition of the experimental diets. Mice were housed, 4 per cage, in
a room with controlled temperature (72 ± 2ºF), humidity (35 ± 5%), and a 12 hour-dark cycle.
Body weight was measured once a week, and food intake was measured twice a week. At
the end of the experimental period (28 days), mice were injected with lipopolysaccharide (LPS;
0.1mg/kg body weight) or phosphate-buffered saline (PBS; 4mL/kg body weight) as a vehicle
after an 8-hour fast and euthanized with CO2 asphyxiation 4 hours later. Serum was separated
after blood collection by centrifugation at 2,000  g at 4C for 10 minutes. Subcutaneous and
epididymal white adipose tissue (WAT), brown adipose tissue (BAT), liver, hamstring muscle,
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and hypothalamus were removed, weighed, and snap-frozen in liquid nitrogen, and stored at 80°C until subsequent analyses.

4.3.2

Fatty Acid Composition of Experimental Diets

Total lipids were extracted from powdered diets using modified Folch method [11]. Fatty acids
in extracted lipid samples were trans-esterified to form fatty acid methyl esters (FAME) by
treatment with sodium methoxide in methanol. FAMEs were extracted with hexane, and the
extracts were analyzed by gas chromatography (Varian 3900 gas chromatography system with
CP-8400 autosampler; Agilent, Santa Clara, CA, USA). Fatty acid composition of diets is shown
in Table 4.2.

4.3.3

Serum Lipid, Glucose, Insulin, and TNF-α Concentrations

Serum triacylglycerol (TAG) was measured using the Sigma Triglyceride Reagent (SigmaAldrich, St. Louis, MO, USA). Serum non-esterified fatty acid (NEFA) and glucose
concentrations were measured using the Wako HR Series NEFA-HR (2) and Wako Autokit
Glucose (Wako Diagnostics, Mountain View, CA, USA). Serum insulin concentration was
measured using the Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Chicago, IL,
USA). Serum TNF-α concentration was measured using the mouse TNF-α ELISA Kit
(Invitrogen, Carlsbad, CA, USA).
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4.3.4

In Vitro Cell Culture

Murine primary stromovascular cells were obtained from the subcutaneous inguinal fat pads of
C57BL/6 mice and grown in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12; SigmaAldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Corning,
Corning, NY, USA) and 1% antibiotic antimycotic solution at 37°C and 5% CO2. Two days after
confluence, cell differentiation was initiated with DMEM/F12 with 10% FBS, 1.7μM insulin,
1μM dexamethasone, 500μM isobutylmethylxanthine (IBMX), 1μM rosiglitazone, 17μM
pantothenic acid, and 33μM biotin for 6 days. Medium was changed every 3 days.
To determine effects of individual 18-carbon fatty acids on response to LPS and
norepinephrine (NE; a non-selective β-adrenergic receptor agonist), on day 6 of differentiation,
fully differentiated adipocytes were pretreated for 24 hours with 50 µM of BSA-bound 18carbon fatty acids: stearic acid (STA; 18:0), oleic acid (OLA; 18:1, ∆9), linoleic acid (LNA;
18:2, ∆9,12), and α-linolenic acid (ALA; 18:3, ∆9,12,15). The fatty acids were free from heavy
metals and of the purest grade (≥ 98% purity; Cayman, Ann Arbor, MI, USA). This was
followed by treatment with or without 100ng/mL of LPS for 2 hours and by another 4 hours of
treatment with or without 10μM of NE (a non-selective β-adrenergic receptor agonist; Cayman
Chemical, Ann Arbor, MI, USA).

4.3.5

Quantitative Real-time PCR

RNA was extracted from tissues and cells using Trizol (Ambion, Austin, TX, USA) and reverse
transcribed to cDNA using M-MLV reverse transcriptase (Promega, Madison, WI, USA).
Quantitative real-time PCR was performed on a Bio-rad iQ5 system (Bio-rad, Hercules, CA,
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USA) using RT2 SYBR Green Fluor qPCR Mastermix (Qiagen, Germantown, MD, USA). The
mRNA levels of Il6, Mcp1, Tnfa, Tlr4, Ucp1, Pgc1a, Cpt1a, Cpt1b, Cpt2, Hamp, Npy, Agrp,
Pomc, and Lepr were quantified and normalized relative to 18S rRNA. Fold changes of gene
expression were calculated by the ΔΔCt method. Specific primer sequences are shown in Table
4.3.

4.3.6

Statistical Analysis

One-way or two-way analysis of variance (ANOVA) with Tukey’s post-hoc test was performed
to determine significant differences among groups. Data were presented with the means ± SEM
and analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

4.4

Results

4.4.1 In Vivo Experiments
4.4.1.1 Body Weight, Calorie Intake, Growth Efficiency, and Tissue Weight
The mice in the HFD-fed groups had higher body weight after 4 weeks of experimental diet
feeding compared to CON group (P=0.0006). The SHB, OO, and SBO groups had about 2-fold
higher body weight increase (P<0.0001) and growth efficiency (P=0.0002) compared to CON.
The OO and SBO group had 1.71 and 1.94 times higher epidydimal WAT (eWAT) weight per
body weight (g WAT weight/100 g body weight), and OO group had 1.76 times higher BAT
weight per body weight than CON group (Table 4.4).
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4.4.1.2 Serum Lipid, Glucose, Insulin, and TNF-α Concentrations
Although serum TAG and NEFA levels were not different among groups, serum glucose level
was significantly lower in LPS-injected mice than vehicle-treated mice (P<0.0001). Injection of
LPS increased serum TNF-α level (P<0.0001) and serum insulin level (P=0.0160), and
decreased glucose:insulin ratio (P<0.0001; Table 4.5).

4.4.1.3 Pro-Inflammatory Cytokines and Thermogenic Gene Expression in BAT, subcutaneous
WAT, and epididymal WAT
The LPS-injected mice had higher Il6 and TNFa expression in BAT (P=0.0005, P=0.0368,
respectively) than those injected with PBS, but there was no effect of LPS on thermogenic gene
expression (Figure 4.1; Table 4.6).
The HFD-fed groups had a higher level of inflammation as shown by the higher Mcp1
expression (P=0.0013) and tended to have higher Tnfa expression (P=0.0867) in subcutaneous
WAT (sWAT). Injection of LPS upregulated Il6 and Mcp1 (P<0.0001, P<0.0001), and Tnfa
(P=0.0291) expression in sWAT. A negative metabolic effect of LPS injection is shown by the
tendency of LPS to downregulate Ucp1 expression (P=0.0930) and significantly downregulated
Pgc1a expression (P=0.0053) in sWAT of the HFD-fed groups. The SHB and OO groups had
higher Cpt1a mRNA expression in sWAT than CON (P=0.0006; Figure 4.2; Table 4.7).
In eWAT, mice that were injected with LPS also had higher Il6 and Mcp1 (P<0.0001),
and Tnfa (P=0.0005) mRNA expression than those treated with PBS. LPS treatment also lowered
Pgc1a expression (P=0.0003) and tended to lower Cpt1a expression in eWAT (P=0.0698;
Figure 4.3; Table 4.8).
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4.4.1.4 Pro-Inflammatory Cytokines and Oxidative Gene Expression in the Liver and Hamstring
Muscle
Injection of LPS upregulated expression of Il6, Mcp1, Tnfa, and (P<0.0001) in the liver, and
tended to upregulate Tlr4 expression (P=0.0863). To determine potential effect of LPS injection
on whole-body iron redistribution, we also measured expression of Hamp (Hepcidin encoding
gene) in the liver because this gene is associated with iron uptake into the liver [12]. LPS
injection led to a significant upregulation of Hamp expression (P<0.0001), suggesting LPS might
impact iron metabolism in these mice. The SBO group had lower hepatic Cpt1b expression than
CON group (P=0.0316). The SHB and OO groups tended to have lower Cpt2 expression than
CON group (P=0.0580), and LPS treatment resulted in lower Cpt2 expression in the liver
(P=0.0196; Table 4.9).
In hamstring muscle, LPS treatment upregulated Il6, Mcp1, and Tnfa expression in HFDfed groups (P=0.0417, P=0.0273, P=0.0130, respectively). The OO group had lower Tlr4
expression than the SBO group (P=0.0203) and tended to have lower Cpt1a expression than
CON group (P=0.0626). LPS injection tended to have lower Cpt1a expression (P=0.0534) in
hamstring muscle of the HFD-fed groups (Table 4.10).

4.4.1.5 Expression of Pro-Inflammatory Cytokines and Neuropeptides in Hypothalamus
The LPS-injected mice had higher Il6, Mcp1, and Tnfa expression (P<0.0001, P<0.0001,
P<0.0001, respectively) compared to their PBS-injected counterparts. The OO group had higher
Tlr4 expression than SBO group (P=0.0299). Compared to CON group, the OO group had lower
Pomc and higher Lepr expression (P=0.0025, P=0.0045, respectively; Table 4.11).
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4.4.2

In Vitro Experiments

Due to lack of a significant effect of the different fatty acids on response to LPS and NE, only
the effects of NE and LPS on thermogenic and inflammatory gene expression are shown in
Figure 4.4. Treatment with NE upregulated Il6, Mcp1, Tnfa, Ucp1, Pgc1a, and Cpt1a
expression (P<0.0001, P<0.0001, P=0.0024, P=0.0091, P<0.0001, P=0.0090, respectively).
Likewise, LPS treatment upregulated Il6, Mcp1, and Tnfa expression (P<0.0001, P<0.0001,
P<0.0001, respectively), and suppressed NE-induced Pgc1a expression (P<0.0001).

4.5

Discussion

Dietary fat plays a key role in the regulation of inflammatory responses. Consumption of HFD
leads to obesity, and upregulation of inflammatory cytokines and chemokines. Dietary fatty acids
are involved in biosynthesis of inflammatory eicosanoids [9]. These inflammatory mediators are
recognized, not only for increasing the risk of metabolic disorders such as dyslipidemia, insulin
resistance, and cardiovascular disease, but also for interference with thermogenic responses by
suppressing brown/beige adipogenesis [2, 3, 6]. However, despite their high level in diets, no
comparative studies have been conducted to investigate effects of different 18-carbon fatty acids
on the regulation of LPS-induced inflammatory and metabolic/thermogenic markers.
In this study, HFD feeding, including SHB (SFA-rich fat), OO (MUFA-rich oil), and
SBO (PUFA-rich oil), induced higher weight gain, growth efficiency, and visceral fat
accumulation compared to CON group. Among the HFD-fed groups, the OO group had the
highest BAT mass, an observation that is consistent with reports from previous studies where
that thermogenic effects of OO have been reported [13-15]. Consumption of OO has also been
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shown to increase oxygen consumption in rats [13] and mice [14], and energy expenditure in
mice [14] and healthy men [15].
The n-6 PUFA-rich SBO group had the highest weight gain and growth efficiency as
previously reported [16]. The high linoleic acid (LNA; n-6) content in SBO is considered a
possible reason for this response because arachidonic acid (ARA), which can be synthesized
from LNA by elongation, is reported to upregulate the activity of endogenous lipid mediators
that increase hepatic de novo lipid synthesis [16] and white fat mass [17] in mice.
Mice fed the SBO diet also had the highest Il6 expression in sWAT and the lowest Pgc1a
expression in eWAT. It has been shown that increasing dietary LNA in isocaloric diets induces
inflammation in WAT by causing larger size of adipocytes and more macrophage infiltration in
mice [18]. ARA has been reported to downregulate thermogenic gene expression and decrease
oxygen consumption rate in differentiated human multipotent adipose-derived stem cells [19].
Therefore, a high content of LNA in SBO diet may be lined to induction of inflammation and the
associated downregulation of thermogenic and oxidative gene expression.
Although HFD feeding was previously reported to inhibit browning of WAT [14, 20-22],
by suppressing activation of β-adrenergic signaling [23], expression of Ucp1 and Pgc1a
expression was not lower in sWAT in mice fed HFD in this study. This discrepancy may be
caused by the duration of HFD feeding. In the previous studies mentioned above [14, 20-22],
experimental animals were fed HFD for 8 to 12 weeks; however, in this study, mice were fed
HFD only for 4 weeks. This is because 4-week HFD feeding has been reported to be sufficient in
inducing higher body fat accumulation [24] and weight gain in mice [24-26]. However, it is
possible that downregulation of thermogenic genes in sWAT does not occur in the early-stages
of HFD-induced obesity.
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Nevertheless, the 4-week HFD feeding upregulated Cpt1a expression in sWAT. The lack
of difference in sWAT mass between CON group and HFD groups in the current study could be
explained by the increased oxidation capacity in sWAT in the HFD fed groups. A higher
expression of Cpt1a and Ppara has also been previously shown in rats fed HFD in the inguinal
subcutaneous fat, and this resulted in lower inguinal fat expansion compared to other fat depots
[27].
We also determined potential effects of dietary fatty acids on LPS-induced acute
inflammation. Mice that were injected with LPS had higher serum TNF-α concentration than
those injected with PBS, and this agrees with a similar outcome in rats injected with LPS [28].
Although HFD-induced weight gain did not lead to a difference in serum metabolites between
the different dietary groups, the LPS-treated mice had higher serum insulin concentration despite
having lower serum glucose concentration than vehicle-treated mice. LPS is known to impair
insulin signaling through activation of NF-κB signaling [29, 30], and this is in accordance with
similar reports of dysregulation of insulin and glucose concentrations in ewes [31] and cattle
[32].
In both sWAT and eWAT, LPS treatment upregulated Il6, Mcp1, and Tnfa expression,
and downregulated Pgc1a expression compared to PBS-injected mice. Multiple in vitro and in
vivo studies have previously reported LPS-induced suppression of thermogenesis in white
adipocytes [2, 21, 33]. In C3H10T1/2 white adipocytes, LPS downregulated Ucp1 and Pgc1a
both at mRNA and protein levels [2], and conditioned medium from LPS-stimulated RAW 264.7
macrophages led to suppression of isoproterenol-induced Ucp1 upregulation [33]. LPS-injected
mice have been shown to have lower thermogenic gene expression, including Ucp1, Pgc1a, and
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Prdm16, and less relative mitochondrial DNA contents in sWAT under acute cold exposure
compared to saline-injected control [21].
However, in BAT, there was no effect of LPS on expression of metabolic markers
although LPS led to an overall upregulation of Il6 and Tnfa expression in the current study. A
possible mechanism underlying the observed inflammation-induced suppression of
thermogenesis in WAT, but not in BAT, may be related to ER stress. In the WAT of mice, LPS
injection or HFD feeding led to upregulation of ER stress markers, including C/EBP homologous
protein (CHOP) and binding immunoglobulin protein (BiP), activation of c-Jun N-terminal
kinase (JNK), and repression of thermogenesis [21, 34]. Additionally, in 10T1/2 white
adipocytes, IL-1β caused activation of extracellular signal-regulated kinase (ERK), and
inhibition of ERK reversed the IL-1β-induced Ucp1 suppression [33]. On the contrary, in WT1
mouse brown adipocytes, LPS treatment did not cause an upregulation of ER stress related
markers, BiP, CHOP, and a transcriptional regulator of ER stress, Trip-br2 [35]. These data
suggest that BAT may be more resistant, compared to WAT, to inflammation-induced ER stress
that may mediate the suppression of thermogenic gene expression.
LPS injection exerted depot-specific effects on thermogenic and metabolic gene
expression in WAT. Ucp1 expression tended to be downregulated by LPS in sWAT but not in
eWAT, indicating that LPS effect on suppression of WAT browning is greater in sWAT than
eWAT. This may be because subcutaneous fat is better able to acquire a brown-like phenotype
than visceral fat [36], perhaps due to the higher number of UCP1+ adipocytes in the
subcutaneous fat depot [37]. In contrast, LPS tended to downregulate Cpt1a expression in eWAT
but not in sWAT. Visceral fat is known to be more metabolically active [38] with a higher
number of macrophages and crown-like structures in obesity-induced inflammation compared to
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subcutaneous fat [39]. This suggests that visceral fat could be more susceptible to LPS-induced
metabolic suppression. Therefore, the structural and phenotypic differences between these two
fat depots could have led to the depot-specific responses to LPS treatment.
The in vitro study demonstrated that LPS treatment reversed NE-induced Ucp1, Pgc1a,
and Cpt1a expression in murine primary white adipocytes, which is in accordance with our in
vivo data. The lack of fatty acid effect on response to LPS and NE also agrees with the in vivo
experiment. Interestingly, although slight, NE treatment led to upregulation of Il6, Mcp1, and
Tnfa mRNA expression in mature primary adipocytes. This could be because NE can bind to αadrenergic, in addition to β-adrenergic receptors [40], and stimulation of α-adrenergic receptors
activates NF-κB signaling involved in the transcription of pro-inflammatory genes [41]. It was
previously reported that α2-agonists induced IκB kinase activation and IκB degradation [42], and
blockade of α1-adrenergic receptor suppressed NE-induced NF-κB activation [40].
Very recently, stimulation of WAT browning by CL316,243, a β3 adrenoceptor agonist
and an anti-obesity agent, was reported to downregulate Hamp (Hepcidin encoding gene) mRNA
expression in the liver and upregulated transferrin receptor expression in sWAT [43]. This
response would potentially lead to increased iron uptake into sWAT to support the browning
process since hepcidin and transferrin receptor control iron absorption. This response supports
the hypothesis that iron redistribution from the liver to WAT occurs during browning of WAT
[43]. Thus, the upregulation of Hamp expression in the liver of LPS treated mice in this study
would indicate that LPS could lead to sequestration of iron in the liver, perhaps preventing iron
enrichment of sWAT or eWAT and inhibition of the browning process in these adipose depots.
This possibility is supported by the lower thermogenic or mitochondrial gene expression in WAT
(sWAT and eWAT) of LPS-treated mice. Thus, it is conceivable that LPS-induced inflammation
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suppresses brown-like phenotype acquisition of WAT by preventing iron redistribution and
enrichment within WAT.
LPS upregulated pro-inflammatory cytokine expression, including Il6, Mcp1, and Tnfa, in
both liver and hamstring muscle as well, and this LPS-induced inflammation downregulated
Cpt2 expression in the liver and Cpt1a expression in hamstring muscle. Non-esterified fatty acids
that are not oxidized can exacerbate insulin resistance caused by LPS-induced inflammation
through binding to TLR4 and activating inflammatory signaling [43]. Therefore, the lower
insulin sensitivity in LPS-injected mice in the current study could be linked to the lower
expression of genes involved in fatty acid oxidation in WAT, liver, and skeletal muscle.
In the hypothalamus, Il6, Mcp1, Tnfa, and Tlr4 expression were upregulated by LPS
administration, indicating that peripheral injection of LPS successfully induced central
inflammation. Peripheral LPS administration was previously reported to upregulate proinflammatory cytokine mRNA expression in other brain regions as well, such as cerebral cortex,
cerebellum, and hippocampus [28]. However, no effect of LPS-induced inflammation on
neuropeptide expression was found in this study. Previous reports about effects of central
inflammation on neuropeptide expression have not been consistent [28, 44]. In Sprague-Dawley
rats, intraperitoneal injection of LPS upregulated mRNA levels of anorexigenic neuropeptide
Pomc and Cart, and lowered food intake [44]. However, in Wistar rats, it did not modulate
neuropeptide expression [28]. On the other hand, the OO group has the highest Lepr expression
in this study although Lepr expression did not change in response to LPS treatment. Since leptin
signaling is known to promote BAT thermogenesis and WAT browning [45], the increased Lepr
expression in the OO group may mediate the higher energy expenditure in the OO group than
other diet groups as previously reported [13-15].
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In sum, LPS administration induced inflammation in the brain and peripheral tissues, and
reduced insulin sensitivity. LPS-induced inflammation downregulated thermogenic gene
expression in WAT of mice and in mature primary adipocytes, but not in BAT. It also
downregulated oxidative gene expression in eWAT, liver, and skeletal muscle. Although the type
of 18-C fatty acid consumed did not affect the response to LPS, consumption of OLA-rich OO
diet resulted in increased BAT mass and hypothalamic Lepr expression. The high content of
LNA in SBO might mediate the higher Il6 expression, and lower Pgc1a and Cpt1a expression in
sWAT compared to other HFD groups. The lack of an advantageous effects of PUFA in this
study indicates that the number of double bonds in dietary fatty acids of 18-carbon length might
not play a significant role in the regulation of the metabolic and inflammatory response to LPS
administration. This contrasts with known effects of long chain PUFA, DHA and EPA, which
have been shown to mitigate the inflammatory and metabolic effects of LPS [46, 47].
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Table 4.1 Composition of the experimental diets1.
High-fat

(10% Kcal Fat)

(45% Kcal Fat)

g

Kcal

g

Kcal

200

800

200

800

3

12

3

12

Sucrose

172.8

691

172.8

691

Cornstarch

452.2

1808.8

72.8

291

Dyetrose

75

300

100

400

SHB, OO, or SBO2

20

180

90

810

Lard

25

225

112.5

1012.5

0.004

0

0.018

0

Cellulose

50

0

50

0

Mineral Mix3

35

0

35

0

Vitamin Mix4

10

40

10

40

Choline Bitartrate

2

0

2

0

1045

4057

848.1

4057

Casein
L-cystine

t-Butylhydroquinone

Total
kcal/ g diet
1

Control

3.69

4.64

Resource: Dyets, Inc., Bethlehem, PA, USA.
SHB, shea butter; OO, olive oil; SBO, soybean oil
3
Thirty five grams of mineral mix (Research Diets, Inc., New Brunswick, NJ, USA, S10026)
provides 1.0g sodium, 1.6g chloride, 0.5g magnesium, 0.33g sulfur, 59mg manganese, 45mg iron,
29mg zinc, 6mg copper, 2mg chromium, 1.6mg molybdenum, 0.16mg selenium, 0.9mg fluoride,
0.2 mg, iodine and 3.99g sucrose.
4
Ten grams of vitamin mix (Research Diets, Inc., V10001) provides 4000 IU vitamin A, 1000 IU
vitamin D3, 50 IU vitamin E, 30 mg niacin, 16 mg pantothenic acid, 7 mg vitamin B6, 6 mg
vitamin B1, 6 mg vitamin B2, 2 mg folic acid, 0.5 mg menadione, 0.2 mg biotin, 10 μg vitamin
B12 and 9.78 g sucrose.
2
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Table 4.2 Fatty acid composition of the experimental diets (% of fatty acids)1.
10% Fat

45% Fat

CON

SHB

OO

SBO

Myristic acid (C14:0)

1.046

0.728

0.681

0.685

Palmitic acid (C16:0)

17.148

13.287

18.595

15.740

Palmitoleic acid (C16:1, ∆9)

0.976

0.998

1.863

0.944

Stearic acid (C18:0)

8.604

23.781

7.503

7.808

Oleic acid (C18:1, ∆9)

27.793

38.828

44.971

28.916

Linoleic acid (C18:2, ∆9,12)

32.187

15.201

18.772

35.580

α-Linolenic acid

3.374

0.858

1.023

3.731

0.142

0.159

0.148

0.154

0.100

0.011

0.022

0.032

0.072

0.044

0.037

0.062

Total saturated fatty acids

27.552

38.422

27.498

24.986

Total monounsaturated fatty acids

30.803

41.411

49.470

31.784

Total polyunsaturated fatty acids

37.663

18.221

21.519

41.364

Total n-6 fatty acids

32.976

16.031

19.549

36.412

Total n-3 fatty acids

3.822

1.622

1.397

4.097

n-6: n-3 ratio

8.628

9.883

13.994

8.887

(C18:3, ∆9,12,15)
Arachidonic acid
(C20:4, ∆5,8,11,14)
Eicosapentaenoic acid
(C20:5, ∆5,8,11,14,17)
Docosahexaenoic acid
(C22:6, ∆4,7,10,13,16,19)

CON, 4.4% soybean oil + 5.6% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil +
25% lard; SBO, 20% soybean oil + 25% lard.
1
Fatty acid composition was determined by a gas chromatography.
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Table 4.3 The primer sequences used for quantitative Real-time PCR1.
Gene

Forward Primer

Reverse Primer

18S

ATC CCT GAG AAG TTC CAG CA

CCT CTT GGT GAG GTC GAT GT

Il6

TTC CTC TCT GCA AGA GAC TTC C

TGA AGT CTC CTC TCC GGA CTT

Mcp1

CAC TCA CCT GCT GCT ACT CA

GCT TGG TGA CAA AAA CTA CAG C

Tnfa

AGC CCC CAG TCT GTA TCC TT

CTC CCT TTG CAG AAC TCA GG

Tlr4

TTC AAG ACC AAG CCT TTC AG

CAT AGT CCT TCC ATG ATA GA

Sirt1

TGA CCG ATG GAC TCC TCA CT

ACA AAA GTA TAT GGA CCT ATC CGC

Dbc1

GAT GGA GAG GAC GAA TTT GGA GCA AGG GAT CCA GCT CCT TAG GC

Ucp1

GGG CCC TTG TAA ACA ACA AA

GTC GGT CCT TCC TTG GTG TA

Pgc1a GTC CTT CCT CCA TGC CTG AC

GTG TGG TTT GCT GCA TGG TT

Cpt1a

GGA CTC CGC TCG CTC ATT

GAG ATC GAT GCC ATC AGG GG

Cpt1b

AAG TTC AGA GAC GAA CGC CC

CAG GCC TCT TCT TCC ACC AG

Cpt2

GCT TTC CAA CCC GAT CTC CT

TGT GAG CGG AAG ATC CCA AC

Hamp

GGG CAG ACA TTG CGA TAC CA

GCA ACA GAT ACC ACA CTG GGA

Npy

TGG CCA GAT ACT ACT CCG CT

TCT TCA AGC CTT GTT CTG GGG

Agrp

CCC TGT CCT AGA CCT TCC AGA

GTG CCT CCC ATT GTG TTG TCT

Pomc

CAA CCT GCT GGC TTG CAT C

CGT ACT TCC GGG GGT TTT CA

Lepr

CAG AAT GAC GCA GGG CTG TA

AGA GTG TCC GTT CTC TTT TGG A

1

18S, 18S ribosomal RNA; Il6, Interleukin 6; Mcp1, Monocyte chemotactic protein 1; Tnfa,
Tumor necrosis factor α; Tlr4, Toll-like receptor 4; Sirt1, Sirtuin 1; Dbc1, Deleted in breast
cancer 1; Ucp1, Uncoupling protein 1; Pgc1a, Peroxisome proliferator-activated receptor gamma
coactivator 1-alpha; Cpt1a, Carnitine palmitoyl-transferase 1A; Cpt1b, Carnitine palmitoyltransferase 1B; Cpt2, Carnitine palmitoyl-transferase 2; Hamp, Hepcidin antimicrobial peptide;
Npy, Neuropeptide Y; Agrp, Agouti-related peptide; Pomc, Proopiomelanocortin; Lepr, Leptin
receptor.

Table 4.4 Body weight, calorie intake, growth efficiency, and tissue weight.
10% Fat

45% Fat

P-value

CON

SHB

OO

SBO

Body weight at 0 week (g)

19.79±0.37

19.69±0.27

19.94±0.44

19.98±0.47

0.9512

Body weight at 4 week (g)

22.75±0.26 B

25.71±0.54 A

25.54±0.73 A

26.60±0.74 A

0.0006

Body weight gain (g)

2.96±0.18 B

6.03±0.60 A

5.60±0.50 A

6.63±0.34 A

<0.0001

Calorie intake (kcal/day)

10.04±0.39

12.62±0.38

11.59±1.03

11.39±0.30

0.0886

10.80±0.77 B

17.29±1.71 A

17.92±1.70 A

21.04±1.14 A

0.0002

1.09±0.14

1.68±0.39

1.72±0.27

2.10±0.30

0.1222

Epidydimal WAT (g/100g body weight)

1.59±0.11 B

2.30±0.34 AB

2.72±0.31 A

3.07±0.30 A

0.0058

Brown adipose tissue (g/100g body weight)

0.49±0.07 B

0.76±0.05 AB

0.86±0.14 A

0.80±0.09 AB

0.0400

Liver (g/100g body weight)

3.63±0.10

3.70±0.16

3.57±0.10

3.66±0.09

0.8707

Thigh (g/100g body weight)

1.44±0.11

1.25±0.16

1.33±0.17

1.27±0.12

0.7868

Growth efficiency (mg/kcal)1
Subcutaneous WAT (g/100g body weight)

Data are presented as means ± SEM, n = 8 for each group.
CON, 4.4% soybean oil + 5.6% lard; SBO, 20% soybean oil + 25% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard.
Different superscripts (A and B) indicate significant differences caused by diets; P < 0.05.
1

Growth efficiency (mg/kcal) = Weight gain (mg) / Total calorie intake (kcal)
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Table 4.5 Serum Lipid, Glucose, Insulin, and TNF-α Concentrations.
10% Fat
45% Fat
P-value4
TRT
CON
SHB
OO
SBO
TRT mean3
TAG (mg/mL)
PBS
0.89±0.15
1.14±0.36
1.83±0.55
1.49±0.44
1.34±0.20
D; .1439
L; .3203
LPS
0.72±0.11
0.97±0.08
1.95±0.74
0.82±0.10
1.12±0.21
2
D*L;
.8137
Diet mean
0.81±0.09
1.06±0.17
1.89±0.43
1.16±0.24
NEFA (mM)
PBS
0.051±0.002
0.083±0.028
0.129±0.041
0.085±0.027
0.087±0.015
D; .1501
L; .3273
LPS
0.051±0.003
0.070±0.010
0.093±0.033
0.053±0.003
0.067±0.009
D*L; .8763
Diet mean2 0.051±0.002
0.076±0.014
0.111±0.025
0.069±0.014
Glucose (mg/dL)
PBS
301.9±75.6
332.8±54.3
382.7±49.6
309.4±33.1
331.7±26.0
D; .2537
L;
<.0001
LPS
144.5±22.9
203.8±27.0
193.6±26.6
179.7±16.3
180.4±12.0*
2
D*L; .8557
Diet mean
223.2±47.1
268.3±37.2
288.1±44.2
244.5±29.9
Insulin (ng/mL)
PBS
0.92±0.19
1.14±0.11
0.76±0.21
1.14±0.36
0.99±0.11
D; .4477
L; .0160
LPS
1.10±0.23
1.32±0.12
1.44±0.18
1.84±0.46
1.43±0.14*
2
D*L; .4748
Diet mean
1.01±0.14
1.23±0.08
1.10±0.18
1.49±0.30
Glucose: Insulin
PBS
3.95±1.42
2.87±0.23
5.67±0.76
4.03±1.45
4.13±0.05
D; .5968
ratio
L; <.0001
LPS
1.67±0.59
1.60±0.25
1.40±0.28
1.21±0.34
1.47±0.18*
2
D*L;
.5641
Diet mean
2.81±0.83
2.23±0.29
3.54±0.89
2.62±0.87
TNF-α (pg/mL)
PBS
14.11±8.06
25.08±15.29
26.95±12.71
11.77±6.36
19.49±5.29
D; .1260
L; <.0001
LPS
70.71±20.34 118.61±16.68
129.58±31.88
68.09±8.65
96.75±11.83*
D*L; .9359
Diet mean2 42.41±14.73
71.85±20.55
78.28±25.07
39.93±11.75
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and LPS.
CON, 4.4% soybean oil + 5.6% lard; SBO, 20% soybean oil + 25% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard.
TRT, treatment (PBS or LPS injection). TAG, triacylglycerol. NEFA, non-esterified fatty acid.
Asterisks (*) indicate significant differences caused by LPS; P < 0.05.
1
Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline (PBS) vehicle (4mL/kg body
weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or LPS-treated mice.
4
D, Diet effect; L, LPS effect; D*L, Interaction effect.
1
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Figure 4.1 Expression of genes involved in inflammation and thermogenesis in BAT (a) Il6 (b) Mcp1 (c) Tnfa (d) Ucp1 (e) Pgc1a
(f) Cpt1a. Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline (PBS) vehicle
(4mL/kg body weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later. Gene expression was
determined by RT-PCR. Data are presented as means ± SEM (n = 8 for each diet group; n = 4 each for PBS and LPS). D*L,
Interaction effect between diet and LPS. CON, control; SHB, shea butter; OO, olive oil; SBO, soybean oil.
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Table 4.6 Expression of genes involved in inflammation and thermogenesis in BAT.
10% Fat
45% Fat
P-value4
TRT
CON
SHB
OO
SBO
TRT mean3
Tlr4
PBS
1.00±0.03
5.64±3.25
3.51±2.57
3.70±2.00
3.64±1.13
D; .5654
L; .8343
LPS
1.60±0.48
2.19±1.18
3.35±1.76
3.74±1.48
2.80±0.64
2
D*L;
.6205
Diet mean
1.30±0.25
3.92±1.73
3.42±1.37
3.72±1.15
Sirt1
PBS
1.00±0.26
3.12±1.92
0.56±0.20
2.71±0.86
1.85±0.55
D; .0156
L; .6925
LPS
2.78±1.20
1.15±0.45
0.72±0.16
3.48±1.66
2.03±0.57
2
AB
AB
B
A
D*L; .2243
Diet mean
1.89±0.66
2.13±0.99
0.64±0.12
3.10±0.88
Dbc1
PBS
1.00±0.21
0.83±0.07
0.53±0.14
0.96±0.18
0.83±0.09
D; .0017
L; .3569
LPS
0.95±0.25
0.48±0.10
0.31±0.06
1.12±0.17
0.70±0.11
2
A
AB
B
A
D*L; .4211
Diet mean
0.98±0.14
0.63±0.09
0.42±0.08
1.04±0.12
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and LPS.
CON, 4.4% soybean oil + 5.6% lard; SBO, 20% soybean oil + 25% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard.
For each variable, diets were compared among each other (after combining PBS and LPS data within each diet), and assigned different
superscripts (A, B, or AB) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
Asterisks (*) indicate significant differences caused by LPS at P < 0.05.
1
Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline (PBS) vehicle (4mL/kg body
weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or LPS-treated mice.
4
D, Diet effect; L, LPS effect; D*L, Interaction effect.
1
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Figure 4.2 Expression of genes involved in inflammation and thermogenesis in subcutaneous WAT (a) Il6 (b) Mcp1 (c) Tnfa (d)
Ucp1 (e) Pgc1a (f) Cpt1a. Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline
(PBS) vehicle (4mL/kg body weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later. Gene
expression was determined by RT-PCR. Data are presented as means ± SEM (n = 8 for each diet group; n = 4 each for PBS and LPS).
Different superscript letters (A and B) indicate significant difference due to diet effect at P < 0.05 by Tukey’s multiple comparison
test. D*L, Interaction effect between diet and LPS. CON, control; SHB, shea butter; OO, olive oil; SBO, soybean oil.
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Table 4.7 Expression of genes involved in inflammation and thermogenesis in subcutaneous WAT.
10% Fat
45% Fat
P-value4
TRT
CON
SHB
OO
SBO
TRT mean3
Tlr4
PBS
1.00±0.19
2.54±0.71
1.24±1.08
1.32±0.16
1.53±0.33
D; .5489
L; .0291
LPS
1.37±0.24
3.15±1.34
4.37±1.06
1.84±0.42
2.68±0.50*
2
D*L;
.0538
Diet mean
1.18±0.16
2.85±0.71
2.81±0.92
1.58±0.23
Sirt1
PBS
1.00±0.08
0.68±0.10
0.27±0.08
0.89±0.16
0.71±0.09
D; .0125
L; .5629
LPS
0.94±0.09
0.85±0.36
0.39±0.12
0.99±0.34
0.79±0.13
2
A
AB
B
A
D*L; .9424
Diet mean
0.97±0.06
0.76±0.17
0.33±0.07
0.94±0.17
Dbc1
PBS
1.00±0.28
1.07±0.24
0.78±0.08
0.95±0.24
0.95±0.10
D; .1534
L; .0727
LPS
0.69±0.14
0.98±0.08
0.39±0.09
0.75±0.22
0.70±0.08
2
D*L; .8631
Diet mean
0.86±0.16
1.03±0.12
0.58±0.09
0.85±0.16
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and LPS.
CON, 4.4% soybean oil + 5.6% lard; SBO, 20% soybean oil + 25% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard.
For each variable, diets were compared among each other (after combining PBS and LPS data within each diet), and assigned different
superscripts (A, B, or AB) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
Asterisks (*) indicate significant differences caused by LPS at P < 0.05.
1
Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline (PBS) vehicle (4mL/kg body
weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or LPS-treated mice.
4
D, Diet effect; L, LPS effect; D*L, Interaction effect.
1
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Figure 4.3 Expression of genes involved in inflammation and thermogenesis in epididymal WAT (a) Il6 (b) Mcp1 (c) Tnfa (d)
Ucp1 (e) Pgc1a (f) Cpt1a. Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline
(PBS) vehicle (4mL/kg body weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later. Gene
expression was determined by RT-PCR. Data are presented as means ± SEM (n = 8 for each diet group; n = 4 each for PBS and LPS).
Different superscript letters (A and B) indicate significant difference due to diet effect at P < 0.05 by Tukey’s multiple comparison
test. D*L, Interaction effect between diet and LPS. CON, control; SHB, shea butter; OO, olive oil; SBO, soybean oil.
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Table 4.8 Expression of genes involved in inflammation and thermogenesis in epididymal WAT.
10% Fat
45% Fat
P-value4
TRT
CON
SHB
OO
SBO
TRT mean3
Tlr4
PBS
1.00±0.34
1.72±0.69
1.80±0.78
1.35±0.51
1.47±0.28
D; .5840
L; .8971
LPS
1.39±0.51
2.02±0.80
0.60±0.21
1.60±0.45
1.40±0.27
2
D*L;
.3715
Diet mean
1.20±0.29
1.87±0.49
1.20±0.44
1.47±0.32
Sirt1
PBS
1.00±0.25
0.33±0.03
0.24±0.06
0.53±0.08
0.53±0.10
D; .0008
L; .4524
LPS
0.72±0.23
0.47±0.15
0.23±0.09
0.45±0.07
0.47±0.08
2
A
AB
B
A
D*L; .7711
Diet mean
0.86±0.17
0.40±0.07
0.23±0.05
0.49±0.05
Dbc1
PBS
1.00±0.19
0.59±0.13
0.40±0.06
1.04±0.17
0.76±0.10
D; .0001
L; .3631
LPS
0.85±0.14
0.52±0.05
0.30±0.11
1.01±0.12
0.69±0.18
2
A
B
B
A
D*L; .9734
Diet mean
0.92±0.11
0.55±0.07
0.36±0.05
1.03±0.10
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and LPS.
CON, 4.4% soybean oil + 5.6% lard; SBO, 20% soybean oil + 25% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard.
For each variable, diets were compared among each other (after combining PBS and LPS data within each diet), and assigned different
superscripts (A, B, or AB) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
Asterisks (*) indicate significant differences caused by LPS at P < 0.05.
1
Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline (PBS) vehicle (4mL/kg body
weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or LPS-treated mice.
4
D, Diet effect; L, LPS effect; D*L, Interaction effect.
1
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Table 4.9 Expression of pro-inflammatory cytokines and oxidative genes in the liver.
TRT mean3
0.70±0.10
72.07±17.41*
1.73±0.44
136.52±31.26*
1.00±0.26
23.86±3.22*
0.93±0.06
1.22±0.16
0.90±0.10
0.93±0.07
0.49±0.11
0.48±0.08
0.68±0.09
0.44±0.04
0.88±0.11
1.83±0.16*

P-value4
D; .0629
L; <.0001
D*L; .0075
D; .2789
L; <.0001
D*L; .6680
D; .3456
L; <.0001
D*L; .3225
D; .3872
L; .0863
D*L; .7459
D; .8831
L; .6116
D*L; .5162
D; .0316
L; .8915
D*L; .3352
D; .0580
L; .0196
D*L; .8027
D; .5200
L; <.0001
D*L; .4711
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10% Fat
45% Fat
TRT
CON
SHB
OO
SBO
Il6
PBS
1.00±0.28
0.76±0.19
0.41±0.05
0.87±0.19
LPS
43.88±25.14
89.42±18.38
133.83±46.66
21.16±20.40
2
Diet mean
22.44±14.18
45.09±18.79
67.12±33.20
11.01±10.19
Mcp1
PBS
1.00±0.70
1.45±0.75
1.77±0.84
2.71±1.30
LPS
83.58±51.46
108.62±21.04
263.02±79.00
90.87±54.68
2
Diet mean
42.29±28.48
55.04±22.48
132.40±61.44
46.79±30.31
Tnfa
PBS
1.00±0.56
0.96±0.62
0.41±0.12
1.61±0.67
LPS
12.85±5.58
29.38±8.15
23.31±4.29
29.90±5.32
2
Diet mean
6.92±3.43
15.17±6.57
11.86±4.76
15.76±5.89
Tlr4
PBS
1.00±0.14
0.87±0.18
0.96±0.10
0.89±0.13
LPS
1.16±0.15
1.12±0.28
1.67±0.52
0.94±0.09
2
Diet mean
1.08±0.10
0.99±0.16
1.32±0.28
0.91±0.07
Cpt1a
PBS
1.00±0.25
0.95±0.27
0.79±0.16
0.86±0.20
LPS
0.85±0.14
0.73±0.14
1.07±0.12
1.05±0.11
2
Diet mean
0.92±0.14
0.84±0.14
0.93±0.11
0.96±0.11
Cpt1b
PBS
1.00±0.36
0.30±0.09
0.41±0.04
0.24±0.04
LPS
0.56±0.19
0.62±0.17
0.51±0.20
0.22±0.06
2
A
AB
AB
Diet mean
0.78±0.21
0.46±0.11
0.46±0.10
0.23±0.03B
Cpt2
PBS
1.00±0.25
0.49±0.08
0.53±0.13
0.69±0.16
LPS
0.57±0.08
0.40±0.05
0.37±0.05
0.41±0.10
2
Diet mean
0.78±0.15
0.44±0.05
0.45±0.07
0.55±0.10
Hamp
PBS
1.00±0.24
0.73±0.22
0.71±0.25
1.07±0.25
LPS
2.15±0.25
1.57±0.18
2.03±0.43
1.55±0.35
2
Diet mean
1.58±0.27
1.15±0.21
1.37±0.34
1.31±0.22
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and LPS.
1

CON, 4.4% soybean oil + 5.6% lard; SBO, 20% soybean oil + 25% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard.
For each variable, diets were compared among each other (after combining PBS and LPS data within each diet), and assigned different
superscripts (A, B, or AB) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
Asterisks (*) indicate significant differences caused by LPS at P < 0.05.
1
Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline (PBS) vehicle (4mL/kg body
weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or LPS-treated mice.
4
D, Diet effect; L, LPS effect; D*L, Interaction effect.
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Table 4.10 Expression of pro-inflammatory cytokines and oxidative genes in hamstring muscle.
10% Fat
45% Fat
P-value4
TRT
CON
SHB
OO
SBO
TRT mean3
Il6
PBS
1.00±0.81
0.03±0.02
0.00±0.00
0.03±0.01
0.27±0.21
D; .0961
L; .0417
LPS
0.11±0.07
0.19±0.15
0.02±0.00
0.63±0.31
0.24±0.10*
2
D*L;
.5303
Diet mean
0.55±0.41
0.11±0.07
0.01±0.00
0.33±0.19
Mcp1
PBS
1.00±0.61
0.09±0.06
0.03±0.02
0.06±0.02
0.30±0.17
D; .5850
L; .0073
LPS
0.35±0.29
1.04±0.58
0.25±0.12
1.05±0.51
0.67±0.21*
2
D*L; .6639
Diet mean
0.68±0.33
0.57±0.33
0.14±0.07
0.55±0.30
Tnfa
PBS
1.00±0.63
0.18±0.08
0.16±0.06
0.19±0.09
0.38±0.17
D; .6653
L; .0130
LPS
0.33±0.18
1.28±0.56
0.40±0.17
1.39±0.52
0.85±0.22*
2
D*L; .0799
Diet mean
0.67±0.33
0.73±0.34
0.28±0.10
0.79±0.33
Tlr4
PBS
1.00±0.23
1.29±0.38
0.76±0.26
0.91±0.18
0.99±0.13
D; .0203
L; .4775
LPS
0.87±0.07
1.01±0.31
0.31±0.22
1.43±0.22
0.90±0.14
2
AB
AB
B
A
D*L; .5024
Diet mean
0.93±0.11
1.15±0.23
0.53±0.18
1.17±0.16
Cpt1a
PBS
1.00±0.31
1.28±0.14
0.85±0.24
1.61±0.40
1.18±0.15
D; .0626
L; .0534
LPS
1.55±0.51
0.84±0.33
0.28±0.16
0.93±0.13
0.90±0.18
2
D*L; .1734
Diet mean
1.28±0.30
1.06±0.19
0.56±0.17
1.27±0.23
Cpt1b
PBS
1.00±0.22
0.85±0.29
4.00±3.20
0.77±0.10
1.66±0.80
D; .3654
L; .4680
LPS
1.09±0.16
0.92±0.15
1.80±0.57
1.16±0.20
1.24±0.17
2
D*L; .9679
Diet mean
1.04±0.12
0.89±0.15
2.90±1.56
0.91±0.13
Cpt2
PBS
1.00±0.12
0.73±0.09
1.32±0.74
1.09±0.15
1.04±0.18
D; .3630
L; .7855
LPS
0.91±0.12
0.95±0.27
1.07±0.39
1.41±0.13
1.08±0.12
2
D*L; .9171
Diet mean
0.96±0.08
0.84±0.14
1.20±0.39
1.25±0.11
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and LPS.
CON, 4.4% soybean oil + 5.6% lard; SBO, 20% soybean oil + 25% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard.
1
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For each variable, diets were compared among each other (after combining PBS and LPS data within each diet), and assigned different
superscripts (A, B, or AB) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
Asterisks (*) indicate significant differences caused by LPS at P < 0.05.
1
Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline (PBS) vehicle (4mL/kg body
weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or LPS-treated mice.
4
D, Diet effect; L, LPS effect; D*L, Interaction effect.
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Table 4.11 Expression of pro-inflammatory cytokines and neuropeptides in hypothalamus.
TRT mean3
2.09±0.56
39.21±7.99*
1.25±0.20
22.71±7.51*
0.87±0.13
4.30±0.44*
1.24±0.12
1.68±0.19*
1.10±0.11
1.06±0.10
0.81±0.08
0.81±0.07
0.91±0.14
0.98±0.13
1.10±0.20
1.16±0.20

P-value4
D; .6730
L; <.0001
D*L; .6565
D; .7906
L; <.0001
D*L; .9165
D; .2893
L; <.0001
D*L; .8762
D; .0299
L; .0454
D*L; .8950
D; .0980
L; .7038
D*L; .1114
D; .2413
L; .8127
D*L; .7622
D; .0025
L; .6608
D*L; .9353
D; .0045
L; .7079
D*L; .4045
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10% Fat
45% Fat
TRT
CON
SHB
OO
SBO
Il6
PBS
1.00±0.85
2.80±1.80
2.16±0.83
2.41±1.04
LPS
48.65±26.24
26.55±8.27
45.10±15.51
36.54±13.51
2
Diet mean
24.83±15.13
14.68±5.96
23.63±10.84
19.48±9.00
Mcp1
PBS
1.00±0.15
1.42±0.80
1.42±0.21
1.18±0.24
LPS
30.42±21.29
9.09±2.03
32.02±22.65
19.32±6.51
2
Diet mean
15.71±11.31
5.26±1.77
16.72±11.97
10.25±4.57
Tnfa
PBS
1.00±0.32
0.67±0.23
1.04±0.27
0.75±0.24
LPS
3.53±0.48
3.59±0.87
5.86±1.09
4.22±0.75
2
Diet mean
2.26±0.55
2.13±0.69
3.45±1.05
2.49±0.75
Tlr4
PBS
1.00±0.22
1.30±0.28
1.62±0.16
1.06±0.20
LPS
1.43±0.21
1.57±0.27
2.49±0.52
1.23±0.22
2
AB
AB
A
Diet mean
1.21±0.16
1.44±0.19
2.05±0.30
1.14±0.14B
Npy
PBS
1.00±0.11
1.22±0.27
1.07±0.21
1.13±0.29
LPS
1.36±0.24
1.10±0.12
0.60±0.04
1.16±0.10
2
Diet mean
1.18±0.14
1.16±0.14
0.84±0.13
1.14±0.14
Agrp
PBS
1.00±0.27
0.68±0.12
0.75±0.09
0.79±0.15
LPS
0.93±0.16
0.64±0.08
0.68±0.12
0.99±0.11
2
Diet mean
0.97±0.15
0.66±0.07
0.72±0.07
0.89±0.09
Pomc
PBS
1.00±0.06
0.99±0.37
0.39±0.07
1.25±0.35
LPS
1.15±0.17
1.07±0.20
0.56±0.31
1.14±0.28
2
A
A
B
Diet mean
1.08±0.09
1.03±0.20
0.48±0.15
1.19±0.21A
Lepr
PBS
1.00±0.35
0.83±0.28
2.09±0.36
0.50±0.16
LPS
0.56±0.08
1.18±0.33
1.84±0.35
1.06±0.51
2
B
AB
A
Diet mean
0.78±0.19
1.01±0.21
1.96±0.24
0.78±0.27B
Data are presented as means ± SEM; n = 8 for each diet group; n = 4 each for PBS and LPS.
1

CON, 4.4% soybean oil + 5.6% lard; SBO, 20% soybean oil + 25% lard; SHB, 20% shea butter + 25% lard; OO, 20% olive oil + 25%
lard.
For each variable, diets were compared among each other (after combining PBS and LPS data within each diet), and assigned different
superscripts (A, B, or AB) if they were significantly different from each other at P < 0.05 by Tukey’s multiple comparison test.
Asterisks (*) indicate significant differences caused by LPS at P < 0.05.
1
Mice were injected with lipopolysaccharide (LPS; 0.1mg/kg body weight) or phosphate-buffered saline (PBS) vehicle (4mL/kg body
weight) after an 8-hour fast at the end of the experimental period, and euthanized 4 hours later.
2
Overall mean of each diet group.
3
Overall mean of PBS-treated mice or LPS-treated mice.
4
D, Diet effect; L, LPS effect; D*L, Interaction effect.
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Figure 4.4 Expression of genes involved in inflammation and thermogenesis in murine primary adipocytes (a) Il6 (b) Mcp1 (c)
Tnfa (d) Ucp1 (e) Pgc1a (f) Cpt1a. Differentiated inguinal fat pad-derived adipocytes were treated for 24 hours with 50 µM of each
fatty acid or BSA. After the initial 24-hour fatty acid treatment, cells were treated or not with 100ng/mL lipopolysaccharide (LPS) for
2 hours, followed by another 4 hours of treatment with or without 10μM NE (a non-selective β-adrenergic receptor agonist). Due to
lack of a significant effect of the different fatty acids on response to LPS and NE, only the effects of NE and LPS on thermogenic and
inflammatory gene expression are shown. Gene expression was determined by RT-PCR. Data are presented as means ± SEM (n=6 for
each group). L*N, Interaction effect between LPS and NE. F*L*N, Interaction effect among fatty acid, LPS, and NE. BSA, bovine
serum albumin; STA, stearic acid; OLA, oleic acid; LNA, linoleic acid; ALA, α-linolenic acid.
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SUMMARY AND FUTURE DIRECTIONS

Long chain fatty acids (LCFA) and their metabolites, as natural agonists or antagonists for
multiple transcription factors, modulate metabolic, oxidative, and inflammatory gene expression,
and contribute to obesity and obesity-related chronic diseases. The different chemical structures
of fatty acids and metabolites, determined by the number and the position of double bonds of
fatty acids, differentially regulate these mechanisms. Although 18-carbon (18-C) fatty acids are
the most abundant fatty acid class in human diets, there are very few studies which have
systemically compared the effects of 18-C fatty acids on the regulation of thermogenesis,
oxidation, and inflammation. Therefore, to determine the effects of the number and the position
of double bonds in 18-C fatty acids on metabolic responses, three different studies using in vitro
and in vivo models were conducted.
In the first in vitro study (Chapter 2), the effects of 18-C fatty acids with distinct number
and position of double bonds were investigated on thermogenic and oxidative gene expression in
four different mature white adipocyte models. Results of this experiment shows that polyunsaturated fatty acids (PUFA), including linoleic, α-linolenic, γ-linolenic, and pinolenic acids,
upregulated Ucp1 expression and tended to upregulate Pgc1a expression in mouse primary
adipocytes, and these genes were also upregulated by treatment of norepinephrine (NE; a nonselective β-adrenergic agonist). In C3H10T1/2 adipocytes, NE, but not fatty acids, upregulated
Ucp1 and Pgc1a expression, and 3T3-L1 adipocytes did not respond to both fatty acids and βadrenergic agonists. Although Ucp1 and Pgc1a expression were not induced by fatty acid or NE
treatment in pig primary adipocytes lacking a functional UCP1 protein, NE was shown to
upregulate Cpt1a expression, a response that was considered a compensatory thermogenic
mechanism to overcome UCP1 absence in pigs. This study demonstrated that different adipocyte
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cell types have different levels of sensitivity to both fatty acids and NE in regard to induction of
the brown-specific gene expression. Among the 4 different cells, mouse primary adipocytes had
the most potential to acquire brown-like phenotype, and that 18-C PUFA may play a role in the
regulation of this process.
To determine the in vivo implication of the first in vitro study, in the second study
(Chapter 3), mice were fed high-fat diets (HFD) with distinct composition of 18-C fatty acids,
and adipose tissue thermogenesis was determined. Results of this experiment showed that mice
fed olive oil (OO; OLA-rich oil) had the highest heat production, leading to the lowest weight
gain and body fat accumulation among HFD-fed groups. Mice in the shea butter (SHB; STA-rich
fat) group had the lowest expression of Ucp1 and Pgc1a in epididymal white adipose tissue
(eWAT). They also had the lowest thermogenesis and highest weight gain and body fat
accumulation. Although safflower oil (SFO; LNA-rich oil) fed mice had higher Ucp1 and Pgc1a
expression in eWAT than SHB-fed mice, their thermogenesis was as low as that of SHB-fed
mice. This might be because the SFO group had the lowest hypothalamic expression of Adrb2
and Adrb3 expression because these genes are involved in thermogenesis and oxidation. Due to
the low expression of β-AR in the hypothalamus, SFO-fed mice also had the lowest oxidative
gene expression in the liver. The SHB and SFO groups, the lowest heat producing groups, had
higher serum glucose and insulin levels compared to CON group. On the other hand, NE highly
upregulated Pgc1a and Prdm16 expression in BAT of CON group, but its effect in HFD groups
was slight or insignificant. However, the HFD-fed mice, irrespective of dietary 18-C fatty acid
composition, had lower Ucp1 expression in both subcutaneous WAT (sWAT) and eWAT
compared to CON group. These results indicate that HFD feeding could lead to suppression of
brown-like phenotype acquisition of WAT, and the n-6/n-3 ratio of dietary fatty acids could
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determine thermogenic responses. Therefore, position of double bonds in dietary fatty acids, in
addition to quantity of dietary fat, might be significant in the regulation of oxidative and
thermogenic conditions in vivo.
Since LCFA are also able to regulate inflammatory responses involved in dysregulation
of energy metabolism, in the third study (Chapter 4), the interaction effects of 18-C fatty acids
and lipopolysaccharides (LPS) on metabolic and inflammatory responses in mice and mouse
primary adipocytes were investigated. Among HFD-fed groups, mice fed soybean oil (SBO;
PUFA-rich oil) had the highest weight gain, this was associated with the highest proinflammatory Il6 expression and the lowest expression of mitochondrial genes including Pgc1a
and Cpt1a in WAT. In contrast, the OO (monounsaturated fatty acid-rich oil) group had the
highest brown adipose tissue (BAT) mass and hypothalamic Lepr expression, supporting a
possibility that they could have higher thermogenic response compared to other groups. LPSinduced acute inflammation resulted in insulin resistance and lower thermogenic gene expression
in mice, and reversed NE-induced upregulation of thermogenic and oxidative gene expression in
mouse primary adipocytes. However, the diets did not exert differential effects on LPS-mediated
inflammatory responses, irrespective of their 18-C fatty acid profile. These results suggest that
saturation degree of 18-C fatty acids may not be a critical factor in their effects on the regulation
of metabolic and inflammatory indicators in response to LPS treatment.
Taken together, the results presented in this dissertation demonstrated that dietary 18-C
fatty acids with different number and position of double bonds may exert differential effects in
the regulation of metabolic and brown adipose-specific genes, although they did not differ in
their effect on LPS-induced inflammation. However, an overall limitation of this study is the lack
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of mechanistic data to provide underlying mechanisms of these fatty acids on metabolic and
inflammatory response and acquisition of the brown-like phenotype in WAT.
A limitation of the work presented in this dissertation is that effects of 18-C fatty acids on
specific genes, such as those involved in UCP1-dependent thermogenesis and β-adrenergic
signaling, adenylyl cyclase, PPARα, PPARγ, and PGC-1α, were limited to measurements of
RNA abundance only by PCR. For most of the genes, protein expression by western blot was
highly variable and unquantifiable. Therefore, future studies should determine regulation of these
genes at the protein level using more sensitive models. In addition, functional assays are needed
to determine the effects of the 18-C fatty acids on the activities of proteins that are involved the
browning phenotype, such as UCP1, CPT1α, PPARα, PPARγ, and PGC-1α. Further experiments
using Ucp1 knock-out mice or Ucp1 knock-down adipocytes could help demonstrate whether a
direct relationship exists between Ucp1 gene and the observed thermogenic responses in adipose
tissues induced by 18-C fatty acids. Additional studies could also help determine the effects 18-C
fatty acids on the regulation of UCP1-independent thermogenic mechanisms such as creatinedriven substrate cycling and SERCA2b-mediated calcium signaling.
In addition, a major weakness of the research described in this dissertation is that the
animal experiments were based on dietary fat that was a mixture of different fatty acids, thus
high in additional fatty acids in addition to the 18-C fatty acids being evaluated. Therefore,
potentially, some in vivo effects attributed to the fatty acids could be affected by the presence of
the other fatty acids as well. Future in vivo studies should separate very clearly those due to the
18-C fatty acids through better diet formulation and experimental design.
Although the implication of the current work on establishment of optimal dietary levels
of 18-C fatty acids is still unclear, the current studies and the future additional studies proposed
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may provide the groundwork for better utilization of 18-C fatty in human diets acids to enhance
the metabolic phenotype of adipose tissue for reducing the risk of obesity and obesity-related
chronic diseases.
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